Effect of Selective Up regulation of Prostacyclin Synthesis On Its Signaling And Vascular Protection by Mohite, Anita
 i 
Effect	  of	  Selective	  Up	  regulation	  of	  Prostacyclin	  Synthesis	  On	  Its	  Signaling	  And	  




A	  Dissertation	  Presented	  to	  
The	  Department	  of	  Pharmacological	  and	  Pharmaceutical	  Sciences	  




In	  Partial	  Fulfillment	  of	  
The	  Requirement	  for	  the	  Degree	  of	  










It	  is	  a	  pleasure	  to	  convey	  my	  gratitude	  to	  all	  of	  those	  who	  made	  this	  dissertation	  
possible.	   I	   owe	  my	  deepest	   gratitude	   to	  my	   advisor,	  Dr.	   Ke-­‐He	  Ruan,	   for	   his	   constant	  
support,	  advice,	  guidance	  and	  encouragement	  through	  out	  the	  entire	  research.	  His	  ideas	  
and	   his	   passion	   for	   research	   has	   always	   inspired	   me	   and	   enriched	   my	   growth	   as	   a	  
student	   and	   a	   researcher.	   I	   would	   like	   to	   thank	   him	   for	   designing	   the	   superenzyme	  
(triple	   catalytic	   enzyme-­‐1)	   and	   for	   giving	   me	   a	   chance	   to	   work	   on	   this	   interesting	  
project.	  	  
I	  am	  heartily	  thankful	  to	  all	  my	  committee	  members,	  Dr.	  Richard	  Bond,	  Dr.	  Louis	  
Williams,	  Dr.	  Rong	  Yu	  and	  Dr.	  Xiaolian	  Gao	   for	   their	   time,	  constructive	  comments	  and	  
suggestions	  on	  this	  dissertation.	  I	  am	  thankful	  that	  in	  the	  midst	  of	  all	  their	  activity,	  they	  
accepted	  to	  be	  members	  of	  my	  dissertation	  committee.	  I	  am	  indebted	  to	  them,	  for	  the	  
friendly	  support	  during	  the	  committee	  meeting	  and	  defense.	  I	  would	  like	  to	  express	  my	  
special	  thanks	  to	  Dr.	  Williams	  for	  his	  fatherly	  support	  and	  encouragement.	  	  
I	   would	   also	   like	   to	   thank	   Dr.	   Brian	   Knoll	   and	   Dr.	   Vincent	   Lau	   for	   their	  
administrative	   support.	   I	   would	   like	   to	   thank	   all	   the	   staff	   memebrs	   of	   the	   PPS	  
department	   for	   their	  hardwork	   in	  providing	  me	  all	   the	  knowledge	  during	   the	   courses.	  
Thank	   you	   Dr.Bond	   for	   being	   such	   a	   wonderful	   teacher	   during	   the	   literature	   review	  
course	   as	   this	   course	   has	   helped	   me	   develop	   my	   presentation	   skills	   as	   well	   as	  
 iii 
confidence.	  I	  thank	  the	  department	  and	  University	  of	  Houston	  for	  giving	  me	  a	  chance	  to	  
study	  and	  finish	  my	  graduate	  degree	  here.	  	  
I	   would	   like	   to	   thank	   all	   the	   graduate	   students	   for	   their	   continuous	   love	   and	  
support.	   I	   am	   deeply	   indebted	   to	   Alice	   and	   Vanessa	   for	   being	   the	   most	   friendly,	  
wonderful	  and	  supportive	  lab	  mates.	  I	  would	  like	  to	  thank	  Jaixin	  for	  his	  help	  in	  teaching	  
me	  LC/MS.	  I	  would	  like	  to	  thank	  Alice	  for	  her	  contribution	  to	  this	  research	  work.	  I	  would	  
also	  like	  to	  thank	  Cori	  and	  Manish	  for	  being	  there	  always	  whenever	  I	  needed	  help	  in	  my	  
research.	   I	  would	   like	   to	   thank	  Anirudha	   for	  his	   support	  and	  guidance	  as	  a	   former	   lab	  
mate.	  	  
I	   would	   like	   to	   thank	   the	   Animal	   House	   Committee	   members	   with	   special	  
mention	  of	  Dr.Blasdel	  and	  Christina	   for	   their	   support	   in	  our	  animal	   related	   research.	   I	  
would	   like	   to	   thank	   Dr.Gao,	   Qi	   and	   LC	   Sciences	   for	   the	   miRNAMicroarray	   services.	   I	  
would	   like	   to	   thank	   UT	   Health	   Science	   Center	   for	   the	   RNA	   illumina	   assay	   and	   MD	  
Anderson	  for	  the	  transgenic	  mice.	  	  	  
My	  parents	  deserve	  special	  mention	   for	   their	   inseparable	  support	  and	  prayers.	  
My	   Father	   and	   mother	   are	   the	   two	   persons	   who	   not	   only	   set	   the	   platform	   for	   my	  
education	   but	   also	   who	   showed	   confidence	   in	   whatever	   decision	   I	   made.	   Thank	   you	  
Achan	   and	   Mummy	   for	   everthing.	   	   Pramila,	   Pinki,	   Chinki,	   Vicky,	   thanks	   for	   being	  
supportive	  and	  caring	  siblings.	  	  
 iv 
Words	  fail	  me	  to	  express	  my	  appreciation	  towards	  my	  wonderful	  husband	  Samit	  
whose	   dedication,	   love	   and	   persistent	   confidence	   in	   me,	   has	   taken	   the	   load	   off	   my	  
shoulder.	   I	  owe	  him	  for	  being	  such	  a	  supportive	  and	  enthusiastic	   life	  partner.	  My	  PhD	  
dissertation	  wasn’t	  possible	  without	  you	  and	  thank	  you	  for	  everthing.	   I	  would	  also	  like	  
to	  thank	  my	  in	  laws,	  Mummy,	  Papa,	  Ma,	  Daddy,	  Bhaiyya,	  Didi	  for	  their	  extended	  support	  
throughout	   these	   years	   of	   research.	   I	   would	   like	   to	   specifically	   mention	   that	   I	   am	  
extraordinarily	   fortunate	   to	   have	   a	  mother	   in	   law	   like	  mine	  whose	  motherly	   support,	  
prayers	   and	   confidence	   has	   helped	   me	   to	   reach	   the	   stage	   of	   completion	   of	   my	  
graduation.	  Thank	  you	  Piku,	  Didu	  and	  my	  sweet	  little	  kiddo,	  Neil.	  Last	  but	  not	  the	  least,	  I	  
would	   like	   to	   thank	  my	  baby,	   Arnavi	  whose	   arrival	   in	  my	   life	   boosted	  my	   energy	   and	  
gave	  me	  all	  the	  strength	  to	  finish	  my	  research	  work.	  Finally	  I	  would	  like	  to	  thank	  God	  for	  















An	  Abstract	  of	  a	  Dissertation	  Presented	  to	  
The	  Department	  of	  Pharmacological	  and	  Pharmaceutical	  Sciences	  




In	  Partial	  Fulfillment	  of	  
The	  Requirement	  for	  the	  Degree	  of	  










Prostacyclin	  (PGI2)	  is	  a	  very	  important	  endogenous	  vascular	  protector.	  It	  provides	  
vascular	   protection	   through	   actions	   like	   vasodilatation,	   platelet	   aggregation	   and	  
vascular	  smooth	  muscle	  cell	  proliferation	   inhibition	  and	  smooth	  muscle	  differentiation	  
regulation.	   Therefore	   since	   decades,	   there	   have	   been	  many	   ongoing	   attempts	   to	   use	  
PGI2	   to	   treat	   vascular	   disorders	   such	   as	   pulmonary	   arterial	   hypertension,	   peripheral	  
artery	   disease	   and	   thrombosis.	   However,	   the	   short	   half-­‐life	   of	   PGI2	   has	   limited	   its	  
therapeutic	  potential.	  
PGI2	   is	   synthesized	   endogenously	   from	   arachidonic	   acid	   using	   enzymes	  
cyclooxygenase	   isoform	   1/2(COX-­‐1/2)	   and	   prostacyclin	   synthase	   (PGIS).	   Single	   gene	  
therapy	   with	   either	   COX	   or	   PGIS	   through	   adenoviral	   vectors	   does	   not	   specifically	  
overproduce	  PGI2	  and	  also	   is	  associated	  with	   inflammatory	   reactions.	  Thus	   to	  address	  
these	   problems,	   our	   lab	   engineered	   a	   single	   hybrid	   gene	   (COX-­‐1-­‐10aa-­‐PGIS)	   by	   fusing	  
COX-­‐1	  with	  PGIS	  through	  transmembrane	  linker	  of	  10	  amino	  acids	  (10aa).	  	  
Adipose	   tissue	  derived	   cells	   have	  been	  used	   therapeutically	   in	   several	   vascular	  
disorders	   due	   to	   their	   regenerative	   properties.	   Thus	  we	   isolated	   and	   cultured	  mature	  
adipocytes	  (MA)	  from	  mouse	  adipose	  tissue	  and	  called	  it	  as	  prostanoid	  synthesizing	  fat	  
cells	  (PSFC).	  Further,	  we	  engineered	  a	  novel	  adipose	  tissue-­‐derived	  cell	  that	  constantly	  
produces	   PGI2,	   through	   transfecting	   of	   the	   engineered	   cDNA	   of	   the	   hybrid	   enzyme	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(human	   COX-­‐1-­‐10-­‐aa-­‐PGIS),	   which	   has	   superior	   triple	   catalytic	   functions	   in	   directly	  
converting	  arachidonic	  acid	  into	  PGI2.	  The	  gene-­‐transfected	  cells	  were	  further	  converted	  
into	   a	   stable	   cell	   line,	   in	  which	   the	   cells	   constantly	   expressed	   the	   hybrid	   enzyme	   and	  
were	  capable	  of	  overproducing	  specifically	  PGI2	  and	  thus	  we	  called	  this	  cell	  line	  as	  PGI2	  
producing	  PSFC	  (PGI2-­‐PSFC).	  When	  the	  results	  of	  the	  HPLC	  activity	  assay	  and	  LC/MS/MS	  
were	   compared	   between	   just	   vector	   transfected	   (PSFC)	   and	   COX-­‐1-­‐10aa-­‐PGIS	   gene	  
transfected	  cells	   (PGI2-­‐PSFC),	   it	  was	  observed	   that	   the	  majority	  of	   the	  endogenous	  AA	  
metabolism	  shifted	  from	  that	  of	  unwanted	  PGE2	  (in	  PSFC)	  to	  that	  of	  the	  preferred	  PGI2	  
(in	  PGI2-­‐PSFC)	  with	  a	  PGI2/PGE2	   ratio	   change	   from	  0.03	   to	  25.	   The	  PGI2-­‐producing	   cell	  
line	   not	   only	   exhibited	   an	   approximate	   50-­‐fold	   increase	   in	   PGI2	   biosynthesis,	   but	   also	  
demonstrated	   superior	   anti-­‐platelet	   aggregation	   in	   vitro,	   and	   increased	   reperfusion	   in	  
the	  mouse	  ischemic	  hindlimb	  and	  thrombogenesis	  models	  in	  vivo.	  
PGI2	   regulates	   functions	   like	   vascular	   smooth	   muscle	   cell	   differentiation	   and	  
proliferation	  and	  apoptosis.	  These	  actions	  are	  mediated	  through	  the	  PGI2	  receptor	  (IP)	  
and	   nuclear	   receptor,	   peroxisome	   proliferator-­‐activated	   receptors	   (PPAR).	  MicroRNAs	  
(miRNAs),	   which	   are	   negative	   regulators	   of	   gene	   expression,	   also	   regulate	   similar	  
functions	  like	  PGI2.	  PGI2	  regulates	  expression	  of	  genes	  by	  signaling	  through	  PPARs.	  Thus	  
to	  find	  out	  if	  PGI2	  regulates	  gene	  expression	  by	  regulating	  miRNA	  expression	  by	  signaling	  
through	  the	  IP	  and	  PPAR,	  a	  miRNA	  microarray	  analysis	  of	  the	  PGI2-­‐PSFCs	  and	  PSFCs	  was	  
performed.	   Analysis	   of	   the	   results	   obtained	   from	  miRNA	   study,	   revealed	   that	   PGI2	   is	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involved	  in	  regulating	  cellular	  microRNA	  (miRNA)	  expression	  through	  its	  receptors	  in	  the	  
mouse	  adipose	  tissue-­‐derived	  primary	  culture	  cell	  line	  overexpressing	  COX-­‐1-­‐10aa-­‐PGIS	  
(PGI2-­‐PSFC).	  The	  miRNA	  microarray	  analysis	  of	  the	  PGI2-­‐PSFC	  revealed	  a	  significant	  up-­‐
regulation	  (711,	  148b,	  and	  744)	  and	  down-­‐regulation	  of	  miRNAs	  of	  interest,	  which	  were	  
reversed	  by	  antagonists	  to	  the	  IP	  and	  PPARγ	  receptors.	  Furthermore,	  we	  also	  found	  that	  
the	   insulin-­‐mediated	   lipid	   deposition	   was	   inhibited	   in	   the	   PGI2-­‐PSFCs.	   The	   study	   also	  
initiated	   a	   discussion,	   which	   suggested	   that	   the	   endogenous	   PGI2	   inhibition	   of	   lipid	  
deposition	   in	  adipocytes	  could	   involve	  miRNA-­‐mediated	   inhibition	  of	  expression	  of	  the	  
targeted	  genes	  specifically	  of	  Akt1.	  	  
To	   translate	   the	   results	   of	   in	   vitro	   study,	   a	   transgenic	   mouse	   permanently	  
expressing	  the	  COX-­‐1-­‐10aa-­‐PGIS	  gene	  was	  generated.	  This	  genetic	  mouse	  animal	  model	  
was	  used	  to	  study	  the	  effect	  of	  COX-­‐1-­‐10aa-­‐PGIS	  overexpression	  on	  PGI2	  production	  in	  
vivo	   and	   as	  well	   as	   its	   vascular	   protective	   effect.	   The	   transgenic	  mice	  was	   genotyped	  
using	  polymerase	  chain	   reaction	  and	   further	  bred	   to	  develop	  a	  colony	  of	  homozygous	  
transgenic	   mice.	   Quantitative	   PCR	   was	   performed	   to	   distinguish	   between	   the	  
hemizygous	   and	   homozygous	  mice.	   PCR	   and	   imunoblot	   analysis	   of	   all	   the	   organs	   and	  
tissues	   of	   mice	   revealed	   the	   expression	   of	   COX-­‐1-­‐10aa-­‐PGIS	   in	   adipose	   tissue,	   brain,	  
heart	  and	  uterus.	  LC/MS	  analysis	  of	  urine	  and	  plasma	  revealed	  approximately	  five-­‐folds	  
increase	  in	  PGI2	  biosynthesis	  permanently	  in	  vivo.	  The	  animals	  showed	  strong	  resistance	  
to	  photochemical	   induced	  thrombosis.	  They	  produced	  healthy	  pups	  with	  a	  an	   increase	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in	   live	   births	   when	   compared	   to	   the	   wild	   type	   without	   significant	   adverse	   effects	   in	  
development	   and	   functions	   of	   major	   organs	   including	   brain,	   heart,	   kidneys.	   Tail	   cuff	  
method	  was	  used	  to	  measure	  blood	  pressure	  of	   the	  mice	  which	  was	  similar	   to	  that	   in	  
the	  wild	  type.	  	  
Thus	  PGI2-­‐PSFCs	  (therapeutic	  cells)	  can	  be	  used	  as	  cell	  therapy	  as	  an	  alternative	  
to	  adenoviral	  gene	  transfer	   to	   treat	   ischemic	  and	  vascular	  conditions.	  The	  cells,	  which	  
have	   an	   ability	   to	   increase	   the	   biosynthesis	   of	   the	   vascular	   protector,	   PGI2,	   while	  
reducing	   that	   of	   the	   vascular	   inflammatory	   mediator,	   PGE2,	   provide	   a	   dual	   effect	   on	  
vascular	  protection,	  which	   is	  not	  available	  through	  any	  existing	  drug	  treatments.	  Thus,	  
the	  current	   finding	  has	  potential	   to	  be	  an	  experimental	   intervention	   for	  PGI2-­‐deficient	  
diseases,	   such	   as	   pulmonary	   arterial	   hypertension.	   PGI2	   mediated	   gene	   expression	  
regulation	   through	   miRNA	   expression	   regulation	   has	   unraveled	   a	   novel	   signaling	  
mechanism	   for	   PGI2.	   This	   signaling	   could	   exist	   in	   broad	   pathophysiological	   processes	  
involving	  PGI2	  (i.e.	  apoptosis,	  vascular	   inflammation,	  cancer,	  embryo	  implantation,	  and	  
obesity).	  The	   results	   of	   the	   transgenic	   mice	   overexpressing	   COX-­‐1-­‐10aa-­‐PGIS	   and	  
producing	  PGI2	  provides	  the	  first	  evidences	  that	  risk	  of	  stroke	  and	  heart	  diseases	  could	  
be	   reduced	   by	   the	   human	   transgene,	   as	   well	   as	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1.	  INTRODUCTION	  AND	  STATEMENT	  OF	  PROBLEM	  
Prostacyclin	  (PGI2)	  is	  one	  of	  the	  most	  important	  vascular	  prostanoid	  synthesized	  
from	   arachidonic	   acid	   (AA)	   with	   the	   help	   of	   enzymes,	   cyclooxygenase	   (COX)	   and	  
prostacyclin	   synthase	   (PGIS)	   (Moncada	   et	   al.	   1977,	   Majerus	   1983).	   PGI2	   provides	  
vascular	  protection	  through	   inhibition	  of	  platelet	  aggregation,	  vascular	  smooth	  muscle	  
cell	  (VSMC)	  proliferation	  and	  leukocyte	  adhesion	  and	  vasodilation	  (Morita	  I.	  et	  al.	  2002;	  
Hinz	  B	  et	  al.	  2002).	  These	  actions	  of	  PGI2	  oppose	  those	  of	  thromboxane	  (TXA2),	  which	  is	  
a	  stimulator	  of	  platelet	  aggregation,	  VSMC	  proliferation	  and	  vasoconstriction	  (Bunting	  S	  
et	   al.	   1976).	   Thus	   a	   balance	   in	   the	   actions	   of	   PGI2	   and	   TXA2	   helps	   in	   regulating	   the	  
homeostasis	  of	   the	  cardiovascular	   system	   (Moncada	  et	  al.	  1979,	  Cheng	  Y	  et	  al.	  2002).	  
Under	  conditions	  of	  damaged	  endothelium,	  PGI2	  synthesis	  is	  decreased.	  Due	  to	  this,	  the	  
equilibrium	  between	  the	  anti-­‐	  and	  proaggregatory	  effects	   is	  disturbed	  with	  the	  former	  
being	  outweighed	  by	  the	  vasoconstrictive	  and	  proaggregatory	  effects	  of	  TXA2	  produced	  
primarily	   by	   the	   activated	   platelets.	   This	   forms	   the	   basis	   for	   the	   formation	   of	  
atherosclerotic	   plaques	   (Pavel	   et	   al.	   2000).	   Peripheral	   artery	   disease	   like	   critical	   limb	  
ischemia	   is	   a	   consequence	  of	   atherosclerosis.	   The	   vascular	  protective	  effect	  of	   PGI2	   is	  
well	  demonstrated	  in	  atherosclerosis	  studies	  in	  mice.	  In	  this	  study	  mice	  deficient	  in	  the	  
PGI2	  receptor	  (IP	  -­‐/-­‐)	  were	  more	  susceptible	  to	  thrombosis	  (Murata	  et	  al.	  1997),	  intimal	  
hyperplasia	  and	  restenosis	  (Cheng	  et	  al.	  2002)	  and	  reperfusion	  injury	  (Xiao	  et	  al.	  2001).	  
Whereas,	   IP(-­‐/-­‐)	   knockout	  mice	  with	   deletion	   of	   the	   TXA2	   receptor	   (TP)	  were	   rescued	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from	  these	  effects	   (Cheng	  et	  al.	  2002).	   In	  another	   study,	   it	  was	  demonstrated	   that,	   in	  
female	   pre-­‐menopausal	   low	   density	   lipoprotein	   receptor	   (LDL-­‐R)	   knockout,	   the	  
atheroprotective	  effect	  of	  estrogen	  was	  significantly	  reduced	  in	  the	  IP	  (-­‐/-­‐)	  mice	  (Egan	  et	  
al.	  2004).	  Recently,	  studies	  have	  shown	  that	  the	  use	  of	  COX-­‐2	  inhibitors	  in	  inflammation	  
poses	  increased	  risk	  to	  cardiovascular	  diseases	  (Bresalier	  et	  al.	  2005)	  and	  the	  most	  likely	  
reason	  is	  found	  to	  be	  a	  decrease	  in	  COX-­‐2	  mediated	  vascular	  PGI2	  production	  without	  a	  
concomitant	  change	  in	  TXA2	  levels	  thus	  disturbing	  the	  balance.	  With	  the	  knowledge	  of	  
the	   importance	   of	   TXA2/	   PGI2	   balance	   in	   the	   pathogenesis	   of	   atherosclerosis	   and	   the	  
vascular	   protective	   actions	   of	   PGI2,	   PGI2	   and	   its	   analogues	   have	   been	   used	   to	   treat	  
pulmonary	   arterial	   hypertension	   (Hinderliter	   et	   al.,	   1997),	   atherosclerosis,	   peripheral	  
vascular	  diseases	  (Pavel	  et	  al.,	  2000,	  Berman	  et	  al.,	  2006),	  and	  congestive	  heart	  failure	  
(Kerbaul	  et	  al.,	  2007).	  The	  administration	  of	  a	  PGI2	  analog	  is	  one	  of	  the	  most	  widely	  used	  
treatments	   for	   Pulmonary	  Artery	  Hypertension	   (PAH)	   and	   has	   been	   associated	  with	   a	  
reduction	  in	  PAH-­‐associated	  mortality	  (Olschewski	  et	  al.,	  2002,	  Simonneau	  et	  al.,	  2002).	  
Thus	   inspite	  of	  having	  cardioprotective	  properties,	   still	   the	  use	  of	   these	  compounds	   is	  
limited	  due	  to	  their	  short	  half	  and	  therefore	  frequent	  administration	  for	  long	  term	  care.	  	  
During	   recent	   studies,	   PGIS	   gene	   transfer	   could	   significantly	   (although	  
temporarily)	   increase	   the	   PGI2	   serum	   levels	   and	   improve	   hemodynamics	   in	   animal	  
models	  (Geraci	  et	  al.,	  1999;	  Nagaya	  et	  al.,	  2000;	  Tahara	  et	  al.,	  2004;	  Suhara	  et	  al.,	  2002).	  
Nevertheless,	   the	  effective	  and	   stable	  biosynthesis	  of	  PGI2	   requires	  an	   increase	   in	   the	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expression	   of	   COX	   coordinated	  with	   PGIS	   since	   COX	   is	   a	   rate-­‐limiting	   enzyme	   in	   PGI2	  
biosynthesis.	   Therefore,	   the	   discovery	   of	   a	   system	   that	   specifically	   increases	   PGI2	  
biosynthesis	   endogenously	   is	   critical	   for	   developing	   a	   preventive	   and	   therapeutic	  
intervention	  against	  vascular	  and	  heart	  diseases.	  Recently,	   the	   specific	  biosynthesis	  of	  
PGI2	   in	   cells	   has	   been	   achieved	   and	   investigated	   through	   our	   engineering	   of	   a	   novel	  
enzyme	   which	   linked	   COX-­‐2	   to	   PGIS,	   and	   contains	   unique	   triple-­‐catalytic	   (Trip-­‐cat)	  
functions	  to	  effectively	  convert	  arachidonic	  acid	  (AA)	  into	  PGI2	  (Ruan	  et	  al.,	  2006).	  The	  
engineered	  enzyme	  was	  termed	  the	  Trip-­‐cat	  enzyme-­‐2.	  Transient	  expression	  of	  the	  Trip-­‐
cat	  enzyme-­‐2	  in	  HEK293	  cells	  could	  specifically	  direct	  AA	  metabolism	  into	  PGI2	  to	  form	  
PGI2-­‐producing	  HEK293	  cells	   (Ruan	  et	  al.,	  2006).	  Thus	  this	   indicated	  that	  we	  could	  use	  
this	  triple	  catalytic	  enzyme	  as	  gene	  therapy	  to	  treat	  vascular	  disorders.	  Further	  our	  lab	  
reengineered	  the	  triple	  catalytic	  enzyme-­‐1	  by	  linking	  COX-­‐1	  instead	  of	  COX-­‐2	  with	  PGIS.	  
We	  selected	  COX-­‐1	  instead	  of	  COX-­‐2	  isoform	  because	  COX-­‐1	  is	  a	  house	  keeping	  enzyme	  
having	   less	   pathological	   impacts	   and	   could	   be	   safer	   for	   gene	   and	   cell	   therapies	  
compared	  with	  COX-­‐2,	  which	  has	  been	  associated	  with	  pathological	  conditions,	  such	  as	  
inflammation	  and	  cancer.	  Thus	  we	  hypothesized	  that	  introducing	  this	  gene	  (COX-­‐1-­‐10aa-­‐
PGIS)	   in	   vivo	  will	   lead	   to	   the	   specific	   upregulation	   of	   PGI2	   production,	   thus	   playing	   a	  
protective	   role	   in	   various	   vascular	  disorders.	  Viral	   vectors	   are	   generally	  used	   for	   gene	  
transfer	   but	   their	   disadvantages	   are,	   transient	   gene	   expression,	   vector	   induced	  
cytotoxicity	  and	   immune	  response	  with	  the	  second	  dose	  (Thomas	  et	  al.,	  2003).	  So	  the	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question	   was	   how	   to	   transfer	   the	   fusion	   gene	   through	   non-­‐viral	   vectors?	   Several	  
endothelial	  progenitor	  cells,	  stem	  cells,	  stromal	  cells	  etc.	  have	  been	  used	  as	  cell	  therapy	  
in	   peripheral	   artery	   disease	   to	   promote	   therapeutic	   angiogenesis	   and	   increase	   blood	  
flow	   in	   the	   limbs	   (Tateishi-­‐Yuyama	  et	  al.,	   2002,	  Miyamoto	  et	  al.,	   2006).	  Recently,	   it	   is	  
been	   reported	   that	   adipose	   tissue	   provides	   with	   a	   wide	   array	   of	   cells,	   which	   can	   be	  
easily	  cultured	  by	  using	  standard	  methods	  (Gimble	  et	  al.,	  2003,	  Miranville	  et	  al.,	  2004,	  
Miyahara	  et	   al.,	   2006,	   Planat-­‐Benard	  et	   al.,	   2002).	   It	   has	   recently	   been	  demonstrated	  
that	   activation	   of	   the	   (COXs)/PGI2/peroxisome	   proliferators-­‐activated	   receptor	   δ	  
(PPARδ)	  pathway	  is	  an	  important	  mechanism	  underlying	  the	  proangiogenic	  function	  of	  
progenitor	   cells	   (Santhanam	   et	   al.,	   2007,	   He	   T	   et	   al.,	   2008).	   Thus	   isolation,	   culture,	  
enzyme	   activity	   assay	   and	   LC/MS	   analysis	   of	   mature	   adipocytes	   (MA)	   from	   mouse	  
adipose	  tissue,	  showed	  that	  MA	  had	  the	  potential	  to	  convert	  endogenous	  AA	  into	  PGE2.	  
These	   observations	   prompted	   us	   to	   think	   that	   if	   these	   cells	   can	   be	   converted	   into	  
therapeutic	   cells	   producing	   PGI2	   by	   overexpressing	   COX-­‐1-­‐10aa-­‐PGIS	   in	  MA.	   Then	   we	  
can	   use	   these	   cells	   as	   a	   medium	   to	   transfer	   the	   triple	   catalytic	   gene-­‐1.	   Further	   we	  
propose	  to	  study	  the	  vascular	  protective	  effect	  of	  this	  PGI2	  producing	  therapeutic	  cells	  in	  
both	  the	  mouse	  hindlimb	  ischemia	  and	  thrombogenesis	  models.	  Moreover,	   it	  can	  be	  a	  
new	  generation	  of	  cDNA	  for	  COX	  gene	  therapy.	   It	   is	  particularly	   interesting	  that	  COX-­‐2	  
inhibitors	   inhibit	   COX-­‐2	   activity	   but	   not	   the	   COX-­‐1	   activity;	   thus,	   introduction	   of	   the	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COX-­‐1-­‐linker-­‐PGIS	  to	  cardiovascular	  systems	  can	  potentially	  overcome	  the	  side	  effects	  of	  
the	  COX-­‐2	  inhibitors	  that	  cause	  damage	  to	  cardiovascular	  functions.	  	  
PGI2	  released	  from	  endothelial	  cells,	  acts	  in	  an	  autocrine	  and	  paracrine	  manner	  
to	   interact	   with	   the	   cell	   surface	   Gs-­‐protein	   coupled	   PGI2	   receptor	   IP,	   expressed	   on	  
platelets	   and	   vascular	   smooth	  muscle	   cells	   (Hara	   et	   al.,	   1995,	  Boie	   et	   al.,	   1994).	   This	  
leads	   to	   the	   activation	   of	   adenylyl	   cyclase,	   accumulation	   of	   the	   second	   messenger	  
cAMP,	   and	   activation	   of	   its	   main	   intracellular	   effector,	   the	   cAMP-­‐dependent	   protein	  
kinase,	   PKA	   (Tateson	   et	   al.,	   1977,	   Jaschonek	   et	   al.,	   1988,	   Stitham	   et	   al.,	   2004).	   IP	  
activation	  inhibits	  platelet	  aggregation	  in	  response	  to	  TXA2,	  inhibits	  VSMC	  proliferation	  
and	  migration,	  and	  promotes	  VSMC	  differentiation	  and	  vasodilation	  (Samuelsson	  et	  al.,	  
1978).	  Both	  COX	  and	  PGIS	  have	  shown	  to	  be	  localized	  not	  only	  at	  endoplasmic	  reticular	  
membranes	  but	   also	  at	  nuclear	  membrane	   (Liou	  et	  al.,	   2000,	   Smith	  et	  al.,	   1983).	   This	  
suggests	  that	  PGI2	  might	  have	  dual	  signaling	  pathways,	  one	  using	  cell	  surface	  IP	  receptor	  
and	  other	  using	  nuclear	  receptors.	  Peroxisome	  proliferators-­‐activated	  receptors	  (PPARs)	  
belong	  to	  a	  family	  of	  nuclear	  receptors,	  which	  are	  ligand-­‐activated	  transcription	  factors.	  
They	   heterodimerize	  with	   a	   retinoid	   X	   receptor	   and	   bind	   to	   peroxisome	   proliferators	  
response	  element	  in	  the	  promoter	  site	  of	  the	  target	  gene	  and	  regulate	  its	  transcription	  
(Kliewer	  et	  al.,	  1992,	  Robyr	  et	  al.,	  2000).	  The	  PPAR	  family	  includes	  three	  isoforms,	  α,	  δ	  
(β)	   and	  γ	   (Braissant	  et	  al.,	   1996,	  Kliewer	  et	  al.,	   1994),	  which	  are	  activated	  by	  a	  broad	  
spectrum	  of	   ligands.	   These	   include	  metabolites	  of	   the	  COX	  and	   lipoxygenase	  pathway	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and	   hypolipidemic	   agents	   eg.	   fibrates,	   which	   regulate	   inflammation,	   lipid	  metabolism	  
and	   insulin	   sensitivity	   (Forman	  et	  al.,	  1997,	  Becker	  et	  al.,	  2006,	   Lefebvre	  et	  al.,	  2006).	  
PPARγ,	  which	  is	  mostly	  expressed	  in	  the	  adipose	  tissue,	  large	  intestine,	  and	  spleen	  (Fajas	  
et	  al.,	  1997),	  is	  also	  the	  only	  PPAR	  that	  can	  be	  activated	  through	  the	  IP	  using	  stable	  PGI2	  
analogues	   (Falcettia	   et	   al.,	   2007).	   Thus	   prostacyclin	   can	   be	   directly	   related	   to	   lipid	  
metabolism	   through	   the	   IP/PPARγ	   receptor.	   To	   date	   there	   is	   conflicting	   evidence	  
regarding	   a	   PGI2-­‐induced	   increase	   or	   decrease	   in	   adipogenesis	   (Hodnett	   et	   al.,	   2009,	  
Massiera	  et	  al.,	  2003).	  However,	  logically	  an	  early	  loss	  of	  endothelial	  PGI2	  could	  lead	  to	  
adipocyte	   lipid	   deposition	   in	   the	   periphery	   and	   vascular	   smooth	   muscle	   cells	  
(atherosclerosis).	  Currently	  atherosclerosis	  is	  characterized	  by	  inflammation	  that	  causes	  
vascular	  endothelial	  damage	  (Páramo	  et	  al.,	  2008).	  	  The	  first	  step	  in	  the	  development	  of	  
atherosclerosis	  is	  the	  formation	  of	  the	  fatty	  streak.	  The	  current	  accepted	  concept	  is	  that	  
when	  LDL	   levels	   increase,	   they	  accumulate	   in	   the	  arterial	   intima	  and	  get	  oxidized	   into	  
proinflammatory	   particles.	   This	   provokes	   an	   innate	   inflammatory	   reaction	   within	   the	  
intima	  and	  thus	   fat	  droplets	  accumulate	   in	   the	  cytoplasm	  of	  smooth	  muscle	  cells.	  The	  
resulting	   hemodynamic	   stress	   causes	   intimal	   thickening	   of	   the	   artery.	   When	   the	  
monocytes	   enter	   the	   artery,	   they	   transform	   into	   macrophages,	   take	   up	   lipids	   and	  
become	  foam	  cells	  (Stary,	  H.C.	  2003,	  Strong	  et	  al.,	  1999).	  However,	  we	  propose	  that	  the	  
localized	   loss	   of	   the	   autocrine	   and	   the	   paracrine	   effect	   of	   endothelial	   PGI2	   could	   be	  
responsible	  for	  the	  sub-­‐endothelial	  deposition	  of	  lipid	  in	  the	  smooth	  muscle	  cells	  of	  the	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vascular	  walls.	  It	  is	  known	  that	  lipid	  deposition	  in	  the	  vessel	  wall	  begins	  as	  fatty	  streaks	  
at	  a	  very	  early	  age	  (Stary,	  H.C.	  2003,	  Strong	  et	  al.,	  1999).	  This	  could	  represent	  an	  early	  
loss	   of	   PGI2	   paracrine	   function.	  We	   further	   propose	   that	   this	   lipid	   deposition	   can	   be	  
confirmed	  by	   identification	  of	  appropriate	  specific	  proteins	   involved	   in	   the	   lipogenesis	  
pathway.	  Thus	  we	  propose	  that	  PGI2	  through	  PPAR	  receptors	  might	  regulate	  expression	  
of	   genes	   that	   are	   involved	   in	   lipid	   accumulation.	   MicroRNAs	   (miRNAs)	   are	   single-­‐
stranded	  non-­‐coding	  RNAs	  with	  21–24	  nucleotide	  (nt)	  in	  length,	  regulating	  target	  genes	  
expression	   at	   the	   post-­‐transcriptional	   level	   through	   translational	   repression	   or	  mRNA	  
degradation	   (Farh	   et	   al.,	   2005,	   Pasquinelli	   et	   al.,	   2005).	   Thus	   they	   are	   endogenous,	  
negative	   regulators	   of	   gene	   expression,	   which	   are	   involved	   in	   regulation	   of	   cell	  
proliferation/growth,	  mobility,	  differentiation,	  and	  apoptosis	  (Ambros	  V.	  2004,	  Du	  et	  al.,	  
2007,	  Hwang	  et	  al.,	  2006,	  Jovanovic,	  M.,	  and	  Hengartner,	  M.O.	  2006,	  Rane	  et	  al.,	  2007).	  
This	   was	   the	   first	   verification	   that	   endogenous	   PGI2	   could	   inhibit	   lipid	   deposition	   in	  
adipocytes	   possibly	   with	   the	   involvement	   of	   regulating	   miRNA	   expression.	   PGI2	   is	   a	  
mediator	   of	   adipocyte	   differentiation	   (Georges	   et	   al.,	   1992),	   a	   regulator	   of	   smooth	  
muscle	   cell	   differentiation	   (Tsai	   et	   al.,	   2009)	   and	   inhibitor	   of	   their	   proliferation.	   Thus	  
miRNAs	  and	  PGI2	  could	  be	   linked	   together	   through	  their	  common	  functions	  as	  well	  as	  
PGI2	  mediated	  gene	  regulation	  by	  signaling	  through	  PPAR	  receptors.	  However,	  there	  has	  
been	   very	   little	   information	   on	   transcription	   factors	   regulating	   miRNA	   expression	   as	  
their	  expression	  is	  controlled	  in	  a	  very	  tissue	  specific	  and	  development	  specific	  manner.	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To	   date,	   c-­‐Myc,	   cyclic	   AMP	   response	   element	   binding	   protein	   and	   myogenic	  
transcription	  factors	  have	  been	  shown	  to	  regulate	  specific	  miRNAs	  in	  mammalian	  cells.	  
But	   recently	   it	   has	   been	   demonstrated	   that	   PPARα	   is	   a	   bonafide	   regulator	   of	   hepatic	  
miRNA	   expression,	   which	   regulates	   liver	   proliferation	   (Yatrik	   et	   al.,	   2007).	   Thus	   we	  
propose	  to	  uncover	  a	  novel	  finding	  if	  miRNAs	  are	  involved	  in	  PGI2	  mediated	  regulation	  
of	   gene	   expression.	   We	   also	   propose	   to	   identify	   any	   target	   gene	   regulated	   by	   PGI2	  
through	   miRNA	   and	   study	   its	   function	   in	   PGI2	   regulated	   processes	   like	   adipocyte	  
differentiation.	  Our	  PGI2	  producing	  therapeutic	  cells	  can	  be	  very	  good	  in	  vitro	  model	  to	  
study	  the	  effect	  of	  endogenous	  PGI2	  on	  microRNA	  expression.	  	  
Adipose	   tissue	  derived	   fat	  cells	  overexpressing	  COX-­‐1-­‐10aa-­‐PGIS	  and	  producing	  
PGI2	  are	  proposed	  to	  produce	  vascular	  protective	  effect	  in	  mouse	  models	  of	  critical	  limb	  
ischemia	   and	   thrombogenesis.	   Thus,	   with	   the	   objective	   of	   translating	   these	   in	   vitro	  
results	  into	  in	  vivo,	  we	  propose	  to	  generate	  transgenic	  mice	  overexpressing	  the	  COX-­‐1-­‐
10aa-­‐PGIS	  and	  study	  the	  benefits	  and	  risks	  of	  permanently	  upregulating	  PGI2	  synthesis	  
in	  vivo.	  The	  biological	  effects	  of	  genetically	  up-­‐regulated	  PGI2	   in	  vivo	  on	  development,	  
organ	   physiology,	   correction	   for	   induced	   stoke	   and	   heart	   diseases	   and	   reproductive	  
functions	  will	  be	  studied.	  	  
Thus	   we	   hypothesized	   that	   1)	   Mature	   adipocytes	   mediated	   gene	   transfer	   of	  
triple	   catalytic	   enzyme	   (COX-­‐1-­‐10aa-­‐PGIS)	   gene/protein	   in	   tissue	   ischemia	   and	  
thrombogenesis	  will	  provide	  vascular	  protection	  through	  a	  sustained	  release	  of	  PGI2	  	  at	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the	   site	   of	   injury,	   2)	   MicroRNAs	   are	   involved	   in	   PGI2	   mediated	   gene	   expression	  
regulation	   and	   3)	   Transgenic	   mice	   overexpressing	   COX-­‐1-­‐10aa-­‐PGIS	   and	   specifically	  
overproducing	  PGI2	   in	   vivo	   can	  be	   created	  and	  used	  as	   a	  model	   to	   study	   the	   vascular	  
protective	  effect	  of	  PGI2	  .	  
	  
Figure	   1:	   The	   schematic	   of	   the	   introduction	   to	   the	   statement	   of	   problem.	  	  
Overexpression	  of	  COX-­‐1-­‐10aa-­‐PGIS	  gene	   in	  primary	  culture	  of	  mature	  adipocytes	  and	  
mice.	  Therefore	  our	  statement	  of	  problem	  is	   to	  determine	  whether:	  1)	   these	  cells	  can	  
be	   used	   therapeutically	   in	   vascular	   disorder	   through	   overproducing	   PGI2	   2)	   cells	  
producing	   PGI2	   regulate	   gene	   expression	   through	   miRNA	   expression	   regulation	   3)	  
transgenic	  mice	   overproducing	   PGI2	   can	   be	   generated	   and	   used	   as	   a	  model	   to	   study	  
vascular	  protective	  effect	  of	  PGI2.	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2.	  REVIEW	  OF	  LITERATURE	  
	  
2.1.	  Biosynthesis	  of	  Prostacyclin	  
Prostanoids	   are	   cyclic	   lipid	   mediators	   belonging	   to	   the	   superfamily	   of	  
eicosanoids	   (in	   greek	   stands	   for	   20,	   in	   that	   case	   twenty	   carbon	  atoms	   in	   a	  molecule).	  
Prostanoids	   are	   produced	   by	   enzymic	   cyclooxygenation	   of	   linear	   polyunstarated	   fatty	  
acids,	   e.g.	   arachidonic	   acid	   (AA	   or	   5,8,11,14-­‐eicosatetraenoic	   acid).	   Biologically	   active	  
prostanoids	   that	   are	   derived	   from	   AA	   include	   stable	   prostaglandins	   (PG),	   e.g.	   PGE2,	  
PGF2α,	   PGD2,	   PGJ2	   as	   well	   as	   labile	   prostanoids,	   i.e.	   PG	   endoperoxides	   (PGG2,	   PGH2),	  
thromboxane	  A2	  (TXA2)	  and	  prostacyclin	  (PGI2).	  PGI2	  is	  one	  of	  the	  five	  major	  products	  of	  
the	   arachidonic	   acid	  metabolism	   that	   is	   synthesized	   via	   the	   cyclooxygenase	   pathway.	  
Biosynthesis	   of	   prostacyclin	   involves	   3	   steps	   (a)	   stimulus-­‐induced	   mobilization	   of	   AA	  
from	   membrane	   phosphoglycerides	   by	   cytosolic	   phospholipase	   A2	   (cPLA2);	   (b)	  
conversion	   of	   AA	   to	   PGG2	   which	   is	   then	   electron	   reduced	   to	   form	   PGH2	   by	   the	  
cyclooxygenase	   and	   peroxidase	   activities	   of	   cyclooxygenase	   isoform	  1	   or	   2	   (COX-­‐1/2);	  
and	   (c)	  conversion	  of	  PGH2	  to	  PGI2	  by	  prostacyclin	  synthase	   (PGIS)	   (Figure	  1).	   	  PGH2	   is	  
also	   isomerized	   to	   other	   biologically	   active	   prostanoid	   end-­‐products,	   (including	  
prostaglandin	  D2	   (PGD2),	  E2	   (PGE2),	   F2	   (PGF2),	  or	  TXA2	  by	   individual	   synthases	   in	   tissue	  
specific	  manners	   (Figure	  1)	   (Needleman	  et	  al.,	  1986,	  Ruan	  et	  al.,	  2006).	  Prostacyclin	   is	  
the	  major	  AA	  metabolite	  of	  the	  vascular	  tissue	  and	  its	  synthesis	  is	  greatest	  at	  the	  intimal	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surface	   (endothelial	   cells)	   and	   gradually	   decreases	   towards	   the	   adventitia	   (vascular	  
smooth	  muscle	  cells)	   (Moncada	  et	  al.,	  1977).	  PGI2	  has	  a	  very	  short	  half	   life	   in	  vivo	   (<2	  
min)	  due	  to	  its	  instability	  at	  physiological	  pH	  and	  the	  inactive	  metabolite	  formed	  is	  the	  
6-­‐keto-­‐prostaglandin	  F1α	  (6-­‐keto-­‐PGF1α;	  Lewis	  et	  al.,	  1983,	  Smyth	  et	  al.,	  2002).	  	  
	  
Figure	   2.	   Biosynthesis	   of	   prostanoids,	   comprising	  of	   prostaglandins	   and	   thromboxane.	  
Arachidonic	  acid	  (AA)	  released	  from	  membrane	  phosphoglycerides	  by	  cPLA2	  is	  converted	  
to	   PGG2,	   which	   is	   further	   metabolized	   to	   PGH2	   by	   COX-­‐1/COX-­‐2.	   PGH2	   is	   further	  
isomerized	  to	  downstream	  PGs	  like	  PGI2,	  TXA2,	  PGE2,	  PGF2	  and	  PGD2	  by	  their	  respective	  
cell	  specific	  downstream	  enzymes.	  
	  
2.2.	  Cyclooxygenase	  1	  and	  2	  (COX-­‐1	  and	  COX-­‐2)	  
The	   COX	   enzymes	   are	   bisfunctional	   proteins,	   possessing	   both	   cyclooxygenase	  
and	   hydroperoxidase	   (HOX)	   activities	   (Smith	   et	   al.,	   2002).	   The	   two	   COX	   enzymes	   are	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encoded	  by	  separate	  genes	  located	  on	  different	  chromosomes	  (Ch1	  for	  COX-­‐2	  and	  Ch9	  
for	  COX-­‐1)	  (Funk	  et	  al	  1991,	  Xie	  et	  al	  1993),	  but	  nevertheless	  serve	  the	  same	  biosynthetic	  
function	   of	   oxygenation	   of	   AA	   into	   PG	   endoperoxide	   intermediates	   PGG2	   and	   PGH2	  
(Smith	  et	  al.,	  1996,	  Smith	  et	  al	  1997,	  Smith	  et	  al.,	  2002).	  COX-­‐1	  is	  a	  house-­‐	  keeping	  gene	  
that	   regulates	   kidney	   and	   stomach	   function	   and	   maintains	   vascular	   homeostasis	   by	  
producing	  prostaglandins	   in	   response	   to	   circulating	  hormones.	  COX-­‐1	   is	   referred	   to	  as	  
the	  constitutive	  form	  (DeWitt	  et	  al.,	  1991)	  as	  its	  expression	  remains	  unchanged	  in	  most	  
tissues	   and	   pathologies	   during	   the	   inflammatory	   reaction	   or	   as	   a	   result	   of	   hormonal	  
stimulation	  (Smith	  et	  al	  1993,	  Brannon	  et	  al	  1994,	  and	  Mroske	  et	  al.,	  2000).	  In	  contrast	  
COX-­‐2	   is	   the	   inducible	   form	   of	   the	   gene	   whose	   expression	   is	   low	   or	   undetectable	   in	  
almost	   all	   of	   the	   tissues	   or	   cells	   but	   is	   increased	   dramatically	   upon	   stimulation,	  
particularly	  during	   inflammation	  by	   inflammatory	   cytokines	  and	  mitogens	   (Herschman	  
1999).	  Both	  COX	  enzymes	   share	   a	   hydrophobic	   tunnel	   that	   affords	   access	   of	   the	   lipid	  
substrate	   to	   the	   active	   site,	   deep	   within	   the	   proteins.	   However,	   the	   COX-­‐2	   tunnel	   is	  
more	  accomadating	  and	  also	  has	  a	  side	  pocket	  that	  is	  not	  present	  in	  COX-­‐1.	  This	  helps	  
COX-­‐2	   to	   have	   broader	   substrate	   recognition	   and	   also	   is	   the	   reason	   for	   the	   ability	   of	  






2.3.	  Prostacyclin	  Synthase	  (PGIS)	  gene	  transfer	  studies	  
Prostacyclin	  synthase	  (PGIS),	  a	  heme	  protein	  is	  a	  membrane-­‐associated	  P450-­‐like	  
enzyme	  that	  has	  a	  molecular	  mass	  of	  52	  kDa	  (DeWitt	  et	  al.,	  1983).	   	   It	   lacks	  the	  typical	  
CYP	  monoxygenase	  activity	  but	  catalyzes	  the	  conversion	  of	  prostaglandin	  H2	   (PGH2)	   to	  
prostacyclin	   (Ullrich	   et	   al.,	   1981,	  Moncada	   et	   al.,	   1979).	   PGIS	   catalytic	   activity	   is	   lost	  
after	   nitration	   of	   the	   Tyr-­‐430	   residue	   by	   peroxynitrite	   (Schmidt	   et	   al.,	   2003).	   PGIS	   is	  
constitutively	  expressed	  in	  vascular	  endothelial	  cells	  and	  smooth	  muscle	  cells	  and	  non-­‐
vascular	  cells	  like	  neurons,	  oviducts,	  embryonic	  cells,	  and	  cancer	  cells	  (Wu	  et	  al.,	  2005).	  
PGIS	   is	   colocalized	  with	   COX-­‐1	   in	   resting	   endothelial	   cells	   (EC)	   and	   is	   also	   colocalized	  
with	  COX-­‐2	   in	  EC	  stimulated	  by	  PMA	  (Liou	  et	  al.,	  2000).	  There	  are	  several	  studies	  that	  
have	   provided	   evidence	   for	   an	   important	   role	   of	   PGIS	   in	   vascular	   integrity.	   PGIS	  
deficiency	   plays	   a	  major	   role	   in	   diverse	   diseases	   including	   arterial	   intimal	   hyperplasia	  
(Yokoyama	  et	  al.,	  2002),	  pulmonary	  hypertension	  (Tuder	  et	  al.,	  1999),	  tissue	  infarction,	  
atherosclerotic	  arterial	  diseases	  and	  endothelial	  dysfunction.	   	  A	  reduced	  expression	  of	  
PGIS	  is	  associated	  with	  reduced	  synthesis	  and	  activity	  of	  prostacyclin	  thus	  contributing	  
to	  an	   imbalance	  between	  prostacyclin	  and	  thromboxane	  actions.	   It	   is	   therefore	   logical	  
to	  consider	  gene	  transfer	  for	  enhancing	  PGI2	  synthesis.	   	  Transfection	  of	  the	  PGIS	  cDNA	  
into	   rat	   vascular	   smooth	   muscle	   cells	   resulted	   in	   an	   increased	   PGI2	   synthesis	   and	  
inhibition	  of	  cell	  proliferation	  suggesting	  that	  in	  vivo	  gene	  transfer	  of	  PGIS	  may	  be	  useful	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for	   gene	   therapy	   in	   vascular	   diseases	   (Hara	   et	   al.,	   1995).	   Overexpression	   of	   PGIS	   in	  
carotid	  arteries	  of	  experimental	  animals	  using	  adenoviral	  vector	  or	   liposome-­‐mediated	  
transfer	  of	  PGIS	  cDNA	  has	  been	  shown	  to	  prevent	  intimal	  hyperplasia	  induced	  by	  carotid	  
injury	  (Todaka	  et	  al.,	  1999).	  This	  effect	  was	  reported	  to	  be	  associated	  with	  increased	  6-­‐
keto-­‐PGF1α	   productions,	   the	   stable	   metabolite	   of	   PGI2	   (Numaguchi	   et	   al.,	   1999).	  
Repeated	  injection	  of	  PGIS	  cDNA	  into	  rat	  skeletal	  muscle	  of	  a	  pulmonary	  hypertension	  
rat	  model	  is	  associated	  with	  an	  increased	  level	  of	  PGI2	  effective	  in	  controlling	  pulmonary	  
hypertension	   and	   vascular	   remodeling	   (Tahara	   et	   al.,	   2004).	   In	   vivo	   injection	   of	  
adenovirus-­‐COX-­‐1	   into	   carotid	   arteries	   increases	   PGI2	   levels	   and	   prevents	   thrombus	  
formation	  in	  a	  porcine	  model	  (Zoldhelyi	  et	  al.,	  1996).	  But	  overexpression	  of	  PGIS	  alone	  
cannot	   contribute	   to	   an	   optimal	   PGI2	   production.	   Data	   from	   PGIS	   overexpression	  
experiments	  have	  provided	  several	  important	  insights	  into	  PGI2	  biosynthesis.	  One	  of	  the	  
important	   observations	   is	   that	   PGI2	   synthesis	   is	   not	   determined	   by	   the	   level	   of	   PGIS	  
expression	  alone	  but	  by	  an	  appropriate	  ratio	  of	  COX-­‐1/COX-­‐2	  to	  PGIS	  expression.	  	  It	  has	  
been	   reported	   that	   bicistronic	   COX-­‐1	   and	   PGIS	   gene	   transfer	   resulted	   in	   selective	  
augmentation	   in	   the	   PGI2	   synthesis	   without	   concurrent	   increase	   in	   other	   prostanoids	  
(Shyue	   et	   al.,	   2001,	   Heng	   et	   al.,	   2002).	   Thus	   overexpression	   of	   PGIS	   with	   concurrent	  
COX-­‐1	   overexpression	   is	   highly	   effective	   in	   controlling	   vascular	   diseases.	   PGI2	  
biosynthesis	   is	   upregulated	   and	   thus	   associated	  with	   an	   increase	   in	   the	   expression	   of	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PGIS	   coordinated	   with	   COX-­‐2	   expression	   during	   embryo	   implantation	   and	  
decidualization	  (Lim	  et	  al.,	  1999).	  	  
	  
2.4.	  Prostacyclin	  pharmacology	  and	  signaling	  
PGI2	   released	   from	   the	   endothelial	   cells,	   acts	   in	   an	   autocrine	   and	   paracrine	  
manner	  to	  interact	  with	  the	  cell	  surface	  G-­‐protein	  coupled	  receptor	  (GPCR)	  referred	  to	  
as	  the	   IP	  receptor	  (IP-­‐International	  Union	  of	  Pharmacology	  nomenclature)	  on	  platelets	  
and	   vascular	   smooth	   muscle	   cells	   (Boie	   et	   al.,	   1994).	   The	   IP	   receptor	   couples	  
predominantly	  to	  the	  Gs	  subunit	  of	  the	  heterotrimeric	  G-­‐protein	  and	  causes	  activation	  
of	  adenylyl	  cyclase	  and	  cyclic	  AMP	  (cAMP)	  production	  (Boie	  et	  al.,	  1994)	  which	  in	  turn	  
activates	  the	  intracellular	  effector	  protein	  kinase	  A	  (PKA).	   IP	  activation	  inhibits	  platelet	  
aggregation	   and	   produces	   vasodilation	   (Smyth	   et	   al.,	   2009),	   inhibits	   vascular	   smooth	  
muscle	  cell	  (VSMC)	  proliferation	  and	  de-­‐differentiation	  (Fetalvero	  et	  al.,	  2006,	  2007).	  In	  
the	  pulmonary	  vasculature,	  PGI2	  reduces	  pulmonary	  blood	  pressure	  as	  well	  as	  bronchial	  
hyperesponsiveness	   (Idzko	   et	   al.,	   2007).	   Both	   COX	   and	   PGIS	   are	   localized	   not	   only	   at	  
endoplasmic	   reticular	   membranes	   but	   also	   at	   nuclear	   membrane	   (Liou	   et	   al.,	   2000,	  
Smith	  et	   al.,	   1983).	   At	   high	   concentrations	   prostacyclin	   agonists	   can	   also	   activate	   the	  
nuclear	  receptors	  such	  as	  the	  peroxisome	  proliferator	  activated	  receptor	  (PPAR)	  (Lim	  et	  
al.,	   2002).	   Peroxisome	   proliferators-­‐activated	   receptors	   (PPARs)	   belong	   to	   a	   family	   of	  
nuclear	  receptors,	  which	  are	  ligand-­‐activated	  transcription	  factors.	  It	  has	  been	  reported	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that	   PGI2	   other	   than	   binding	   to	   IP	   receptor,	   also	   activates	   PPARδ.	   This	   activation	  
regulates	  actions	   like	  embryo	   implanatation,	   vascular	   functions,	   and	  apoptosis	   (Lim	  et	  
al.,	  1999,	  Zhang	  et	  al.,	  2002,	  Hatae	  et	  al.,	  2001).	  Stable	  PGI2	  analogues	  like	  iloprost	  and	  
carbacyclin,	  directly	  bind	  to	  and	  cause	  transcriptional	  activation	  of	  PPARα	  and	  PPARδ	  in	  
vitro	   (Forman	   et	   al.,	   1997).	   The	   anti-­‐	   proliferative	   effects	   of	   treprostinil	   in	   lung	  
fibroblasts	  may	  in	  part	  be	  due	  to	  PPARδ	  activation.	  PGI2	  analogues	  produce	  IP	  receptor	  
dependent	   PPARγ	   receptor	   activation	   (Falcettia	   et	   al.,	   2007).	   PPARγ	   is	   an	   important	  
regulator	  of	  cell	  differentiation	  and	  growth,	  particularly	  in	  the	  lung	  (Becker	  et	  al.,	  2006),	  
and	  therefore	  loss	  or	  dysfunctionality	  of	  the	  IP	  receptor	  could	  alter	  the	  control	  of	  these	  
processes.	   Vascular	   inflammation	   is	   one	   of	   the	   primary	   causes	   of	   atherosclerosis.	  
Cytokines	  such	  as	  tumor	  necrosis	  factor	  α	  released	  during	  inflammation	  stimulates	  the	  
biosynthesis	  of	  PGI2	  and	  upregulation	  of	  PPARδ	  in	  vascular	  smooth	  muscle	  cells.	  Thus,	  it	  
has	   been	   proposed	   that	   PGI2	   by	   acting	   as	   a	   ligand	   for	   PPARδ,	   might	   release	   a	  
transcriptional	  repressor	  of	   inflammation	  which	   in	  turn	  might	   inhibit	  the	   inflammatory	  
proliferation	   of	   vascular	   smooth	  muscle	   (Ruan	  et	   al.,	   2006).	   Thus	   PGI2	  might	   regulate	  
gene	  expression	  through	  PPAR	  receptors.	  
	  
2.5.	  Balance	  between	  PGI2	  and	  TXA2	  mediates	  vascular	  homeostasis	  
Recent	  reports	  of	  the	  withdrawal	  of	  COX-­‐2	  inhibitors	  (e.g	  Vioxx)	  due	  to	  increased	  
cardiovascular	   risks	  associated	  with	   their	  use	  has	  highlighted	  the	  cardioprotective	  role	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of	  prostacyclin	  (Wong	  et	  al.,	  2005).	  Studies	  of	  the	  selective	  COX-­‐2	  inhibitors	  suggest	  that	  
a	   balance	   between	   thromboxane	   (TXA2)	   and	   prostacyclin	   is	   a	   critical	   factor	   in	   the	  
regulation	   of	   cardiovascular	   homeostasis	   and	   disturbances	   of	   this	   balance	   might	  
underlie	   some	   forms	   of	   vascular	   pathology	   (Moncada	   et	   al.	   1976a).	   	   The	   finding	   that	  
small	  doses	  of	  aspirin	  is	  an	  effective	  anti-­‐thrombotic	  treatment	  came	  from	  the	  research	  
originating	  from	  the	  concept	  of	  the	  balance	  between	  PGI2	  and	  TXA2.	  TXA2	  derived	  from	  
the	  COX-­‐1	  catalyzed	  arachidonic	  acid	  metabolism	  in	  the	  platelets	  is	  a	  potent	  activator	  of	  
platelets	   and	   a	   vasoconstrictor	   wheras	   PGI2	   inhibits	   these	   actions	   of	   TXA2	   through	  
platelet	  aggregation	   inhibition	  and	  vasodilation	   (FitzGerald	  et	  al.,	  1991,	  Samuelsson	  et	  
al.,	   1978).	   Genetic	   deletion	   of	   both	   the	   TXA2	   (TP)	   and	   IP	   receptor	   in	   mice	   provided	  
evidence	   that	   PGI2	   regulates	   cardiovascular	   homeostasis	   by	   opposing	   the	   actions	   of	  
TXA2.	  Neointimal	  proliferation	  was	  induced	  in	  both	  IP	  knockout	  (-­‐/-­‐)	  and	  wild	  type	  mice	  
after	  catheter	  induced	  carotid	  artery	  injury	  but	  a	  more	  enhanced	  proliferative	  response	  
was	  observed	  in	  IP	  (-­‐/-­‐)	  mice.	  Also	  this	  proliferative	  response	  of	  the	  carotid	  artery	  after	  
injury	  was	   reduced	   after	   deletion	   of	   the	   TP	   receptor	   (Cheng	  et	   al.,	   2002).	   Thus	   these	  
studies	  indicated	  that	  the	  cardiovascular	  effects	  of	  TXA2	  are	  regulated	  by	  the	  actions	  of	  
PGI2	   in	   the	   vasculature.	   The	   undesirable	   effects	   of	   the	   selective	   COX-­‐2	   inhibitors	   are	  
explained	  on	  the	  basis	  of	  an	  imbalance	  theory	  between	  TXA2	  and	  PGI2.	  According	  to	  this	  
theory	  selective	   inhibition	  of	  COX-­‐2	   leads	  to	  a	  reduction	   in	  the	  production	  of	  the	  anti-­‐
atherogenic	   PGI2	   while	   production	   of	   the	   COX-­‐1	   derived	   atherogenic	   TXA2	   remains	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unaltered.	  	  This	  shifting	  of	  the	  balance	  between	  these	  two	  prostanoids	  in	  favor	  of	  TXA2	  
disrupts	  the	  vascular	  homeostasis	  and	  increases	  the	  susceptibility	  to	  thrombosis	  and	  the	  
onset	  and	  progression	  of	  atherosclerosis	  (Wong	  et	  al.,	  2005).	  
	  
2.6.	  Role	  of	  PGI2	  in	  Pulmonary	  Hypertension	  
Pulmonary	   arterial	   hypertension	   (PAH)	   is	   characterized	   by	   pulmonary	  
vasoconstriction,	   VSMC	   proliferation,	   endothelial	   loss	   or	   dysfunction	   and	   thrombosis	  
(Faber	   et	   al.,	   2004).	   The	   vascular	   changes	   that	   occur	   in	   PAH	   has	   at	   least	   in	   part	  
attributed	  to	  disruption	   in	  the	  balance	  of	  PGI2	   to	  TXA2	  ratio.	   It	  has	  been	  found	  that	   in	  
PAH	  patients,	  the	  expression	  of	  prostacyclin	  synthase	  within	  the	  pulmonary	  arteries	  as	  
well	  as	  6-­‐keto-­‐PGF1α	  (metabolite	  of	  PGI2)	   in	  the	  urine	  was	  decreased	  whereas	  levels	  of	  
TXB2	   (thromboxane	  metabolite)	  were	   increased	   (Christman	   et	   al.,	   1992).	   Owing	   to	   its	  
potent	  vasodilatory,	  anti-­‐thrombotic	  and	  antiproliferative	  effects,	  PGI2	  and	  its	  analogues	  
have	  been	  effectively	  used	  in	  the	  treatment	  of	  PAH.	  Continous	  intravenous	  prostacyclin-­‐
analog	  epoprostenol	   (FlolanTM)	  has	  been	  used	  as	  a	   first	   line	  agent	   to	   improve	  overall	  
symptoms	  and	  hemodynamics	  and	  increase	  exercise	  tolerance	  in	  PAH	  patients	  (Barst	  et	  
al.,	  2009).	  However,	  due	  to	  epoprostenol’s	  short	  half-­‐life	  (3-­‐5	  min)	  and	  instability	  at	  low	  
pH,	  long	  term	  use	  requires	  a	  permanent	  venous	  catheter	  and	  a	  portable	  infusion	  pump	  
which	   is	   associated	   with	   side-­‐effects	   such	   as	   bleeding	   and	   catheter-­‐related	   sepsis	  
(Sitbon	   et	   al.,	   2002).	   New	   prostacyclin	   analogs	   have	   been	   developed	   as	   alternative	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therapy	  administered	  via	  different	  routes	   like	  subcutaneous	  treprostinil	   (Simonneau	  et	  
al.,	   2002),	   oral	   beraprost	   (Galie	   et	   al.,	   2002),	   and	   inhaled	   iloprost	   (Olschewski	   et	   al.,	  
2002,	  Hoeper	  et	  al.,	  2000).	  These	  drugs	  are	  more	  stable	  with	   long	  half-­‐lives,	  but	  have	  
variable	  safety	  and	  clinical	  efficacy	  in	  comparison	  to	  epoprostenol	  (Barst	  et	  al.,	  1996).	  	  
Recently,	  endogenous	   lung	   tissue	  content	  of	  PGI2	  metabolite	  6-­‐keto	  PGF1α	  was	  
successfully	   increased	   through	   gene	   therapy.	   When	   the	   human	   PGIS	   gene	   was	  
intratracheally	  transfected	  into	  the	  lungs	  of	  rats	  with	  monocrotaline-­‐induced	  pulmonary	  
hypertension,	   high	   levels	   of	   PGIS	   expression	   and	   PGI2	   production	   were	   found	   in	   the	  
bronchial	   epithelial	   cells.	   In	   these	   animals,	   the	  mean	  pulmonary	   arterial	   pressure	   and	  
total	   pulmonary	   resistance	   was	   significantly	   attenuated	   (Nagaya	   et	   al.,	   2000).	   Given	  
these	  results,	  in	  the	  future	  gene	  transfer	  may	  be	  a	  potential	  candidate	  as	  an	  alternative	  
for	  continuous	  intravenous	  PGI2	  infusion	  for	  PAH	  patients.	  	  
	  
2.7.	  Role	  of	  PGI2	  in	  Atherosclerosis	  
Atherosclerosis	   is	   a	   complex	   cardiovascular	   disease	   characterized	   by	  
inflammation,	   endothelial	   dysfunction,	   lipid	   accumulation,	   cell	   death	   and	   fibrosis	  
(Hanson	  et	  al.,	  2006).	  Prostaglandins	  in	  atherosclerosis	  antagonize	  each	  others	  actions.	  
TXA2	   and	   PGE2	   have	   atherogenic	   effects	   whereas	   PGD	   and	   PGI2	   are	   antiatherogenic.	  	  
PGI2	   protects	   from	   atherothrombosis	   by	   inhibiting	   platelet	   activation,	   leukocyte	  
adhesion,	  and	  VSMC	  modulation	  like	  dedifferentiation,	  proliferation	  and	  migration.	  The	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imbalance	   theory	   between	   PGI2	   and	   TXA2	   also	   explains	   the	   pathophysiology	   of	  
atherosclerosis.	   PGI2	   has	   been	   reported	   to	   induce	   cholesterol	   ester	   hydrolase	   activity	  
that	  catalyzes	  the	  first	  step	  in	  the	  removal	  of	  cholesterol	  from	  the	  foam	  cells	  (Hajjar	  et	  
al.,	  1983).	  Circulating	  high	  density	  lipoprotein	  induces	  the	  expression	  of	  COX-­‐2	  and	  thus	  
PGI2	  biosynthesis	  in	  the	  endothelial	  cells	  and	  the	  VSMC	  which	  further	  supports	  the	  anti-­‐
atherogenic	   role	   of	   PGI2	   (Pomerantz	   et	   al.,	   1985).	   Iloprost	   (stable	   analogue	   of	  
prostacyclin)	   is	   reported	   to	   down-­‐	   regulate	   lymphocyte	   adhesion	   to	   endothelial	   cells,	  
suggesting	  an	  ability	  to	  block	  the	  early	  events	  of	  atherosclerosis	  (Della	  Bella	  et	  al.,	  2001).	  
In	   response	   to	   vascular	   injury,	   VSMC	  dedifferentiate	   to	   a	   synthetic	   phenotype	   due	   to	  
downregulation	   of	   contractile	   proteins	   and	   proliferate.	   This	   phenotypic	   plasticity	  
contributes	   to	   the	   pathophysiological	   processes	   of	   atherosclerosis,	   restenosis,	   and	  
hypertension	   (Owens	   et	   al.,	   2004).	   Treatment	   with	   the	   stable	   PGI2	   analog	   Iloprost	  
induces	  differentiation	  of	  VSMC	  including	  changes	  in	  morphology.	  Along	  with	  this	  it	  also	  
initiates	   a	   transcriptional	   upregulation	   of	   contractile	   proteins	   via	   the	   cAMP/PKA	  
pathway	   (Fetalvero	   et	   al.	   2006).	   It	   was	   also	   demonstrated	   that	   iloprost	   treatment	   of	  
VSMC	  upregulated	  COX-­‐2	  expression	  that	  leads	  to	  subsequent	  PGI2	  release	  and	  inhibited	  
Akt-­‐1	   expression	   (Kasza	   et	   al.,	   2009).	   The	   role	   of	   PGI2	   as	   an	   atheroprotective	   is	   well	  
demonstrated	   in	   prostacyclin	   receptor	   IP	   knock	   out	   mice	   (IP-­‐/-­‐)	   studies.	   These	   mice	  
displayed	  an	   increased	  proliferative	   response	   to	   carotid	  vascular	   injury	  with	   increased	  
intima	  to	  media	  ratios,	  enhanced	  thrombosis,	  and	  increased	  atherosclerosis	  (Murata	  et	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al.,	   1997,	  Cheng	  et	  al.,	   2002).	   Similarly,	  mice	  deficient	   in	  prostacyclin	   through	  genetic	  
disruption	   of	   the	   prostacyclin	   synthase	   gene	   developed	   thickening	   of	   vascular	   walls,	  
especially	   in	   the	   kidneys	   (Yokoyama	   et	   al.,	   2002).	   Clinical	   studies	   on	   COX-­‐2	   inhibition	  
further	  support	  the	  role	  of	  PGI2	  in	  inhibiting	  atherothrombosis.	  The	  VIGOR	  (Bombardier	  
et	  al.,	  2000)	  and	  APPROVe	  (Breasalier	  et	  al.,	  2005)	  trials	  confirmed	  the	  hypothesis	  that	  
patients	  with	  underlying	  cardiovascular	  risk	  factors	  were	  susceptible	  to	  coronary	  events	  
due	  to	  decreased	  PGI2	  and	  therefore	  increased	  prothrombotic	  TXA2	  ratio	  when	  treated	  
with	   COX-­‐2	   selective	   inhibitors.	   It	   has	   been	   shown	   that	   PGIS	   gene	   transfer	   in	   balloon	  
injured	   arteries	   could	   inhibit	   neointimal	   formation	   and	   the	   proposed	   mechanism	   of	  
action	   was	   that	   excessive	   PGH2	   derived	   from	   COX-­‐2	   after	   a	   balloon	   injury	   can	   be	  
converted	   into	   PGI2,	   in	   the	   presence	   of	   over	   expressed	   PGIS	   induced	   by	   the	   gene	  
transfer	  (Yamada	  et	  al.,	  2002)	  	  
	  
2.8.	  Cell	  mediated	  gene	  therapy	  in	  peripheral	  vascular	  disease	  
2.8.1.	  Peripheral	  vascular	  disease	  
Lower	   extremity	   peripheral	   arterial	   disease	   (PAD)	   is	   a	   highly	   prevalent	  
atherosclerotic	   syndrome	   that	   is	   characterized	   by	   a	   decrease	   in	   peripheral	   circulation	  
due	  to	  clogged	  peripheral	  arteries.	  It	  can	  lead	  to	  claudication	  and	  critical	  limb	  ischemia	  
(CLI),	  a	  endstage	  lower	  extremity	  PAD	  occurring	  due	  to	  severe	  obstruction	  in	  blood	  flow	  
which	  results	  in	  ischemic	  rest	  pain,	  ulcers,	  and	  a	  significant	  risk	  for	  limb	  loss.	  It	  has	  been	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suggested	  that	  surgical	  or	  endovascular	  revascularization	  aimed	  at	  improving	  blood	  flow	  
as	   a	   standard	   therapy	   for	   severe,	   limb-­‐threatening	   ischemia.	   However	   such	  
interventions	  are	  suitable	  in	  approximately	  50%	  of	  patients	  with	  CLI	  and	  amputation	  is	  
the	  only	  option	   left.	  To	   improve	  the	  symptoms	  of	  PAD,	  research	  has	  been	  focusing	  on	  
the	  concept	  of	  therapeutic	  angiogenesis	  to	   improve	  vascularization	  of	  the	  ischemic	   leg	  
by	  the	  use	  of	  cell	  therapy	  and	  angiogenic	  growth	  factors	  gene	  therapy.	  Pharmacological	  
treatment	   like	   use	   of	   prostacyclin	   analogs	   has	   also	   been	   suggested	   to	   improve	   the	  
symptoms	   and	   decrease	   the	   mortality	   rate	   in	   the	   CLI	   patients.	   The	   concept	   of	  
therapeutic	  angiogenesis	  was	  driven	  by	  the	  theoretical	  concept	  that	  Bone-­‐marrow	  (BM)	  
derived	   endothelial	   progenitor	   cells	   (EPCs)	   could	   incorporate	   into	   damaged	   vessel	  
endothelium	  and	  promote	  collateral	  vessel	  formation.	  	  
	  
2.8.2.	  Cell	  therapy	  
Cells	   are	   attractive	   mode	   of	   therapy	   due	   to	   several	   reasons:	   1)	   Cells	   are	  
multifunctional;	   2)	   Cells	   have	   distinct	   autocrine,	   paracrine	   and	   endocrine	   effects	   or	  
combination	  of	   these	  effects;	  3)	  Multiple	   sources	  of	  donor	   cells	  exist;	  4)	  Cells	  may	  be	  
modified	   in	   culture	   or	   genetically	   to	   provide	   unique	   potencies	   for	   therapy.	   EPCs	   can	  
mobilize	   from	   the	   BM	   and	   can	   promote	   neovascularization	   at	   sites	   of	   ischemia.	   The	  
therapeutic	   potential	   of	   BMCs	   has	   been	   evaluated	   in	   various	   small	   and	   large	   animal	  
model	  studies.	  These	  studies	  reported	  that	  BMCs	  and	  EPCs	  functionally	  contributed	  to	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increased	   capillary	   density,	   improved	   muscle	   perfusion	   and	   thus	   wound	   healing	   in	  
hindlimb	   ischemia	  models.	   In	  addition	   to	  EPCs	  and	  BMCs,	   several	  other	  candidate	  cell	  
therapies	  have	  also	  been	  proposed	  which	  include	  including	  mesenchymal	  stem	  cells	  and	  
adipose	   tissue	  derived	   stromal	   cells.	   	   Adipose	   tissue	  derived	   stromal	   vascular	   fraction	  
cells	   express	   both	   hematopoietic	   and	   endothelial	   markers,	   and	   have	   the	   capacity	   to	  
differentiate	   into	   endothelial	   cells,	   and	   promote	   post-­‐ischemic	   neovascularization	   in	  
murine	   hindlimbs.	   These	   proangiogenic	   effects	   of	   these	   cells	   is	   due	   to	   their	   ability	   to	  
secrete	  proangiogenic	  growth	  factors	  like	  vascular	  endothelial	  growth	  factor	  (VEGF)	  and	  
other	  growth	  peptides	  that	  prevent	  endothelial	  cell	  apoptosis	  and	  incorporate	  into	  the	  
murine	   vasculature.	   Studies	   of	   these	   cells	   have	   reported	   their	   ability	   to	   potentially	  
promote	   neovascularization	   and	   endothelial	   regeneration	   in	   the	   ischemic	   tissue.	   For	  
cells	   to	   participate	   in	   therapeutic	   angiogenesis,	   they	   should	   have	   the	   ability	   to	  
successfully	  home	  at	  the	  site	  of	  ischemia.	  Ex-­‐vivo	  modification	  of	  these	  cells	  is	  done	  to	  
improve	  their	  functional	  activities	  as	  disease	  states	  can	  impair	  the	  therapeutic	  efficacy	  
of	  these	  cells.	   	  Mangi	  et	  al	  reported	  that	  MSCs	  overexpressing	  the	  anti-­‐apoptotic	  gene	  






2.8.3.	  Gene	  therapy	  
	   Gene	   therapy	   can	  be	  defined	  as	   the	   treatment	  of	   diseases	   through	   transfer	  of	  
genes	   to	   the	   diseased	   tissues.	   The	   transferred	   gene	   can	   replace	   a	   defective	   gene,	  
introduce	  a	  new	  function	  to	  the	  cell	  or	  can	  enhance	  the	  function	  of	  the	  cell.	  Wolff	  et	  al.	  
demonstrated	   that	   intramuscular	   injection	   of	   naked	   plasmid	   deoxyri-­‐	   bonucleic	   acid	  
(DNA)	  is	  feasible,	  and	  striated	  muscle	  as	  suitable	  for	  heterologous	  transgene	  expression.	  
It	  was	  thought	  that	  gene	  therapy	  with	  angiogenic	  growth	  factors	  to	  achieve	  therapeutic	  
angiogenesis	   was	   a	   promising	   concept	   due	   to	   the	   close	   relation	   between	   the	   target	  
(micro-­‐	  vascular	  circulation)	  and	  the	  source	  (striated	  muscle	  fibres).	  It	  has	  been	  reported	  
by	   several	   studies	   that	   angiogenic	   growth	   factors	   stimulate	   endothelial	   re-­‐growth	   in	  
denuded	   arteries	   leading	   to	   inhibition	   of	   neointimal	   thickening,	   reduction	   in	  
thrombogenicity,	   and	   restoration	   of	   endothelium-­‐	   dependent	   vasomotor	   reactivity.	  
Non-­‐viral	   gene	   delivery	   techniques	   include	   the	   use	   of	   naked	   plasmid	   DNA,	  
electroporation,	   particle	   bombardment,	   and	   cationic	   liposomes	   and	   these	   have	  
comparatively	   lower	   efficiency	   but	   may	   have	   demonstrable	   biologic	   effects	   due	   to	  
secretion	   of	   high	   potency	   product.	   Viral	   vectors	   on	   the	   other	   hand	   are	   based	   on	   the	  
introduction	  of	  new	  genes	  within	  genetically	  modified	  viruses	  and	  are	  associated	  with	  
high	   transfection	   efficiencies.	   Adenoviruses	   are	   most	   often	   used	   in	   cardiovascular	  
clinical	   gene	   therapy.	   Gene	   transfer	   through	   viral	   vectors	   is	   associated	   with	  
inflammatory	   reactions.	   Besides	   this,	   a	  major	   disadvantage	   is	   that	   it’s	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treat	   repeatedly	   using	   viral	   vectors	   because	   transduction	   efficiency	   is	   limited	   by	   prior	  
viral	  exposure.	  This	   is	  a	  very	  critical	   issue	  as	   the	   induction	  of	  a	   robust	  neovasculariza-­‐	  
tion	  is	  dependent	  on	  an	  angiogenic	  stimulus	  over	  a	  particular	  period	  of	  time.	  Also	  since	  
the	  angiogenic	  proteins	  have	  a	  very	  short	  half-­‐	  life,	  repeated	  treatment	  is	  necessary	  for	  
a	  significant	  therapeutic	  effect.	  	  	  
	  
2.8.4.	  Cell	  Mediated	  Gene	  therapy	  
Cell-­‐based	   gene	   therapy	   involves	   the	   harvesting	   of	   cells	   from	  patients,	  ex	   vivo	  
modification	  of	   the	  cells	   to	  express	   therapeutic	  genes,	  and	  subsequent	  reimplantation	  
of	   genetically-­‐modified	   autologous	   cells.	   There	   are	   very	   few	   studies	   in	   this	   area.	   The	  
maximum	  benefit	   from	  cell	   therapy	  depends	  on	  their	  survival	  at	   the	   ischemic	  site	  and	  
their	  function.	  However	  cases	  of	  graft	  failure	  is	  a	  major	  issue.	  There	  are	  several	  findings	  
that	  have	  shown	  that	  progenitor	  function	  and	  mobilization	  could	  be	  impaired	  in	  certain	  
disease	   states.	  Genetic	  modification	  of	  EPCs	   to	  overexpress	  angiogenic	  growth	   factors	  
not	  only	  enhances	  the	  angiogenic	  response	  but	  also	  extends	  the	  lifespan	  of	  EPCs.	  More	  
importantly,	   it	   has	   been	   shown	   in	   experiment	   that	   the	   number	   of	   EPCs	   needed	   to	  
achieve	   limb	   salvage	   was	   comparatively	   less	   than	   that	   required	   in	   the	   previous	  
experiments	   involving	   unmodified	   EPCs.	   Other	   than	   improving	   the	   function	   of	   cells	  
through	   gene	   transfection,	   these	   cells	   can	   be	   used	   as	   vectors	   to	   transfer	   gene	   for	  
therapeutic	  angiogenesis.	  Ishii	  et	  al	  has	  shown	  that	  mesenchymal	  stem	  cell	  (MSC)	  based	  
 26 
gene	   therapy	   with	   prostacyclin	   synthase	   enhanced	   neovascularization	   in	   hindlimb	  
ischemia	  through	  sustained	  release	  of	  PGI2	  
	  
2.9.	  Triple	  catalytic	  enzyme	  1	  
As	   discussed	   earlier,	   the	   prostanoids	   are	   biosynthesized	   through	   the	  
arachidonate-­‐COX	  pathway	  through	  3	  catalytic	  steps.	  The	  first	  catalytic	  step	  is	  in	  which	  
arachidonic	  acid	  (AA)	   is	  first	  converted	  into	  prostaglandin	  G2	  (PGG2)	  and	  in	  the	  second	  
catalytic	   step	   PGG2	   further	   converted	   to	   prostaglandin	   endoperoxide	   (PGH2)	   by	   COX	  
isoform-­‐1	  (COX-­‐1)	  or	  COX-­‐2	  in	  cells.	  In	  the	  third	  catalytic	  step	  PGH2	  serves	  as	  a	  common	  
substrate	   for	   downstream	   synthases	   and	   is	   isomerized	   to	   prostaglandin	   D2	   (PGD2),	   E2	  
(PGE2),	   F2	   (PGF2),	   and	   I2	   (PGI2)	   or	   thromboxane	   A2	   (TXA2)	   by	   individual	   synthases.	  
Considering	   the	   vascular	   protective	   functions	   of	   PGI2,	   increasing	   its	   biosynthesis	   was	  
thought	  to	  be	  a	  very	  useful	  way	  of	  protecting	  the	  vascular	  system.	  Specifically	  increasing	  
PGI2	   biosynthesis	   requires	   a	   highly	   efficient	   chain	   reaction	   between	   COX	   and	   PGIS,	  
which	   consists	   of	   the	   triple	   catalytic	   (Trip-­‐cat)	   functions	   mentioned	   above.	  With	   this	  
view	  in	  mind,	  a	  hybrid	  enzymatic	  protein	  was	  engineered	  with	  the	  ability	  to	  perform	  the	  
Trip-­‐cat	   functions	   by	   linking	   the	   constitutive	   human	   COX-­‐1	   to	   PGIS	   through	   a	  
transmembrane	   domain	   of	   10	   amino	   acids	   (His-­‐Ala-­‐Ile-­‐Met-­‐Gly-­‐Val-­‐Ala-­‐Phe-­‐Thr-­‐Trp	  
(10aa)).	   Thus	   this	   enzyme	   was	   referred	   as	   the	   Triple-­‐catalytic	   Enzyme-­‐1	   (Trip-­‐cat	  
Enzyme-­‐1)	  (Figure	  3).	  	  (Ruan	  et	  al.,	  2006,	  2008).	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Figure	  3.	  A	  model	  of	  the	  newly	  designed	  Trip-­‐cat	  Enzyme-­‐1.	  The	  Trip-­‐cat	  Enzyme-­‐1	  was	  
created	   by	   linking	   COX-­‐1	   to	   PGIS	   through	   an	   optimized	   TM	   linker	   (10	   amino	   acid	  
residues)	  without	  alteration	  of	   the	  protein	   topologies	   in	   the	  ER	  membrane.	  The	   three	  
catalytic	  sites	  and	  reaction	  products	  in	  COX-­‐1	  and	  PGIS	  enzymes	  are	  shown.	  
	  
Studies	   with	   this	   enzyme	   demonstrated	   that	   the	   Trip-­‐cat	   Enzyme-­‐1	   could	   be	  
stably	  expressed	  in	  HEK293	  cells.	  These	  cells	  when	  treated	  with	  exogenous	  AA	  were	  able	  
to	   convert	   most	   of	   the	   AA	   into	   PGI2.	   In	   addition,	   the	   stable	   HEK293	   cell	   line,	   with	   a	  
capacity	   to	   biosynthesize	   PGI2,	   revealed	   strong	   antiplatelet	   aggregation	   properties	  
through	   its	   unique	   dual	   functions	   (increasing	   PGI2	   production	   while	   decreasing	   TXA2	  
production)	   in	  the	  TXA2	  synthase	  (TXAS)	  platelet	  rich	  plasma	  (PRP).	  The	  engineering	  of	  
the	  triple	  catalytic	  enzyme-­‐1	  and	  its	  capacity	  to	  stably	  express	  in	  a	  human	  cell	  line	  and	  
upregulate	   PGI2	   biosynthesis	   provided	   a	   basis	   for	   developing	   a	   PGI2-­‐	   producing	  
therapeutic	  cell	  line	  against	  vascular	  diseases.	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2.10.	  MicroRNA	  	  
MicroRNAs	   (miRNAs)	   are	   short	   single-­‐stranded	   non-­‐coding	   RNAs	   with	   21–24	  
nuclotide	   in	   length,	   which	   play	   an	   important	   role	   in	   several	   regulatory	   pathways.	  
MiRNAs	   negatively	   regulate	   gene	   expression	   at	   the	   post	   transcriptional	   level	   by	   two	  
ways:	   1)	   miRNAs	   cause	   translational	   repression/	   gene	   silencing	   by	   binding	   to	   the	  
sequences	   on	   the	   target	   gene;	   2)	   miRNAs	   cause	   mRNA	   degradation	   by	   forming	  
complementary	   base	   pairing	  with	   the	   target	   gene	   sequences.	   The	   human	   encodes	   at	  
least	  more	  than	  over	  1000	  miRNAs,	  which	  may	  target	  about	  60%	  of	  mammalian	  genes.	  
MiRNAs	   show	   very	   different	   characteristics	   between	   plants	   and	   animals.	   In	   animals,	  
miRNAs	   bind	   to	   target	   sequences	   in	   the	   3’-­‐UTR	   of	   the	   target	   gene	   through	   imperfect	  
base	  pairing	   and	   resulting	   in	   the	   arrest	   of	   translation.	  Wheras	   in	   plants,	  miRNAs	  bind	  
with	   the	   target	   sequences	   through	   perfect	   or	   near	   perfect	   complementarity,	   causing	  
direct	  cleavage	  and	  degradation	  of	  the	  mRNA.	  It	  is	  reported	  that	  one	  miRNA	  can	  target	  
many	   different	   sites	   on	   the	   same	  mRNA	   or	   on	  many	   different	   mRNAs.	   By	   regulating	  
gene	  expression,	  miRNAs	  are	  proposed	  to	  be	  involved	  in	  several	  biologic	  processes	  like	  
proliferation,	  differentiation,	  apoptosis,	  embryogenesis	  and	  oncogenesis.	  	  
Furthermore,	   miRNAs	   genes	   have	   been	   shown	   to	   be	   transcribed	   by	   both	   RNA	  
polymerase	   II	   and	   III	   and	   are	   termed	   as	   pri-­‐miRNAs,	   that	   contain	   Cap	   structures	   and	  
poly(A)-­‐tails	  and	  are	  hundreds	  or	  thousands	  of	  nucleotides	  in	  length.	  The	  maturation	  of	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small	  RNAs	  occurs	  with	  the	  help	  of	  two	  RNA	  type-­‐III	  endonucleases,	  named	  Drosha	  and	  
Dicer.	   Drosha	   along	   with	   DGCR8	   (RNA	   binding	   protein),	   processes	   the	   pri-­‐miRNA	  
transcript	   in	   the	   nucleus	   by	   cleaving	   it	   at	   the	   bottom	   of	   its	   stem	   loop.	   The	   resulting	  
double-­‐stranded	  RNA	  precursor	  molecule	  called	  as	  pre-­‐	  miRNA	  is	  then	  exported	  into	  the	  
cytoplasm,	   with	   the	   help	   of	   exportin,	   a	   nuclear	   transport	   receptor.	   Once	   in	   the	  
cytoplasm,	   pre-­‐miRNAs	   are	   further	   processed	   by	   Dicer	   to	   form	   the	   short	   21-­‐24	   nt	  
mature	  miRNA	  duplexes.	   These	  duplexes	   are	   then	   incorporated	   into	   the	  RNA-­‐induced	  
silencing	   complex	   (RISC),	   and	   based	   on	   the	   thermodynamic	   properties;	   one	   strand	   is	  
eliminated	  whereas	  the	  other	  one	  remains	  in	  the	  complex.	  Of	  the	  several	  proteins	  of	  the	  
argonaute	  family	  that	  are	  associated	  with	  the	  RISC	  complex,	  argonaute–2	  was	  shown	  to	  
be	  responsible	  for	  mRNA	  cleavage.	  MiRNAs	  expression	  can	  be	  studied	  using	  microarray	  
technique	  in	  which	  miRNAs	  are	  hybridized	  with	  chips	  that	  contain	  probes	  to	  hundreds	  or	  
thousands	  of	  miRNas	  targets	  and	  thus	  the	  relative	   level	  of	  different	  miRNA	  expression	  
can	  be	  compared.	  The	  miRNa	  expression	  can	  be	  further	  quantified	  by	  quantitative	  real	  








3.	  METHODS	  AND	  MATERIALS	  
	  
3.1.	   Engineering	  of	   the	   cDNA	  plasmid	   encoding	   the	  hybrid	   enzyme	  COX-­‐1-­‐10aa-­‐PGIS	  
sequences.	  
The	  pcDNA	  3.1	  vector	  containing	  a	  cytomegalovirus	  early	  promoter	  was	  cloned	  
with	   cDNAs	   of	   the	   COX-­‐1	   and	   PGIS	   using	   a	   PCR	   (polymerase	   chain	   reaction)	   cloning	  
approach.	   The	   sequences	   were	   confirmed	   by	   DNA	   sequencing	   and	   endonuclease	  
digestion	  analyses.	  The	  sequence	  of	  COX-­‐1	  was	  linked	  with	  the	  PGIS	  sequence	  through	  a	  
10	   amino	   acid	   (10aa) (His-­‐Ala-­‐Ile-­‐Met-­‐Gly-­‐Val-­‐Ala-­‐Phe-­‐Thr-­‐Trp)	   linker	   to	   form	   COX-­‐1-­‐
10aa-­‐PGIS	  (Triple	  catalytic	  enzyme-­‐1)	  on	  the	  pcDNA	  3.1(+)	  vector	  (Ruan	  et	  al.,	  2008).	  	  
	  
3.2.	  	  Establishing	  a	  primary	  cultured	  cell	  line	  derived	  from	  adipose	  tissue.	  
Inguinal	  adipose	  tissue,	  excised	  from	  a	  C57BL/6	  mouse,	  was	  washed	  thoroughly	  
with	   phosphate	   buffered	   saline	   (PBS),	   pH	   7.5,	   and	   then	   digested	   by	   collagenase	  
(2mg/mL)	  at	  37˚	  C	  for	  1hr.	  The	  digested	  adipose	  tissue	  was	  then	  filtered	  through	  glass	  
wool	   and	   subjected	   to	   low	   speed	   centrifugation	   for	   further	   separation.	   The	   mature	  
adipocytes	   collected	   from	   the	   upper-­‐layer	   of	   the	   collagenase-­‐digested	  mouse	   adipose	  
tissue	  were	  placed	  between	  two	  cover	  slides	   in	  a	  10-­‐cm	  cell	  culture	  dish	  with	  DMEM-­‐
F12	  containing	  10%	  newborn	  calf	   serum	  (NCS)	  and	  1%	  antibiotic	  and	  antimycotic,	  and	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then	  were	   grown	   at	   37˚	   C	   in	   a	   humidified	   5%	   CO2	   incubator.	   After	   15	   days,	   the	   lipid	  
droplets	  within	  the	  cells	  completely	  disappeared.	  Furthermore,	  the	  cells	  had	  converted	  
into	  attached	  “Fat	  Cells”	  with	  the	  capacity	   to	  synthesize	  endogenous	  prostanoids,	  and	  
were	  referred	  to	  as	  prostanoid-­‐synthesizing	  fat	  cells	  (PSFCs).	  The	  protocol	  was	  approved	  
by	  the	  Animal	  Safety	  Committee	  of	  the	  University	  of	  Houston.	  
	  
3.3.	  	  Stable	  expression	  of	  the	  Trip-­‐cat	  enzyme-­‐1	  in	  the	  cultured	  fat	  cells.	  
The	  PSFCs	  were	  grown	  and	  transfected	  with	  the	  cDNA	  of	  pcDNA3.1-­‐COX-­‐1-­‐10aa-­‐
PGIS	   by	   the	   Lipofectamine	   2000	   method	   following	   the	   manufacturer's	   instructions	  
(Invitrogen).	  The	  stable	  cell	  line	  was	  created	  after	  4	  weeks	  of	  using	  Geneticin	  (G418)	  as	  
the	  selection	  antibiotic.	  The	  cells	  stably	  expressing	  the	  Trip-­‐cat	  enzyme-­‐1	  were	  further	  
identified	  by	  enzyme	  assays,	  western	  blot	  analysis	  and	  LC/MS	  analysis	  and	  were	  termed	  
“PGI2–PSFCs.”	  
	  
3.4.	  Enzyme	  Activity	  Determination	  for	  the	  Trip-­‐cat	  Enzyme-­‐1	  Using	  the	  HPLC	  Method.	  
To	  determine	  the	  activities	  of	  the	  COX-­‐1-­‐10aa-­‐PGIS	  enzyme,	  [14C]	  AA	  (10μM)	  was	  
added	   to	   the	   PGI2-­‐PSFCs	   in	   a	   total	   reaction	   volume	   of	   0.1mL.	   After	   incubation,	   the	  
reactions	  were	  stopped	  with	  0.2mL	  of	  the	  solvent	  (solvent	  A)	  containing	  0.1%	  acetic	  acid	  
and	  35%	  acetonitrile.	  After	  centrifugation	  (12,000	  rpm	  for	  5min),	   the	  supernatant	  was	  
injected	   into	   a	   C18	   column	   (Varian	   Microsorb-­‐MV	   100-­‐5,	   4.6	   ×	   250	   mm)	   using	   the	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solvent	  A	  with	   a	   gradient	   from	  35	   to	  100%	  of	   acetonitrile	   for	   45min	  at	   a	   flow-­‐rate	  of	  
1.0mL/min.	   The	   [14C]-­‐labeled	   AA	  metabolites,	   including	   6-­‐keto-­‐PGF1α	   (degraded	   PGI2),	  
were	  monitored	  directly	  by	  a	  flow	  scintillation	  analyzer	  (Packard	  150TR).	  	  
	  
3.5.	   Determination	   of	   the	   endogenous	   AA	   metabolisms	   in	   the	   cultured	   cells	   using	  
LC/MS.	  	  
Simultaneous	  quantification	  of	  AA	  metabolites	   in	   the	   cultured	  PSFCs	   (with	  and	  
without	  transfection	  of	  the	  Trip-­‐cat	  Enzyme-­‐1	  cDNA)	  was	  detected	  by	  LC/MS	  following	  
the	   reported	  methods	   (Ruan	   et	   al.,	   2006,	   Ruan	   et	   al.,	   2008).	   Briefly,	   the	   cell	   culture	  
media	   was	   collected	   and	   applied	   to	   a	   C18	   cartridge	   (Honeywell	   Burdick	   &	   Jackson	   -­‐	  
Model	  BJ9575).	  After	  washing	  with	  water,	   the	  AA	  metabolites	   bound	   to	   the	   cartridge	  
were	  eluted	  with	  acetone,	  dried	  by	  nitrogen	  gas,	  and	  then	  dissolved	  in	  solvent	  A	  (0.1%	  
acetic	  acid	  and	  35%	  acetonitrile).	  The	  sample	  was	   injected	   into	  the	  Waters	  Micromass	  
LC/MS/MS	  system	  by	  an	  auto-­‐sampler.	  The	  metabolites	  are	   first	   separated	  by	   the	  RP-­‐
HPLC	  C18	  column	  and	  then	  automatically	  injected	  into	  the	  mass	  detector	  equipped	  with	  
an	   ESI	   source	   in	   a	   negative	   mode.	   Synthetic	   AA	   and	   6-­‐keto-­‐PGF1α,	   obtained	   from	  
Cayman	   Chemical	   Company	   (Ann	  Arbor,	  MI),	  were	   used	   as	   standards	   to	   calibrate	   the	  
LC/MS	   system,	   identify	   the	   corresponding	   prostanoids,	   and	   normalize	   the	   detection	  




3.6.	  Immunoblot	  analysis.	  
The	   stable	   transfected	   cells	   (PGI2-­‐PSFCs)	   expressing	   the	   Trip-­‐cat	   Enzyme-­‐1	   or	  
those	  PSFCs	  transfected	  with	  vector	  (pcDNA	  3.1)	  alone	  were	  collected	  and	  washed	  with	  
PBS.	   Membrane	   proteins	   were	   separated	   by	   10%	   (w/v)	   SDS-­‐PAGE	   under	   denaturing	  
conditions	   and	   then	   transferred	   to	   a	   nitrocellulose	   membrane.	   Bands	   recognized	   by	  
specific	   primary	   antibodies	   (PGIS,	   COX-­‐1,	   or	   cPGES)	   were	   visualized	   with	   horseradish	  
peroxidase-­‐conjugated	  secondary	  antibody.	  
	  
3.7.	  Anti-­‐Platelet	  Aggregation	  Assays.	  	  
Fresh	  blood	  was	  collected	  from	  healthy	  adult	  rabbits	  (in	  University	  of	  Texas)	  in	  a	  
3.2%	   sodium	   citrate	   tube	   and	   then	   centrifuged	   to	   seperate	   the	   platelet-­‐rich	   plasma	  
(PRP).	  A	  total	  of	  0.45mL	  PRP	  was	  placed	  inside	  the	  37˚	  C	  incubator	  of	  an	  aggregometer	  
(Chrono-­‐Log)	  for	  a	  total	  of	  3	  min.	  Fifty	  microliters	  of	  sodium	  arachidonate	  (5mg/mL)	  was	  
added	  to	  the	  PRP	  in	  the	  absence	  and	  presence	  of	  the	  PSFCs	  and	  PGI2-­‐PSFCs.	  The	  platelet	  
aggregation	  was	   then	  monitored	  and	   the	   readings	  by	   the	  anticoagulant	  analyzer	  were	  






3.8.	  	  Mouse	  Hindlimb	  Ischemia	  Model.	  	  	  
The	   male	   C57BL/6J	   mice	   (8-­‐10	   wk)	   were	   anesthetized	   using	   isoflurane	  
anesthesia.	  Excess	  hair	  was	  removed	  by	  depilatory	  cream	  from	  both	  hindlimbs,	  and	  the	  
proximal	   portion	   of	   the	   femoral	   artery	   (right	   side)	  was	   ligated	  with	   a	   silk	   suture.	   The	  
overlying	  skin	  was	  closed	  with	  three	  surgical	  staples.	  The	  mice	  were	  then	  randomized	  to	  
three	  groups	   (n=6)	   for:	   (i)	  PBS	   injection;	   (ii)	  PGI2-­‐PSFC	   injection	  and	   (iii)	  PSFC	   injection	  
(empty	  vector	  transfected).	  24h	  post-­‐femoral	  artery	  ligation,	  PBS,	  PSFCs,	  or	  PGI2-­‐PSFCs	  
(1.5	  x	  106	   cells)	  were	   injected	   intramuscularly	  at	  3-­‐different	   sites	  around	   the	   ischemic	  
region.	  Blood	  flow	  recovery	  was	  assessed	  by	  the	  Laser	  Doppler	  Perfusion	  Imager	  (LDPI)	  
technique.	   Specifically,	   blood	   flow	   reperfusion	  was	   evaluated	   at	   0hr	   (before	   ligation),	  
24hr,	   3	   day,	   7	   day,	   14	   day	   and	   21	   day	   post	   ligation	   using	   LDPI.	   The	   results	   were	  
expressed	  as	  the	  ratio	  of	  perfusion	  in	  the	  ischemic	  and	  the	  non-­‐ischemic	  limb.	  	  
	  
3.9.	  	  Determination	  of	  the	  endogenous	  AA	  metabolisms	  in	  the	  mice	  urine	  using	  LC/MS	  
analysis.	  	  	  
Urine	  samples	  were	  collected	  from	  mice	  induced	  with	  ischemia	  (PBS,	  PGI2-­‐PSFC	  
and	  PSFC	  groups,	  n=6)	  at	  time	  points	  0	  (before	  femoral	  artery	  ligation),	  3,	  7,	  14	  and	  21	  
days	   (post	   femoral	   artery	   ligation).	   These	   urine	   samples	   were	   further	   processed	   for	  
injection	  into	  the	  Waters	  Micromass	  LC/MS/MS	  as	  discussed	  in	  method	  3.5.	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3.10.	  	  Mouse	  Running	  Time	  model.	  	  
To	   further	   confirm,	   if	   the	   mice	   with	   limb	   ischemia	   after	   treatment	   showed	  
recovery	   in	   perfusion,	   a	   functional	   mobility	   assay	   was	   performed.	   Mice	   were	  
familiarized	  with	   treadmill	   running	   each	   day	   from	   the	   beginning	   for	   one	  week	   before	  
hindlimb	  unilateral	  femoral	  artery	  ligation.	  Only	  those	  mice	  that	  were	  able	  to	  run	  on	  a	  
treadmill	  for	  1hr	  underwent	  the	  complete	  process	  of	  running	  time	  testing.	  After	  1	  week,	  
the	  mice	  were	   ligated	  and	  each	  of	   the	   three	   treated	  groups	   (PBS,	  PGI2-­‐PSFC	  and	  PSFC	  
groups,	  n=6)	  were	  placed	  on	  a	  treadmill	  at	  a	  7-­‐degree	  angle	  for	  5	  minutes	  at	  5	  m/min	  to	  
acclimate,	  and	  then	  speed	  was	  increased	  to	  10	  m/min	  (t	  =	  0).	  Speed	  was	  increased	  every	  
2	  minutes	  until	  fatigue	  (when	  animals	  spent	  more	  than	  5	  seconds	  on	  the	  stimulator	  grid	  
at	  the	  rear	  of	  the	  treadmill).	  The	  mice	  were	  tested	  for	  running	  time	  on	  days	  3,	  7,	  14	  and	  
21	  days	  postligation.	  
	  
3.11.	  Thrombotic	  occlusion	  model.	  (Photochemical	  vascular	  injury)	  	  
A	  photochemical	  thrombotic	  occlusion	  model	  was	  used	  to	  produce	  injury	  in	  the	  
mouse	   carotid	   artery.	   Briefly	   the	   male	   mice	   were	   anesthetized	   with	   sodium	  
pentobarbital	   (80mg/kg,	   i.p.)	   and	   placed	   in	   a	   supine	   position.	   After	   a	  midline	   cervical	  
incision,	   a	   cannula	   was	   inserted	   into	   the	   left	   jugular	   vein	   for	   administration	   of	   Rose	  
Bengal	  (Sigma	  Aldrich).	  The	  left	  common	  carotid	  artery	  was	  exposed	  and	  a	  laser	  doppler	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flow	   probe	   407	   connected	   to	   Laser	   Doppler	   Perfusion	   Monitor	   (LDPM)	   Unit-­‐Periflux	  
System	  (PF)	  5010	  was	  placed	  on	  the	  artery	  for	  recording	  the	  blood	  flow.	  After	  recording	  
a	   constant	   baseline	   blood	   flow,	   approximately	   1.5	   x	   106	   PGI2-­‐PSFCs	   (overexpressing	  
COX-­‐1-­‐10aa-­‐PGIS)	   or	   empty	   vector	   transfected	   PSFCs	   were	   added	   locally	   over	   the	  
carotid	  artery.	  Next,	  the	  carotid	  artery	  was	  exposed	  to	  1.5mW	  green	  laser	  beam	  540nm	  
(Melles	  Griot,	  CA,	  USA)	  from	  a	  distance	  of	  5cm	  and	  rose	  bengal	  (50mg/kg)	  was	  injected	  
through	   the	   jugular	   vein.	   At	   this	   point	   blood	   flow	  was	   constantly	   recorded	   using	   the	  
accompanying	  software.	  The	  formation	  of	  an	  occlusive	  thrombus	  was	   indicated	  by	  the	  
cessation	  of	  blood	  flow.	  	  
	  
3.12.	  	  MiRNA	  Microarray	  Analysis.	  
PSFCs	  and	  PGI2-­‐PSFCs	  were	  cultured	  as	  described	  above	  and	  after	  24hrs	  the	  total	  
RNA	  was	  isolated	  using	  TRIZOL	  reagent.	  In	  another	  experiment,	  PGI2-­‐	  PSFCs	  were	  serum	  
starved	  for	  5-­‐6	  hrs	  and	  then	  one	  plate	  was	  treated	  with	  IP	  antagonist	  CAY10441	  (1μM)	  
and	   the	   other	   with	   PPARγ	   antagonist	   GW9662	   (5μM).	   After	   24hrs,	   total	   RNA	   was	  
isolated.	   Total	   RNA	   samples	  were	   analyzed	   by	   LC	   Sciences	   (Houston,	   TX,	   USA),	  which	  
provided	   microarray	   analyses.	   Briefly,	   detection	   was	   done	   by	   fluorescence	   labelling	  
using	   tag-­‐specific	  Cy3	   (for	  PSFCs)	  and	  Cyc	  5	  dyes	   (for	  PGI2-­‐PSFC).	  Hybridization	   images	  
were	  collected	  using	  a	  laser	  scanner.	  The	  ratio	  of	  the	  two	  sets	  of	  detected	  signals	  (log2	  
transformed,	   balanced)	   and	   P-­‐	   values	   of	   the	   t-­‐	   test	   were	   calculated.	   Differentially	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detected	  signals	  were	  those	  with	  less	  than	  0.05	  P-­‐	  values.	  Upon	  receiving	  their	  results,	  a	  
search	  was	  performed	  on	  the	  target	  genes	  of	  the	  individual	  miRNAs	  using	  the	  website,	  
microrna.sanger.ac.uk.	  
	  
3.13.	  	  Quantitative	  Real	  Time	  PCR	  (qRT-­‐PCR).	  
The	  miRNA-­‐711	  expression	  upregulation	  observed	  in	  the	  microarray	  was	  further	  
confirmed	   and	   quantified	   by	   qRT-­‐PCR	   approach	   using	   three	   kits	   obtained	   from	   SA	  
Biosciences	   (Frederick,	  MD)	   following	   the	  detailed	   instructions	   in	   the	   kits.	   	   Firstly,	   the	  
miRNAs	  were	   isolated	   from	   the	   cultured	   PGI2-­‐PSFCs	   or	   control	   PSFCs	   using	   RT²	   qPCR-­‐
Grade	  miRNA	   Isolation	  Kit.	   Secondly,	   the	   isolated	  miRNAs	  were	   converted	   into	   cDNAs	  
using	  RT2	  miRNA	  First	  Strand	  Kit;	  and	   finally,	   the	  cDNAs	  were	  mixed	  with	  another	  kit,	  
RT²	  SYBR®	  Green	  qPCR	  Master	  Mix,	  the	  primer	  for	  miRNA711	  and	  sno	  RNA-­‐142	  (control),	  
and	   then	   analyzed	   by	   qPCR	   using	   Applied	   Biosystems	   7300	   Real	   Time	   PCR	   System.	  	  
Differential	   expression	   of	   miRNA-­‐711	   in	   the	   cells	   was	   analyzed	   by	   the	   ΔΔCT	   method	  
using	  the	  mouse	  housekeeping	  sno	  RNA-­‐142	  (small	  nucleolar	  RNA)	  as	  the	  endogenous	  






3.14.	  Illumina	  gene	  expression	  assay	  
Two	  hundred	  nanograms	  of	  total	  RNA	  from	  PSFCs	  and	  PGI2-­‐PSFCs	  were	  amplified	  
and	  purified	  using	  Illumina	  TotalPrep	  RNA	  Amplification	  Kit	  (Ambion,	  Inc.)	  following	  the	  
manufacturer’s	  instructions.	  Briefly,	  the	  first	  strand	  cDNA	  was	  synthesized	  by	  incubating	  
RNA	  with	  T7	  oligo(dT)	  primer	  and	  reverse	  transcriptase	  mix	  at	  42	  °C	  for	  2	  hours.	  RNase	  
H	   and	   DNA	   polymerase	   master	   mix	   were	   immediately	   added	   into	   the	   reaction	   mix	  
following	   reverse	   transcription	  and	  were	   incubated	   for	  2	  hours	   at	   16	   °C	   to	   synthesize	  
second	   strand	   cDNA.	   RNA,	   primers,	   enzymes	   and	   salts	   that	   would	   inhibit	   in	   vitro	  
transcription	   were	   removed	   through	   cDNA	   filter	   cartridges	   (part	   of	   the	   amplification	  
kit).	  In	  vitro	  transcription	  was	  performed	  and	  biotinylated	  cRNA	  was	  synthesized	  by	  14-­‐
hour	   amplification	   with	   dNTP	   mix	   containing	   biotin-­‐dUTP	   and	   T7	   RNA	   polymerase.	  
Amplified	   cRNA	  was	   subsequently	   purified	   and	   the	   concentration	  was	  measured	   by	   a	  
NanoDrop	  ND-­‐1000	  Spectrophotometer	  (NanoDrop	  Technologies,	  DE).	  An	  aliquot	  of	  1.5	  
micrograms	   of	   amplified	   products	   were	   loaded	   onto	   Illumina	   Sentrix	   Beadchip	   Array	  
Mouse-­‐6	  arrays,	  hybridized	  at	  58	  °C	  in	  an	  Illumina	  Hybridization	  Oven	  (Illumina,	  Inc.)	  for	  
17	  hours,	  washed	  and	  incubated	  with	  streptavidin-­‐Cy3	  to	  detect	  biotin-­‐labeled	  cRNA	  on	  
the	  arrays.	  Arrays	  were	  dried	  and	  scanned	  with	  BeadArray	  Reader	  (Illumina,	  Inc.).	  Data	  
were	   analyzed	   using	   BeadStudio	   software	   (Illumina,	   Inc.).	   Clustering	   and	   pathway	  
analysis	   were	   performed	   with	   BeadStudio	   and	   Ingenuity	   Pathway	   Analysis	   (Ingenuity	  
Systems,	  Inc.)	  software	  respectively.	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3.15.	  Akt1	  immunoblot.	  
Cells	  were	  harvested	  and	  lysed	  in	  lysis	  buffer	  [50mM	  Tris-­‐HCl	  (pH	  7.4),	  1%	  Triton	  
X-­‐100,	  150mM	  NaCl,	  1mM	  EDTA,	  1mM	  phenylmethanesulphonylfluoride,	  1%	  aprotinin,	  
10mg/mL	   leupeptin,	   1mM	   sodium	   orthovanadate,	   and	   1mM	   sodium	   fluoride.	   Cell	  
lysates	  were	  centrifuged	  at	  12,000	  g	  for	  10	  min	  at	  4ºC.	  Protein	  concentration	  of	  the	  cell	  
lysate	  was	  determined	  by	  performing	  BCA	  protein	  assay.	  SDS-­‐PAGE	  sample	  buffer	  was	  
added	  to	  the	  lysates,	  which	  were	  then	  heated	  to	  100°C	  for	  5	  min.	  25μg	  of	  protein	  was	  
loaded	   in	  each	  well	   of	  10%	  acrylamide	  gel	   and	   separated	  by	  electrophoresis.	   Proteins	  
were	   transferred	   onto	   a	   nitrocellulose	  membrane,	  which	  was	   incubated	  with	   primary	  
antibody	   against	   Akt1	   and	   a	   horseradish	   peroxidase	   conjugated	   secondary	   antibody.	  
Chemiluminescence	  was	  detected	  using	  ECL	  Kit	  (Amersham).	  	  	  	  
	  
3.16.	  	  Lipid	  accumulation	  study	  in	  PSFCs	  and	  PGI2-­‐PSFCs.	  
PSFCs	   and	   PGI2-­‐PSFCs	   were	   grown	   to	   50%	   confluency	   in	   DMEM-­‐F12	   medium	  
containing	   10%	   newborn	   calf	   serum.	   This	   medium	   was	   then	   replaced	   by	   adipogenic	  
medium:	  DMEM	  containing	  10%	  fetal	  bovine	  serum	  (FBS),	  1µM	  dexamethasone	  (Sigma-­‐
Aldrich),	   0.5mM	   Isobutyl	  methyl	   xanthine	   (IBMX)	   and	   insulin	   (10µg/mL),	   and	   the	   cells	  
were	  allowed	  to	  grow	  in	  this	  medium	  for	  4	  days.	  After	  4	  days	  the	  cells	  were	  re-­‐fed	  with	  
DMEM-­‐F12	   media	   containing	   10%	   FBS	   and	   10µg/mL	   insulin,	   and	   were	   grown	   for	   an	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additional	   3	   days.	   Images	   were	   taken	   everyday	   to	   observe	   cells	   accumulating	   lipid	  
droplets.	  	  
	  
3.17.	  	  Oil	  Red-­‐O	  staining.	  
After	   treating	   the	   cells	   with	   differentiation	  media	   for	   7	   days,	   accumulation	   of	  
intracellular	   lipid	   was	   identified	   by	   Oil	   Red-­‐O	   (Sigma-­‐Aldrich)	   staining.	   A	   0.36%	   (w/v)	  
solution	  of	  Oil	  Red-­‐O	  was	  prepared	   in	  60%	   isopropanol.	   	  The	  cells	  were	  washed	   twice	  
with	  PBS	  and	  fixed	  with	  4%	  paraformaldehyde	  for	  5	  min	  and	  then	  washed	  with	  PBS	  and	  
isopropanol.	  The	  cells	  were	  then	  stained	  with	  Oil	  Red-­‐O	  solution	  for	  30	  min	  and	  rinsed	  
with	  isopropanol.	  	  Cells	  were	  observed	  via	  light	  microscope	  with	  100X	  magnification	  and	  
then	  photographed	  using	  a	  Kodak	  DC	  290	  Zoom	  Digital	  Camera	  (NY,	  USA).	  	  	  
	  	  
3.18.	   Construction	   of	   the	   cDNA	   plasmid	   for	   generating	   the	   transgenic	   mice	  
overexpressing	  COX-­‐1-­‐10aa-­‐PGIS.	  
The	   sequence	  of	  COX-­‐1	   linked	   to	  PGIS	   through	  a	  10	  amino	  acid	   linker	   (COX-­‐1–
10aa–PGIS,	   Trip-­‐cat	   enzyme-­‐1)	   was	   generated	   by	   a	   PCR	   approach	   and	   subcloning	  
procedures	   provided	   by	   the	   vector	   company	   (Invitrogen).	   The	   resulting	   cDNA	   of	   the	  
engineered	  COX-­‐1-­‐10aa-­‐PGIS	  was	   successfully	   subcloned	   into	   the	  pcDNA	  3.1	   vector	   at	  
KpnI	  and	  BamHI	  sites	  containing	  a	  cytomegalovirus	  early	  promoter	  using	  a	  polymerase	  
chain	  reaction	  (PCR)	  cloning	  approach.	  The	  procedures	  have	  been	  previously	  described	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[Ruan,	   2006,	   Ruan,	   2008].	   The	   correct	   cDNA	   sequences	   were	   confirmed	   by	   DNA	  
sequencing	  and	  restriction	  enzyme	  digestion	  analyses.	  A	  3.2	  Kb	  cDNA	  plasmid	  construct	  
(COX-­‐1-­‐10aa-­‐PGIS)	  containing	  CMV	  promoter	  and	  PGH	  polyadenylation	  site	  (pA)	  was	  cut	  
at	   the	  NruI	   and	   SphI	   sites.	   The	   identity	   of	   the	   construct	  was	   confirmed	   by	   restriction	  
enzyme	  mapping	  and	  DNA	  sequence	  analysis.	  	  	  
	  
3.19.	  	  Generation	  of	  Transgenic	  Mice	  overexpressing	  COX-­‐1-­‐10aa-­‐PGIS.	  
The	   transgene	   construct	   fragment	   was	   gel	   purified	   with	   QIAGEN	   Kit.	   All	   live	  
animal	  procedures	  were	   conducted	  with	   the	  approval	  of	   institutional	   animal	   care	  and	  
use	   committee.	   The	   transgenic	   mice	   were	   generated	   using	   pronuclear	   microinjection	  
technique	  (Nature	  Protocols	  2,	  2007)	  	  in	  the	  M.D.	  Anderson	  Institute.	  Mice	  used	  for	  the	  
generation	  of	  transgenic	  mice	  were	  maintained	  on	  a	  14hr	  light/10hr	  dark	  cycle.	  FVB/NJ	  
(Jackson	   Lab)	   female	   mice	   were	   superovulated	   with	   5	   IU	   of	   pregnant	   mare	   serum-­‐
gonadotropin	   and	   after	   48hrs	   with	   5	   IU	   of	   human-­‐chorionic	   gonadotropin.	   These	  
females	  were	  placed	  with	  intact	  FVB	  males	  for	  mating.	  Fertilized	  oocytes	  were	  collected	  
from	   the	   isolated	   oviducts	   of	   the	   superovulated	   females	   the	   following	   morning	   and	  
treated	   briefly	   with	   bovine	   hyaluronidase	   in	   M2	   medium	   to	   remove	   the	   associated	  
debris.	   The	   purified	   cDNA	   construct	   was	   diluted	   just	   before	   microinjection	   to	   a	  
concentration	   of	   3ng/uL.	   The	   cDNA	   (COX-­‐1-­‐10aa-­‐PGIS)	   was	   microinjected	   into	   the	  
pronucliei	  of	  fertilized	  oocytes	  using	  standard	  techniques,	  and	  the	  manipulated	  oocytes	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were	   transferred	   surgically	   into	   the	  oviducts	   of	   surrogate	   (pseudo-­‐pregnant)	   recipient	  
female	  mice	  and	  allowed	  to	  develop	  to	  full	  term.	  
	  
3.20.	  Identification	  of	  the	  Transgenic	  Mice	  by	  PCR	  Analysis.	  	  
The	  initial	  screening	  of	  founder	  mice	  for	  COX-­‐1-­‐10aa-­‐PGIS	  transgene	  was	  carried	  
out	  by	  PCR	  analysis	  on	  mouse	  tail	  DNA.	  This	  protocol	  was	  developed	  by	  Jon	  Neumann	  
(http://cmn.osu.edu/1894.cfm).	  Briefly,	  tail	  samples	  (1.5-­‐2	  mm)	  were	  digested	  in	  100	  μl	  
of	   1xPCR	   buffer	   with	   added	   detergents	   (0.45%	   NP40,	   0.45%	   TWEEN	   20)	   and	   10	   μl	  
Proteinase	  K	   (10	  mg/ml)	  @	  60°C	  overnight.	  The	  sample	  was	  further	  denatured	  for	  the	  
Proteinase	  K	  by	  boiling	  for	  15	  min,	  and	  then	  cooled	  on	   ice	  for	  5	  minutes.	  The	   isolated	  
genetic	  DNA	  (2uL	  tail	  DNA	  was	  added	  into	  a	  final	  20uL	  volume	  reaction)	  was	  subjected	  
to	  PCR	  analysis	  using	  PCR	  Reaction	  Buffer	  (1x	  PCR	  buffer,	  2.5	  mM	  MgCl2,	  200	  μM	  dNTPs,	  
1	  μM	  each	  designed	  primer	  and	  1	  unit	  Taq	  Polymerase	  with	  conditions	  (hold	  @	  94°C	  for	  
4.5	  min,	  30x	  step	  cycles	  of	  94°C	  for	  30	  sec	  (requires	  annealing	  temperature	  for	  20	  sec	  -­‐	  
varies	   according	   to	   G/C	   content	   of	   primers),	   72°C	   for	   1	  min	   and	   holding	  @	   4°C	   until	  
ready	   to	   analyze.	   PCR	  was	   performed.	   The	   primer	   sets	   for	   the	   COX-­‐1-­‐10aa-­‐PGIS	   gene	  
are:	   sense	   5’-­‐CCTCAAGGGTCTCCTAGGGA-­‐3’	   and	   antisense	   5’-­‐
GTGCTTCTCCTTCATCCTCGT-­‐3’.	  The	  amplified	  product	  length	  is	  445	  bp.	  The	  PCR	  product	  
was	  analyzed	  by	  agarose	  gel.	  The	  RNA	   isolated	  from	  tail	  clips	  of	   the	  mice	  was	  used	  as	  
template	  for	  qPCR	  using	  the	  designed	  primers.	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3.21.	  Breeding	  of	  the	  transgenic	  mice	  to	  get	  a	  colony	  of	  homozygous	  mice.	  
	   The	  hemizygous	  FVB/N	   founder	  mice	  expressing	  COX-­‐1-­‐10aa-­‐PGIS	  were	   further	  
bred	  with	  wild	  type	  FVB/N	  mice	  to	  get	  a	  colony	  of	  F1	  heterozygous	  mice.	  After	  achieving	  
enough	   number	   of	   heterozygous	   mice	   and	   identifying	   them	   by	   tail	   clip	   PCR,	   these	  
heterozygous	   mice	   were	   bred	   (male	   and	   female	   mating)	   to	   further	   get	   a	   colony	   of	  
homozygous	  mice	  expressing	  COX-­‐1-­‐10aa-­‐PGIS.	  	  
	  
3.22.	  	  Identification	  of	  homozygous	  transgenic	  mice	  by	  qPCR.	  
	   The	   tail	   clips	   collected	   from	  a	   set	   of	   heterozygous,	   homozygous	   and	  wild	   type	  
mice	  was	  cut	  into	  small	  pieces	  with	  the	  help	  of	  sterile	  razor	  blade.	  About	  100mg	  of	  the	  
tissue	  was	  crushed	  with	  the	  help	  of	  pestle	  in	  a	  porcelain	  mortar	  containing	  1mL	  of	  TRIzol	  
reagent	   from	   Invitrogen.	   The	   ground	   tissue	  was	   transferred	   to	   eppendorff	   tubes	   and	  
allowed	  to	  stand	  for	  5	  minutes	  and	  then	  the	  tubes	  were	  centrifuged	  at	  10,000g	  for	  15	  
minutes	  at	  4°C.	  The	  supernatant	  was	  isolated	  and	  the	  procedure	  was	  followed	  as	  given	  
in	  the	  Invitrogen	  protocol	  to	  isolate	  the	  RNA.	  The	  concentration	  of	  RNA	  was	  measured	  
using	  Nanodrop	  Bioanalyzer.	  First	  strand	  cDNA	  was	  synthesized	  using	  the	  Superscript	  III	  
First-­‐Strand	  Synthesis	  System	  for	  RT-­‐PCR	  from	  Invitrogen.	  5μg	  of	  total	  RNA	  was	  used	  as	  
the	   starting	   material.	   The	   first	   strand	   cDNA	   obtained	   in	   the	   synthesis	   reaction	   was	  
further	  amplified	  using	  PCR	  and	  Qiagens	  QuantiTect	  SYBR	  Green	  PCR	  kit	  and	  platinum	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Pfx	  DNA	  polymerase.	  The	  cDNA	  used	  was	  diluted	   in	  a	  1:10	  ratio	  and	  8μL	  of	   this	  cDNA	  
was	  used	   in	  a	  final	  reaction	  volume	  of	  20μL.	  Real	  time	  quantitative	  PCR	  was	  run	  using	  
the	   ABI7500	   Fast	   Real	   Time	   PCR	   system.	   The	   PCR	   conditions	   were	   95°C	   for	   15mins.	  
Subsequent	  PCR	  amplification	  consisted	  of	  35	  cycles	  with	  95°C	  for	  15s,	  annealing	  at	  60°C	  
for	  30s	  and	  72°C	  for	  30s.	  GAPDH	  was	  used	  as	  the	  internal	  control.	  Each	  sample	  was	  run	  
as	  duplicate.	  Ct	  values	  were	  obtained	  and	  compared.	  	  	  
	  
3.	  23.	  Bleeding	  time	  measurement.	  
A	  2mm	  tip	  of	  the	  tail	  was	  cut	  with	  scissor	  and	  time	  was	  noted	  as	  0	  seconds	  and	  
blood	  was	  blot	  on	  the	  filter	  paper.	  Then	  every	  30	  seconds	  the	  tip	  of	  tail	  drop	  was	  blot	  on	  
a	   filter	   paper.	   This	   was	   continued	   until	   there	   was	   no	   stain	   of	   blood	   and	   this	   was	  
considered	   as	   the	   bleeding	   time.	   The	   bleeding	   time	  was	   compared	   between	   the	  wild	  
type	  and	  transgenic	  mice.	  
	  
3.24.	   Determination	   of	   endogenous	   PGI2	   production	   in	   transgenic	   mice	   by	   LC/MS	  
analysis.	  
	   Each	  of	  the	  wild	  type	  mice	  and	  transgenic	  mice	  were	  placed	  in	  metabolic	  cages	  
and	  the	  urine	  was	  collected	  until	  a	   final	  volume	  of	  1mL.	  Then	  the	  urine	  samples	  were	  
processed	  for	  LC/MS	  injection	  as	  above	  in	  method	  section	  3.5.	  The	  data	  was	  analyzed	  to	  
detect	  6-­‐keto-­‐PGF1α,	  TXB2	  and	  PGE2	  in	  both	  wild	  type	  (WT)	  and	  transgenic	  (TG)	  mice.	  The	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values	  of	  the	  corresponding	  prostanoids	  were	  normalized	  with	  background	  and	  then	  the	  
ratio	  of	  6-­‐keto-­‐	  PGF1α	  to	  other	  protanoids	  was	  calculated	  and	  plotted.	  
	  
3.25.	   Determination	   of	   COX-­‐1-­‐10aa-­‐PGIS	   expression	   in	   the	   different	   organs	   in	  
transgenic	  mice	  by	  PCR	  analysis.	  	  
The	  mice	  were	  euthanized	  and	  	  organs	  and	  tissues	  (brain,	  heart,	  adipose	  tissue,	  
liver,	   lung,	  kidney,	  uterus,	  pancreas,	   intestine)	  were	   isolated	   from	  the	  mice	   (both	  wild	  
type	  ad	  transgenic	  mice)	  .	  Photographs	  were	  taken	  to	  identify	  any	  phenotype	  difference	  
between	  the	  WT	  and	  TG	  mice.	  	  Then	  about	  50mg	  of	  the	  tissue	  was	  taken	  in	  eppendorff	  
tubes	   and	  digested	  overnight	   using	   the	   same	  procedure	   as	   described	   above.	   Then	  on	  
the	  next	  day,	  DNA	  was	  isolated	  using	  Qiagens	  DNAeasy	  mini	  kit.	  400ng	  of	  DNA	  was	  used	  
as	  the	  starting	  material	  for	  running	  the	  PCR.	  PCR	  was	  run	  using	  the	  same	  procedure	  as	  
described	  above	  in	  method	  section	  3.20.	  
	  
3.26.	   Immunoblot	   analysis	   of	   COX-­‐1-­‐10aa-­‐PGIS	   in	   the	   different	   organs	   of	   transgenic	  
mice.	  
The	  organs	  were	  isolated	  from	  mice	  and	  100mg	  tissue	  were	  homogenized	  on	  ice	  
in	   lysis	   buffer	   (protease	   inhibitor,	   1mM	  PMSF,	   1M	   Tris	   (pH	   7.4),	   0.5	  M	   EDTA)	   for	   2-­‐3	  
mins.	   The	   lysate	   was	   centrifuged	   at	   10,000	   rpm	   for	   10	   mins	   at	   4°C.	   Protein	  
concentration	  was	  determined	  by	  BCA	  protein	  assay	  method.	  A	  concentration	  of	  25μg	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protein	  was	  loaded	  in	  each	  well	  and	  bands	  were	  visualized	  using	  specific	  anitbodies	  of	  
COX-­‐1	  and	  PGIS.	  
	  
3.27.	  Blood	  pressure	  and	  heart	  rate	  measurement.	  	  
	   The	   blood	   pressure	   (BP)	   and	   heart	   rate	   (HR)	  was	  measured	   using	   the	   tail	   cuff	  
method	  using	  the	  CODA	  system	  from	  Kent	  Scientific	  Corporation,	  Torrington,	  CT.	  Blood	  
pressure	  of	  every	   individual	  mouse	  was	  measured	   for	   three	  consecutive	  days	   to	  allow	  
for	  acclimatization	  and	  thereby	  obtain	  a	  more	  accurate	  measure.	  Systolic,	  Diastolic	  BP,	  
and	   HR	   were	   measured	   and	   plotted	   to	   compare	   any	   change	   in	   these	   parameters	  
between	  WT	  and	  TG	  mice.	  
	  
3.28.	  Thrombotic	  occlusion	  model.	  (Photochemical	  vascular	  injury)	  in	  transgenic	  mice.	  	  
A	  photochemical	  thrombotic	  occlusion	  model	  was	  used	  to	  produce	  injury	  in	  the	  
mouse	  carotid	  artery	  of	  both	  the	  wild	  type	  and	  transgenic	  mice.	  Briefly	  the	  male	  mice	  
were	   anesthetized	   with	   isoflurane	   and	   placed	   in	   a	   supine	   position.	   After	   a	   midline	  
cervical	   incision,	  the	  left	  common	  carotid	  artery	  was	  exposed	  and	  a	   laser	  doppler	  flow	  
probe	  407	  connected	  to	  Laser	  Doppler	  Perfusion	  Monitor	   (LDPM)	  Unit-­‐Periflux	  System	  
(PF)	   5010	   was	   placed	   on	   the	   artery	   for	   recording	   the	   blood	   flow.	   After	   recording	   a	  
constant	   baseline	   blood	   flow,	   the	   carotid	   artery	   was	   exposed	   to	   1.5mW	   green	   laser	  
beam	  540nm	  (Melles	  Griot,	  CA,	  USA)	  from	  a	  distance	  of	  5cm	  and	  rose	  bengal	  (50mg/kg)	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was	   injected	   through	   the	   tail	   vein.	   At	   this	   point	   blood	   flow	   was	   constantly	   recorded	  
using	   the	   accompanying	   software.	   The	   formation	   of	   an	   occlusive	   thrombus	   was	  
indicated	  by	   the	   cessation	  of	  blood	   flow.	   	   The	  blood	  perfusion	  was	  measured	   for	  120	  
mins	   and	   perfusion	   values	   were	   plotted	   in	   both	   the	   WT	   and	   TG	   groups	   of	   mice	   at	  



















4.1.	   Isolation,	  culture,	  and	  conversion	  of	   the	  adipocytes	   into	  prostanoid-­‐synthesizing	  
fat	  cells	  (PSFCs).	  	  	  
It	   has	   been	   reported	   that	   adipocytes	   could	   be	   reversely	   differentiated	   into	  
bipotent	   cells	   with	   a	   characteristic	   loss	   of	   lipid	   synthesis	   and	   increased	   adherence	  
tendency.	  Figure.	  4.	  A	  shows	  the	  time	  course	  display	  of	  the	  differentiation	  of	  adipocytes	  
with	   the	   conditional	   medium.	   The	   lipid	   droplets	   within	   the	   adipocytes	   gradually	  
disappeared	  and	   formed	  attached	   cells	   (Figure	  4A).	   The	   cells	  were	  able	   to	  metabolize	  
endogenous	  AA	  and	  synthesize	  a	  large	  amount	  of	  PGE2	  (3ng/10-­‐cm	  dish	  cells)	  and	  a	  very	  
small	  amount	  of	  6-­‐keto-­‐PGF1a	   (0.1ng/10-­‐cm	  dish	  cells),	  as	   identified	  by	  LC/MS	  analysis	  
(Table	  1,	  Figure.5.	  B).	  To	  further	  confirm	  the	  AA	  metabolism	  in	  the	  cells,	  an	  exogenous	  
AA-­‐metabolized	   profile	   was	   investigated	   by	   an	   assay	   using	   [14C]	   AA	   as	   a	   starting	  
substrate	  (Figure	  5A).	   	  The	  assay	  clearly	  showed	  that	  both	  [14C]	  PGE2	  and	  [14C]	  6-­‐keto-­‐
PGF1α	  were	   produced	  when	   [14C]	  AA	  was	   added	   (Figure.5A).	   This	   indicated	   that	   these	  
cells,	  similar	  to	  the	  endothelial	  cells,	  contain	  the	  enzymes	  necessary	  to	  synthesize	  PGE2	  
and	  PGI2.	  Using	  Western	  blot	  analysis,	   the	  cell’s	  expression	  of	  COX-­‐1,	  PGIS,	  and	  cPGES	  
were	  confirmed	  and	  the	  inducible	  COX-­‐2	  and	  mPGES-­‐1	  were	  not	  detectable	  (Figure	  4B,	  
panel	   i).	   	   The	   cells	   expressing	   the	   TXA2	   receptor	   (TP),	   PGI2	   receptor	   (IP),	   and	   the	   four	  
PGE2	  subtype	  receptors	  (EP1-­‐	  EP4)	  were	  also	  detected	  (Figure	  4B,	  panel	  ii).	  	  In	  addition,	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the	   ability	   to	   be	   reproduced	   for	   many	   passages	   (a	   stromal	   cell	   property)	   was	   also	  
confirmed	  in	  the	  cells.	  	  
	  
Figure.	   4.	  A.)	   Time-­‐course	  of	   the	  differentiation	  of	  mouse	   adipocytes	  under	   a	   conditional	  medium.	   The	  
days	   of	   the	   culture	   are	   indicated	   as	   labeled.	   Black	   bar,	   50μm.	   Briefly,	   mature	   adipocytes	   from	   the	  
supernatant	   of	   the	   digested	   adipose	   tissue	   was	   placed	   between	   two	   coverslips	   and	   then	   allowed	   to	  
differentiate	   in	   the	   DMEM	   F-­‐12	   medium.	   B.)	   Profiles	   of	   the	   Western	   blot	   analyses	   for	   prostanoids‟	  
synthesizing	   enzymes	   (i)	   and	   receptors	   (ii)	   for	   the	   prostanoid-­‐synthesizing	   cells.	   The	   COX-­‐1,	   PGIS,	   and	  
cPGES	  were	  identified	  in	  panel	  i,	  and	  the	  IP,	  TP,	  EP1,	  EP2,	  EP3	  and	  EP4	  receptors	  were	  identified	  in	  panel	  ii	  
in	   lanes	   1,	   2,	   3,	   4,	   5	   and	   6	   respectively.	   The	   inducible	   COX-­‐2	   (lane	   2)	   and	  mPGES-­‐1	   (lane	   5)	   were	   not	  
present	  (i).	  	  
	  
Thus,	   these	   cells	   were	   referred	   to	   as	   prostanoid-­‐synthesizing	   fat	   cells	   (PSFCs).	  	  
The	   generated	   cells	   also	   demonstrated	   some	   endothelial	   cell	   properties,	   such	   as	   the	  
expression	   of	   endogenous	   PGI2	   synthase	   and	   its	   receptor,	   which	   are	   part	   of	   the	  








Figure.	  5.	  A.)	  Determination	  of	   the	   [14C]AA	  metabolism	   in	   the	  PSFC	  using	  an	   isotope-­‐HPLC	  method.	  The	  
cells	   (∼0.1	  ×	  106)	   transfected	  with	  the	  empty	  vector	  pcDNA	  3.1	  were	  washed	  three	  times,	  suspended	   in	  
0.01	  M	  phosphate	  buffer,	  pH	  7.4	  containing	  0.15%	  NaCl	  (PBS)	  and	  then	  incubated	  with	  [14C]-­‐AA	  (10	  μM)	  in	  
a	   total	   volume	  of	   100	  μL.	   After	   5	  min,	   the	   reaction	  was	   terminated	   by	   the	   addition	   of	   200	  μL	   of	   0.1%	  
acetic	   acid	   containing	   35%	   acetonitrile	   (buffer	   A),	   and	   centrifuged	   at	   12	   000	   rpm	   for	   5	   min.	   The	  
supernatant	  was	  separated	  by	  HPLC	  on	  a	  C18	  column	  (4.5	  ×	  250	  mm)	  using	  buffer	  A	  with	  a	  gradient	  of	  35-­‐
100%	  acetonitrile.	  The	  [14C]-­‐AA	  metabolites	  were	  determined	  by	  a	  liquid	  scintillation	  analyzer	  built	  in	  the	  
HPLC	  system.	  The	  retention	  times	  of	  [14C]-­‐6-­‐keto-­‐PGF1α	  and	  [
14C]-­‐AA	  were	  calibrated	  by	  standards	  under	  
the	  same	  conditions.	  The	  amounts	  of	  produced	  6-­‐keto-­‐PGF1α	  represented	  the	  amounts	  of	   the	  produced	  
PGI2.	  	  
B.)	  LC/MS	  analysis	  of	  PSFCs	  showing	  endogenous	  metabolism	  of	  AA	  to	  PGE2.	  (i)	  chromatogram	  of	  PGE2	  at	  
16.8	  mins,	  (ii)	  Mass	  spectrum	  of	  PGE2	  (molecular	  weight	  351	  in	  negative	  mode).	  Cells	  were	  cultured	  in	  a	  
10cm	  plate.	  The	  supernatant	  was	  passed	  through	  C18	  column	  and	  eluted	  with	  acetone.	  It	  was	  dried	  and	  







4.2.	  Engineering	  and	  cloning	  of	  the	  triple	  catalytic	  enzyme	  -­‐1	  (COX-­‐1-­‐10aa-­‐PGIS)	  	  
	  
A	  cDNA	  sequence	  encoding	  a	  novel	  Trip-­‐cat	  Enzyme-­‐1	  (COX-­‐1-­‐10aa-­‐PGIS),	  linking	  
the	  C-­‐terminus	  of	  human	  COX-­‐1	  to	  the	  N-­‐terminus	  of	  human	  PGIS	  by	  a	  helical	  linker	  with	  
10	   amino	   acid	   residues	   (His-­‐Ala-­‐Ile-­‐Met-­‐Gly-­‐Val-­‐Ala-­‐Phe-­‐Thr-­‐Trp	   (10aa))	   derived	   from	  
human	  rhodopsin,	  was	  created	  by	  a	  PCR	  approach	  and	  then	  subcloned	  into	  pcDNA3.1,	  
with	  a	  CMV	  promoter	   (Figure	  6)	  using	  a	   similar	  approach,	  as	  described	  by	  Ruan	  et	  al,	  
2006.	  
	  
Figure.6.	   Engineered	   cDNA	   plasmid	   containing	   COX-­‐1	   linked	   to	   PGIS	   cDNA	   ,	   through	   the	   10aa	   sequence	  
generated	   by	   PCR	   approach	   and	   subcloning	   procedures	   .	   The	   pcDNA	   3.1	   vector	   containing	   a	  
cytomegalovirus	  early	  promoter	  was	  cloned	  with	  cDNAs	  of	  the	  COX-­‐1	  and	  PGIS	  using	  a	  PCR	  (polymerase	  
chain	  reaction)	  cloning	  approach.	  The	  sequences	  were	  confirmed	  by	  DNA	  sequencing	  and	  endonuclease	  
digestion	  analyses.	  The	  sequence	  of	  COX-­‐1	  was	   linked	  with	  the	  PGIS	  sequence	  through	  a	  10	  amino	  acid	  
(10aa)	  (His-­‐Ala-­‐Ile-­‐Met-­‐Gly-­‐Val-­‐Ala-­‐Phe-­‐Thr-­‐Trp)	  linker	  to	  form	  COX-­‐1-­‐10aa-­‐PGIS	  (Triple	  catalytic	  enzyme-­‐




4.3.	  Redirecting	  the	  PSFC	  line	  to	  specifically	  and	  constantly	  convert	  AA	  into	  PGI2,	  
	  thereby	  forming	  the	  PGI2-­‐PSFC	  line.	  	  
The	  PSFCs	  are	  suitable	  to	  be	  engineered	  into	  PGI2-­‐producing	  cells	  because	  these	  
cells	  contain	  endogenous	  AA,	  which	  can	  be	  metabolized	  to	  PGI2	  by	  overexpressing	  COX-­‐
1-­‐10aa-­‐PGIS.	  The	  PSFCs	  were	  transfected	  with	  the	  pcDNA3.1-­‐COX-­‐1-­‐10aa-­‐PGIS	  plasmid.	  
Using	   G418	   screening	   approach,	   which	   was	   followed	   for	   more	   than	   three	   weeks,	  
generated	   the	   stable	   cell	   line.	   Subsequently,	   the	   successful	   overexpression	   of	   the	  
recombinant	   COX-­‐1-­‐10aa-­‐PGIS	   protein	   in	   the	   PSFCs	  was	   confirmed	   by	   a	  Western	   blot	  
analysis	   that	   showed	   the	   correct	   molecular	   mass	   of	   the	   PGI2-­‐producing	   enzyme,	  
approximately	  130	  kDa	  (Figure	  7A,	  panel	  i).	  The	  stable	  transfection	  of	  COX-­‐1-­‐10aa-­‐PGIS	  
in	  PSFCs	  cells	  and	  its	  enzymic	  activity	  was	  further	  confirmed	  by	  the	  metabolism	  of	  the	  
[14C]	  AA	  into	  [14C]	  6-­‐keto-­‐PGF1a	  (degraded	  [14C]	  PGI2,	  Figure	  7B,	  panel	   i)	  as	  analyzed	  by	  
HPLC	   assay.	   The	  endogenous	  AA	   that	  was	  metabolized	   into	  PGE2	   (by	   the	   endogenous	  
cPGES,	   Figure.	   5B)	   in	   the	   PSFC	   line	   was	   redirected	   to	   produce	   PGI2	   in	   the	   PSFC	   line	  
overexpressing	  the	  Trip-­‐cat	  Enzyme-­‐1	  (PGI2-­‐PSFC	  line)	  as	  analyzed	  by	  the	  LC/MS	  analysis	  
(Figure.	   7A	   and	   B,	   panel	   ii).	   Thus,	   this	   cell	   line	   was	   termed	   the	   “PGI2-­‐PSFC”	   line,	   an	  
exceptional	   model	   for	   studying	   the	   biological	   functions	   of	   continuously	   produced,	  
unstable	  PGI2	  from	  the	  endogenous	  AA.	  By	  transfecting	  the	  COX-­‐1-­‐10aa-­‐PGIS	  cDNA	  into	  
the	   PSFCs,	   the	   vascular	   protector	   (PGI2)	   production	  was	   increased	   by	   50-­‐fold	   and	   the	  
inflammatory	   PGE2	   synthesis	   was	   decreased	   by	   15-­‐fold	   (Table	   1).	   Thus,	   the	   cells	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resulting	   from	   this	   cell	   line	   were	   termed,	   PGI2-­‐PSFCs	   in	   respect	   to	   their	   specific	  
biosynthesis	  of	  PGI2.	  	  
	  
Figure.7.i.	   (A)	   Western	   blot	   analysis	   of	   the	   PGI2-­‐	   prostanoid-­‐synthesizing	   cells	   using	   7%	   SDS-­‐PAGE.	  
Untransfected	  prostanoid-­‐synthesizing	  cells	  (Lane	  1),	  HEK293	  cells	  positively	  expressing	  COX-­‐1-­‐10aa-­‐PGIS	  
(Lane	  2)	   the	  PGI2-­‐PSFCs	   stably	  expressing	  COX-­‐1-­‐10aa-­‐PGIS	   (Lane	  3).	   The	  Trip-­‐cat	  enzyme-­‐1	   is	   indicated	  
with	  an	  arrow	  at	  130kDa.	  B).	  Determination	  of	  the	  [14C]	  AA	  metabolism	  in	  the	  PGI2-­‐PSFCs	  to	  6-­‐keto-­‐PGF1α	  .	  
The	   same	   method	   as	   described	   in	   figure	   5	   was	   followed.	   6ii.	   LC/MS	   analysis	   of	   PGI2-­‐PSFCS.	   A)	  
chromatogram	  of	  6-­‐keto-­‐PGF1α	  at	  9.8	  mins	  with	  B)	  spectrum	  showing	  molecular	  weight	  369.	  
	  
4.4.	  PGI2-­‐PSFCs	  inhibiting	  platelet	  aggregation	  in	  vitro	  
It	   is	   known	   that	   platelets	   primarily	   convert	   AA	   into	   TXA2	   through	   the	   coupling	  
actions	  of	  COX-­‐1	  and	  TXAS.	  In	  the	  platelet	  rich	  plasma	  (PRP),	  the	  majority	  of	  the	  added	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AA	  was	  metabolized	  into	  TXA2,	  which	  triggered	  platelet	  aggregation	  in	  minutes	  (Figure	  
8A).	  However,	   in	   the	  presence	  of	  PGI2-­‐PSFCs,	   the	  platelet	  aggregation	  was	  completely	  
blocked	  (Figure	  8C),	  which	  indicated	  that	  the	  cells	  were	  able	  to	  shift	  the	  AA	  metabolisms	  
from	   TXA2	   to	   PGI2	   and	   thereby	  mediate	   anti-­‐platelet	   aggregation	   in	   the	   PRP.	   On	   the	  
other	  hand,	  the	  empty	  vector	  transfected	  PSFCs,	  which	  produce	  PGE2,	  could	  only	  delay	  
and	   not	   completely	   block	   platelet	   aggregation	   (Figure	   8B).	   This	   indicates	   that	   the	  
engineered	  COX-­‐1-­‐10aa-­‐PGIS,	  expressed	  in	  the	  PSFCs,	  was	  able	  to	  effectively	  compete	  in	  
the	  AA	  metabolism	  with	  the	  endogenous	  TXAS.	  Furthermore,	  the	  results	  imply	  that	  the	  
PGI2-­‐PSFCs	  should	  be	  able	  to	   increase	  PGI2	   levels	  and	  decrease	  TXA2	  production	   in	  the	  
circulation	  for	  vascular	  protection	  if	  the	  cells	  are	  delivered	  into	  the	  circulation	  system.	  	  
	  
4.5.	  Effect	  of	  the	  PGI2-­‐PSFCs	  on	  mouse	  thrombotic	  occlusion	  model.	  	  
PGI2-­‐PSFCs’	   effect	   producing	   PGI2	   upon	   thrombogenesis	   in	   mice	   was	  
investigated.	   Blood	   flow	   was	   recorded	   before	   and	   after	   thrombotic	   occlusion	   in	   the	  
mouse	   carotid	  artery	   in	   the	  presence	  of	  PGI2-­‐PSFCs	  and	   the	  empty	  vector	   transfected	  
PSFCs	   -­‐	   the	   control.	   Photochemical	   injury	   induced	   by	   rose	   bengal	   and	   laser	   light	  
produced	   a	   cessation	   of	   blood	   flow.	   Although	   eventually	   restored	   in	   the	   presence	   of	  
PGI2-­‐PSFCs	  (Figure	  9A),	  the	  blood	  flow	  continuously	  decreased	  in	  the	  presence	  of	  PSFCs,	  
the	   negative	   control	   (Figure	   9B).	   This	   suggested	   that	   PGI2-­‐PSFCs,	  which	   produce	   PGI2,	  
 56 
help	   to	   abolish	   the	   formation	   of	   a	   thrombus	   in	   the	   carotid	   artery	   almost	   completely	  
when	  applied	  locally.	  
	  
Figure	  8.	  Effects	  of	   the	  PGI2-­‐PSFCs	  on	  platelet	  aggregation.	  The	  platelet-­‐rich	  plasma	  was	   incubated	  with	  
100	  µM	  AA	  at	   37°C	   in	   the	  presence	  of	   50μL	  PBS	   (A),	   PSFCs	  empty	   vector	   transfected	   (B)	   and	   the	  PGI2-­‐
PSFCs	  expressing	  Trip-­‐cat	  Enzyme-­‐1	  (C).	  The	  amount	  of	  cells	  used	  for	  the	  experiments	  were	  approximately	  




4.6.	  Effect	  of	  the	  PGI2-­‐PSFCs	  on	  mouse	  ischemic	  hindlimb	  model.	  	  	  
To	   test	   the	   vascular	   protection	   of	   the	   PGI2-­‐PSFCs	   in	   vivo,	   a	   mouse	   ischemic	  
hindlimb	  model	  was	  generated	  by	  placing	  a	   ligature	  on	  the	  right	   femoral	  artery	  of	  the	  
C57BL/6J	  mice,	   following	   the	  procedures	  described	  previously.	   The	   reduction	   in	  blood	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flow	  in	  the	  right	  hindlimb,	  following	  the	  ligation,	  was	  clearly	  detected	  (Figure	  10A,	  panel	  





Figure.9.	   Effect	   of	   the	   cell	   treatment	   on	   blood	   perfusion	   induced	   with	   thrombogenesis	   using	  
photochemical	  vascular	  thrombotic	  occlusion	  model.	  The	  cessation	  of	  blood	  flow	  in	  the	  presence	  of	  1.5	  x	  
106	   locally	   applied	   PGI2-­‐PSFCs	   (A)	   or	   PSFCs	   (B)	   is	   shown.	   Thrombus	   formation	   was	   induced	   with	   rose	  
bengal	  and	   laser	  beam.	  Blood	  flow	  was	  measured	  with	  a	   laser	  Doppler	  flow	  probe	  monitor.	   	  Blood	  flow	  
was	  recorded	  for	  a	  period	  of	  120	  mins	  to	  see	  obstruction	  in	  blood	  flow.	  	  
	  
the	  unligated	  left	  hindlimb	  (Figure	  10A,	  panel	  i	  –	  ‘1’).	  A	  single	  injection	  of	  the	  PGI2-­‐PSFCs	  
at	   the	   ischemic	   hindlimb	   resulted	   in	   a	   significantly	   greater	   enhancement	   of	   limb	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perfusion	   recovery	   (Figure	   10C,	   panel	   i).	   In	   contrast,	   the	   injection	   of	   empty	   vector	  
transfected	   PSFCs	   did	   not	   significantly	   improve	   the	   ischemic	   condition	   (Figure	   10B,	  
panel	   i).	   On	   days	   3,	   7,	   14,	   and	   21	   post	   ligation,	   the	   ischemic/	   non-­‐ischemic	   hindlimb	  
blood	  perfusion	  ratio	  as	  evaluated	  by	  LDPI	  were	  significantly	  increased	  in	  the	  PGI2-­‐PSFC	  
treated	   group	   (Figure	   10,	   panel	   ii,	   triangles)	   when	   compared	   with	   PSFCs	   (Figure	   10,	  
panel	   ii,	   )	   and	   control	   group	   (Figure	   10,	   panel	   ii,	   n)	   (P<0.01,	   n=6	   per	   group).	   No	  
autoamputation	   occurred	   in	   the	   PGI2-­‐PSFC	   treated	   group	   whereas	   autoamputations	  
were	  significantly	  more	   in	   the	  control	  group	  and	  PSFC	  group	  by	  day	  21.	  These	  studies	  
further	   validated	   the	   therapeutic	   potential	   of	   the	   PGI2-­‐PSFCs	   used	   for	   ischemic	  
protection	  and	  treatment.	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Figure	  10.	  Effects	  of	  the	  PGI2-­‐PSFCs	  on	  reperfusion	  of	  the	  mouse	  hindlimb-­‐ischemic	  model	  as	  monitored	  
by	  LDPI.	  The	  blood	   flow	   images	   (Panel	   i)	   and	  perfusion	   intensity	   (Panel	   ii)	  of	   the	  mouse	  hindlimbs	  with	  
(Panel	  i	  –	  “2”)	  and	  without	  (Panel	  i	  –	  “1”)	  femoral	  artery	  ligation	  are	  displayed.	  The	  red	  color	  within	  the	  
circled	  areas	   (Panel	   i,	  A-­‐C)	   in	  both	  hindlimbs	  represents	   the	  blood	   flow	   intensity	   (perfusion),	  which	  was	  
integrated	   and	   plotted,	   as	   shown	   in	   Panel	   ii.	   The	   perfusion	   after	   injection	   of	   PBS	   (n),	   PGI2-­‐PSFCs	  
(triangles),	  or	  empty	  vector	  transfected	  PSFCs	  ()	  in	  the	  femoral	  artery-­‐ligated	  hindlimb	  are	  shown	  (n=7).	  




4.7.	   Determination	   of	   the	   endogenous	   AA	   metabolisms	   in	   the	   mouse	   urine	   using	  
LC/MS.	  
LC/MS	   analysis	   of	   urine	   from	   mice	   group	   treated	   with	   PGI2-­‐PSFCs	   showed	   a	  
significant	  increase	  in	  6-­‐keto-­‐PGF1α	  (stable	  metabolite	  of	  PGI2)/PGE2	  ratio	  on	  days	  3	  and	  
7	  when	  compared	  to	  the	  control	  group	  and	  PSFCs-­‐treated	  group	  (Figure	  11A;	  P	  <0.001;	  
n=6).	   	   This	  was	   followed	  by	  a	   subsequent	  decrease	  on	  days	  14	  and	  21.	   This	   indicated	  
that	  PGI2-­‐PSFCs	  when	  injected	  in	  mice	  induced	  with	  ischemia	  in	  the	  hindlimb	  were	  able	  
to	  significantly	  produce	  PGI2	  during	  the	  21	  day	  study	  period.	  	  
	  
4.8.	  Determination	  of	  Mouse	  Running	  Time	  in	  hindlimb	  ischemia	  model.	  	  
In	  order	  to	  illustrate	  that	  the	  enhanced	  recovery	  of	  ischemic	  hind	  limb	  perfusion	  
is	   indeed	   improved,	   a	   unilateral	   ligation	   of	   the	   femoral	   artery	   in	   ischemic	   mice	  
dramatically	   inhibited	   mouse	   performance	   in	   a	   treadmill	   stress	   test	   (P	   <	   0.05).	  
Treatment	   with	   PGI2-­‐PSFCs	   producing	   PGI2	   (P	   <	   0.05)	   significantly	   increased	  
performance	   in	   the	   treadmill	   test,	   with	   improved	   performance	   lasting	   over	   21	   days	  
(Figure	  11B).	  After	  3,	  7,	  14	  and	  21	  days	   treatment	  with	  PGI2-­‐PSFCs	  post	   ligation,	  mice	  
ran	  significantly	  longer	  than	  mice	  in	  the	  PBS	  ischemia	  group	  and	  ischemia	  group	  treated	  
only	  with	  PSFCs.	  	  Results	  represent	  mean±SD	  treadmill	  run	  time.	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Figure	  11 A.)	  LC/MS	  analysis	  showing	  the	  specific	  PGI2	  production	  expressed	  as	  the	  ratio	  of	  6-­‐keto	  PGF1α	  
(stable	  metabolite	  of	  PGI2)	  and	  PGE2.	  Shown	  here	  is	  the	  PGI2	  production	  in	  the	  urine	  of	  ischemia	  induced	  
mice	  treated	  with	  PGI2-­‐PSFCs	  (triangles),	  non-­‐transfected	  PSFCs	  ()	  or	  PBS	  (n),	  where	  n=6	  for	  each	  group,	  
P<0.001.	   B).	   Treadmill	   running	   time.	   Mouse	   performance	   on	   a	   treadmill	   was	   recorded	   following	   a	  
unilateral	  ligation	  of	  the	  femoral	  artery	  and	  treatment	  with	  PGI2-­‐PSFCs	  (triangles),	  non-­‐transfected	  PSFCs	  




4.9.	  Detection	  of	  miRNA	  expression	  in	  the	  PGI2-­‐PSFCs	  	  
The	   miRNA	   microarray	   analysis	   of	   the	   total	   RNA	   in	   the	   cultured	   PGI2-­‐PSFCs	  
(Figure.	   12a,	   panel	   ii)	   showed	   a	   significant	   change	   in	   the	   expression	   levels	   of	   114	  
miRNAs	   in	   the	   cells.	   The	   expression	   level	   of	   these	   miRNAs	   in	   the	   empty	   vector	  
transfected	  PSFCs	  (derived	  from	  the	  same	  source	  of	  adipocytes),	  were	  used	  as	  a	  control	  
(Figure.	  12a,	  panel	   i).	  High	  quality	   signals	   for	   the	  miRNAs	   in	  both	  cells	  were	  obtained.	  
From	  these	  analyses	  it	  was	  determined	  that	  after	  comparison	  with	  the	  control	  (Figure.	  
12a,	   panel	   i),	   several	  miRNAs	   in	   the	  PGI2-­‐PSFCs	   (Figure.	   12a,	   panel	   ii)	  were	  either	  up-­‐
regulated	  (circles)	  or	  down-­‐regulated	  (squares).	  
	  
4.10.	   Profile	   of	   the	  miRNAs	   that	   are	   up-­‐regulated	   by	   the	   endogenous	   PGI2	   in	   PGI2-­‐
PSFCs.	  	  
After	   comparing	   the	  miRNAs’	  expression	   levels	   in	   the	  PGI2-­‐PSFCs	  and	   the	  PSFC	  
control	  cells,	  we	  observed	  that	  64	  out	  of	  114	  miRNAs	  showed	  different	  folds	  of	  increase.	  
Of	   these	  64	  miRNAs,	  5	   showed	  an	   increase	  of	  more	   than	  2-­‐folds	   (Figure.	  12b).	   	  There	  
was	   an	   approximate	   15-­‐,	   4-­‐,	   and	   3-­‐fold	   increase	   in	   the	   miRNAs	   711,	   31*	   and	   720	  
respectively	   (Figure.12b).	   Interestingly,	   these	   miRNAs	   have	   predicted	   target	   genes	  
(microRNA.sangers.ac.uk)	   that	   are	   associated	   with	   adipocyte	   differentiation,	  
atherosclerosis,	   tumors,	   and	   brain	   angiogenesis	   as	   listed	   in	   Table	   2.	   Therefore	   we	  
postulate	   that	   up-­‐regulated	  miRNAs	   in	   PGI2-­‐PSFCs	  will	   inhibit	   the	   expression	   of	   these	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target	  genes	  and	  thus	  have	  a	  protective	  role	  in	  atherosclerosis	  and	  tumors.	  In	  particular,	  
the	  expression	  level	  of	  the	  miRNA711	  increased	  by	  almost	  15-­‐folds	  (Figure	  12b),	  making	  
this	   a	   very	   significant	   observation	   because	   endogenous	   PGI2	   could	   be	   a	   powerful	   up-­‐
regulator	  for	  the	  miRNA711	  expression	  in	  mammalian	  cells.	  	  
	  
4.11.Profile	  of	   the	  miRNAs	  that	  are	  down-­‐regulated	  by	  the	  endogenous	  PGI2	   in	  PGI2-­‐
PSFCs.	  	  
There	   were	   54	   miRNAs	   down-­‐regulated	   by	   PGI2	   in	   the	   PGI2-­‐PSFCs	   when	  
compared	  with	  the	  control	  PSFCs.	  The	  top	  five	  miRNAs	  with	  more	  than	  a	  5-­‐fold	  decrease	  
in	   their	   expression	   levels	   are	   shown	   in	   Figure	   12b,	   and	   the	   target	   genes	   for	   these	  
miRNAs	  are	  listed	  in	  Table	  3.	  The	  most	  significantly	  down-­‐regulated	  miRNA	  is	  the	  466f-­‐
3p	   (13.5-­‐fold	   decrease),	   which	   might	   regulate	   the	   expression	   of	   target	   genes	   whose	  
biological	   function	   is	   associated	  with	   lipid	   clearance,	   tumors,	   and	   apoptosis	   (Table	   3).	  
There	  was	  also	  an	  approximate	  10-­‐fold	  decrease	  in	  miRNAs	  148a	  and	  467b*,	  which	  have	  
similar	  functions	  to	  that	  of	  the	  466f-­‐3p.	  It	  was	  also	  worth	  noting	  that	  a	  4-­‐fold	  decrease	  
in	   miRNAs	   206	   and	   574-­‐5p	   (data	   not	   shown),	   whose	   predicted	   target	   genes	   are	  





Figure	  12:	  (a.)	  MiRNA	  microarray	  profiles	  showing	  PSFC	  miRNA	  expression	  (panel	  i)	  and	  PGI2-­‐PSFC	  miRNA	  
expression	  (panel	  ii).	  Circle	  indicates	  the	  expression	  profile	  of	  the	  up-­‐regulated	  miRNA-­‐711	  and	  the	  square	  
indicates	  the	  expression	  profile	  of	   the	  down-­‐regulated	  miRNA-­‐466f-­‐3p.	  RNA	  was	   isolated	  from	  both	  the	  
PGI2-­‐PSFCs	   and	   PSFCs	   and	   send	   to	   LC	   sciences	   for	   microarray	   analysis.	   The	  miRNAs	   were	   detected	   by	  
fluorescence	   labeling	   using	   tag-­‐specific	   Cyc3	   (PSFCs)	   and	   Cyc5	   dyes	   (PGI2-­‐PSFCs).	   Hybridization	   images	  
were	  collected	  as	  shown	  above	   in	  11a	  by	   laser	  scanner.	  The	  values	  obtained	  from	  the	  ratio	  of	  detected	  
signals	   of	   Cyc5	   to	   Cyc3	   was	   used	   to	   calculate	   the	   p	   values	   and	   student	   t	   -­‐test	   	   was	   performed.	  
Differentially	   detected	   signals	   were	   those	   with	   less	   than	   0.05	   p-­‐values.	   	   (b.)	   The	   top	   5	   miRNAs’	   fold	  
increase	  and	  decrease	  in	  PGI2-­‐PSFCs	  when	  compared	  to	  PSFCs.	  	  MiRNAs	  that	  showed	  a	  significant	  change	  
in	   signals	   in	   PGI2-­‐PSFCs	  when	   comapred	  with	   PSFCs	  were	   selected	   and	   fold	   change	  was	   calculated	   and	  
plotted.	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Table	  2.	  Up-­‐regulated	  miRNAs	  in	  the	  PGI2-­‐PSFCs	  and	  their	  predicted	  target	  genes	  and	  




Predicted	  target	  genes	   Predicted	  biological	  function	  
miR-­‐711	   CCAAT/C/EBP	  beta	   ↓	  Adipocyte	  differentiation	  	  
↓	  Tumorigenesis	  
CD160	   ↓	  Pathologic	  neovascularization	  
Akt1	   ↓	  Adipogenesis,	  VSMC	  
differentiation/proliferation,	  
proliferation/invasion	  of	  malignant	  tumors,	  and	  
vascular	  dysfunction	  in	  obesity	  
Lipase	   ↓	  Atherogenesis	  
miR-­‐31*	   PPARα	   ↓	  Adipocyte	  differentiation	  
Brain	  specific	  angiogenesis	  
inhibitor	  
↓	  Angiogenesis	  
miR-­‐720	   Lipase	  endothelial	   ↓	  Atherogenesis	  
miR-­‐140*	   Amyloid	  beta	  (A4)	  precursor	  
protein-­‐binding,	  family	  A	  
↓	  Alzheimer’s	  disease	  
3-­‐hydroxy-­‐3-­‐methylglutaryl-­‐
coenzyme	  A	  synthase	  2	  
↓	  Ketogenesis	  
miR-­‐106a	   Tumor	  susceptibility	  gene	   ↓	  Tumors	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Table 3. Down-­‐regulated	  miRNAs	  in	  the	  PGI2-­‐PSFCs	  and	  their	  predicted	  target	  genes	  
and	  biological	  functions	  (microrna.sangers.ac.uk/genetargets)	  
Down-­‐regulated	  microRNAs	   Predicted	  target	  genes	   Predicted	  biological	  function	  
miR-­‐466f-­‐3p	   ABC1	   ↑	  Lipid	  clearance	  
Large	  tumor	  suppressor	   ↓	  Tumors	  	  
Lipase	   ↓	  Atherogenesis	  
miR-­‐148a	   ABC7	   ↑	  Lipid	  clearance	  
miR-­‐467b*	   CASP8	  and	  FADD-­‐like	  apoptosis	  
regulator	  
↑	  Apoptosis	  regulation	  
miR-­‐7a	   Insulin	  induced	  gene	  2,	  insulin	  
receptor	  substrate	  1	  and	  2	  
↑	  Insulin	  sensitivity	  
Block	  of	  proliferation	  1	   ↓	  Proliferation	  
miR-­‐374	   Suppression	  of	  tumorigenicity	  gene	   ↓	  Tumors	  
	  
	  
4.12.	   Inhibition	   of	   up-­‐regulated	   miRNA	   expression	   in	   PGI2-­‐PSFCs	   using	   PPARγ	  
antagonist.	  	  
PGI2-­‐PSFCs	  were	  treated	  with	  the	  PPARγ	  antagonist,	  GW	  9662	  (5μM),	  for	  24hrs	  
and	   the	   total	   RNA	   was	   isolated	   using	   TRIZOL	   reagent	   and	   analyzed	   by	   microarray	  
(Figure.	  13a,	  panel	  i).	  Interestingly,	  the	  effects	  of	  the	  endogenous	  PGI2-­‐upregulated	  and	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downregulated	  miRNAs’	  expression	  in	  the	  PGI2-­‐PSFCs	  were	  inhibited	  (Figure	  13b,	  panel	  
i).	   It	   was	   particularly	   interesting	   to	   note	   that	   the	   miRNAs	   711	   and	   466f-­‐3p,	   whose	  
expression	  levels	  were	  up/down-­‐regulated	  more	  than	  12-­‐folds	  by	  PGI2	  signaling	  (Figure.	  
12b)	   returned	   to	   or	   below	   their	   basal	   level	   (Figure	   13b,	   panel	   i).	   This	   result	   indicated	  
that	  1)	  PPARγ	  signaling	  is	   involved	  in	  regulating	  miRNA	  expression	  in	  mammalian	  cells;	  
2)	   PGI2-­‐mediated	   up-­‐regulation	   and	   down-­‐regulation	   of	   miRNA	   expression	   could	   be	  
through	  PPARγ;	  and	  3)	  at	   least	  miRNA711	  and	  466f-­‐3p	  are	  targets	  for	  the	  endogenous	  
PGI2	  signaling	  through	  PPARγ.	  
	  
4.13.	  	  Inhibition	  of	  up-­‐regulated	  miRNA	  expression	  in	  PGI2-­‐PSFCs	  using	  IP	  antagonist	  
	  	  The	   effects	   of	   the	   IP	   antagonist	   (CAY	   10441,	   1μM)	   on	   the	   changes	   in	   the	  
miRNAs’	  expression	  in	  PGI2-­‐PSFCs	  were	  compared	  with	  that	  of	  the	  control	  PSFCs	  (Figure.	  
13a,	  panel	  ii).	  Interestingly,	  the	  top-­‐five	  up-­‐regulated	  and	  down-­‐regulated	  miRNAs	  in	  the	  
PGI2-­‐PSFCs	  were	  inhibited	  (Figure.	  13b,	  panel	  ii)	  similar	  to	  the	  PPARγ	  antagonist	  (Figure.	  
13b,	   panel	   i).	   Again,	   the	   expression	   of	   the	   dramatically	   up-­‐regulated	   miRNA711	   and	  
down-­‐regulated	  466f-­‐3p	  (by	  the	  PGI2	  signaling)	  was	  blocked	  by	  the	  IP	  antagonist	  (Figure.	  
13b,	   panel	   ii).	   These	   results	   demonstrated	   that:	   1)	   up-­‐regulated	   and	   down-­‐regulated	  
miRNAs’	  expression	  in	  PGI2-­‐cells	   indeed	  results	  from	  the	  PGI2	  produced	  by	  the	  cells;	  2)	  
both	  IP	  and	  PPARγ	  are	  involved	  in	  PGI2	  signaling	  -­‐	  affecting	  miRNA	  expression;	  3)	  there	  is	  
likely	   a	   signaling	   molecule	   linking	   IP	   with	   PPARγ	   during	   the	   PGI2	   signaling	   affecting	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miRNA	  expression;	  and	  4)	  Since	  the	  nuclear	  receptor,	  PPARγ,	  is	  directly	  involved	  in	  the	  
regulation	  of	  gene	  expression,	  it	  can	  be	  deduced	  that	  PPARγ	  is	  a	  downstream	  target	  and	  
IP	  is	  an	  upstream	  target	  mediating	  the	  PGI2	  signaling	  for	  miRNA	  expression.	  	  
	  
4.14.	  Quantitative	  determination	  of	  miRNA711	  up-­‐regulated	  in	  PGI2-­‐PSFCs	  by	  qRT-­‐PCR	  
approach.	  	  
We	   further	   validated	   the	   observation	   of	   the	  miRNAs	   regulated	   by	   PGI2	   in	   the	  
PGI2-­‐PSFCs.	   The	  miRNA711	   which	   has	   the	   highest	   level	   up-­‐regulated	   in	   the	   cells	   was	  
selected	  as	  a	   target	   for	  qRT-­‐PCR	   analysis.	   	  As	  a	   result,	   the	   level	  of	  miRNA711	   in	  PGI2-­‐
PSFCs	   was	   up	   to	   6-­‐fold	   higher	   than	   that	   of	   the	   control	   PSFCs	   (Figure	   14).	   This	  
information	  is	  similar	  to	  that	  of	  the	  miRNA	  microarrays’	  results	  shown	  in	  Figure.	  12a	  and	  
b,	  in	  which	  the	  miRNA711	  was	  increased	  by	  more	  than	  10-­‐folds,	  compared	  to	  that	  of	  the	  
control	  cells.	  This	  quantitative	  data	  has	  further	  confirmed	  that	  miRNA711	  could	  be	  used	  




Figure	   .13.	   (a.)	   MiRNA	  microarray	   profiles	   showing	   PGI2-­‐PSFC	  miRNA	   expression	   when	   treated	   with	   IP	  
antagonist	   (panel	   i)	  and	  PPARγ	  antagonist	   (panel	   ii).	  Circle	   indicates	  the	  expression	  profile	  of	  miRNA711	  
and	  the	  square	  indicates	  the	  expression	  profile	  of	  miRNA-­‐466f-­‐3p.	  PGI2-­‐PSFCs	  were	  serum	  starved	  for	  5-­‐6	  
hrs	  and	  then	  one	  plate	  was	  treated	  with	  IP	  anatagonist	  (CAY10441,	  1μM)	  and	  the	  other	  was	  treated	  with	  
PPARγ	  antagonist	  GW9662	   (5μM).	  After	  24hrs,	   total	  RNA	  was	   isolated	  using	  TRIZOL	   reagent.	   Total	  RNA	  
was	   send	   to	   LC	   Sciences	   for	   performing	  miRNA	  microarray.	   Detection	   was	   performed	   by	   fluorescence	  
labeling.	  Hybridization	   images	  were	  collected	  using	   laser	   scanner.	   (b.)	  The	   return	   to	  baseline	  of	   the	  up-­‐
regulated	  and	  down-­‐regulated	  miRNA	  with	  PPARγ	  antagonist	  (panel	   i)	  or	   IP	  antagonist	  (panel	   ii)	   in	  PGI2-­‐
PSFCs	   is	   shown.	   	  The	  detected	  signal	  values	  obtained	   from	  miRNA	  microarray	  analysis	   from	  both	   the	   IP	  
and	  PPARγ	  antagonists	   treated	  PGI2-­‐PSFCs	  was	   compared	  with	   the	   values	  of	   PGI2-­‐PSFCs	   and	   the	   values	  
were	  plotted	  to	  see	  the	  inhibition.	  The	  signals	  returned	  to	  baseline	  level	  after	  treatment	  with	  antagonists	  




Figure.	   14.	   Quantification	   of	   miRNA	   711	   expression	   in	   PGI2-­‐PSFC	   by	   qRT-­‐PCR.	   The	   miRNA711	   was	  
measured	  by	  qRT-­‐PCR	  approach	  using	  RT²	  SYBR®	  Green	  qPCR	  Master	  Mix,	  the	  primer	  for	  miRNA711	  and	  
sno	  RNA-­‐142	  (housekeeping	  endogenous	  control),	  and	  then	  analyzed	  by	  qPCR	  using	  Applied	  Biosystems	  
7300	  Real	  Time	  PCR	  System.	  	  Differential	  expression	  of	  miRNA711	  in	  the	  cells	  was	  analyzed	  by	  the	  ΔΔCT	  
method.	  The	  levels	  of	  miRNA711	  in	  the	  cells	  were	  calculated	  using	  the	  formula	  2	  ^	  (-­‐∆∆Ct)	  (n=3).	  Firstly,	  
the	  miRNAs	  were	   isolated	   from	   the	   cultured	  PGI2-­‐PSFCs	  or	   control	   PSFCs	  using	  RT²	   qPCR-­‐Grade	  miRNA	  
Isolation	  Kit.	  Secondly,	  the	  isolated	  miRNAs	  were	  converted	  into	  cDNAs	  using	  RT²	  miRNA	  First	  Strand	  Kit;	  
and	   finally,	   the	   cDNAs	  were	  mixed	  with	  another	   kit,	   RT²	   SYBR®	  Green	  qPCR	  Master	  Mix,	   the	  primer	   for	  







4.15.	  Inhibition	  of	  lipid	  accumulation	  in	  PGI2-­‐PSFCs.	  	  
There	  was	  reduced	  accumulation	  of	  lipid	  droplets	  in	  PGI2-­‐PSFCs	  as	  compared	  to	  
the	  control	  PSFCs	  detected	  by	  Oil	  Red	  O	  staining	  after	  7	  days	  (Figure.	  15).	  PGI2-­‐PSFCs	  did	  
not	   accumulate	   lipid	   droplets	   when	   treated	   with	   adipogenic	   media	   containing	  
dexamethasone,	   IBMX,	  and	   insulin.	  This	   indicates	   that	  PGI2,	   through	   the	  up-­‐regulation	  
of	  miRNAs	  711,	  744	  and	  148b,	  could	  inhibit	  lipid	  accumulation	  (Figure.	  15).	  
	  
4.16.	  Detection	  of	  down-­‐regulated	  mRNAs	  using	  illumina	  gene	  expression	  assay.	  	  
This	  assay	  showed	  a	  more	  than	  a	  2-­‐fold	  increase	  in	  354	  mRNAs	  (Figure	  16i)	  and	  
more	  than	  a	  2-­‐fold	  decrease	  in	  471	  mRNAs	  in	  PGI2-­‐PSFCs	  in	  comparison	  to	  PSFCs	  (Figure.	  
16ii).	   In	  addition,	   the	  mRNA	  Akt1	  was	   identified	   to	  be	  down-­‐regulated	  by	  4-­‐folds.	  The	  
up-­‐regulated	  miRNA	  711	  (Table	  2),	  744,	  and	  148b,	  identified	  by	  microarray	  analysis	  also	  
have	   Akt1	   as	   one	   of	   their	   gene	   target	   (microrna.sangers.ac.uk/genetargets).	   Upon	  










Figure	  .15.	  (a.)	  Simple	  microscopy	  (Row	  1)	  of	  the	  PSFCs	  (arrow	  indicates	  lipid	  droplets)	  and	  PGI2-­‐PSFCs.	  Oil	  
Red	  O	  staining	  (Row	  2)	  of	  PSFCs	  (arrow	  indicates	  red	  color	  of	  lipid	  droplets)	  and	  PGI2-­‐PSFCs	  showing	  lipid	  
accumulation.	  PSFCs	  and	  PGI2-­‐PSFCs	  were	  treated	  with	  adipogenic	  medium:	  DMEM	  containing	  10%	  fetal	  
bovine	   serum	   (FBS),	   1µM	  dexamethasone	   (Sigma-­‐Aldrich),	   0.5mM	   Isobutyl	  methyl	   xanthine	   (IBMX)	   and	  
insulin	   (10µg/mL),	  and	   the	  cells	  were	  allowed	   to	  grow	   in	   this	  medium	  for	  4	  days.	  After	  4	  days	   the	  cells	  
were	   re-­‐fed	   with	   DMEM-­‐F12	  media	   containing	   10%	   FBS	   and	   10µg/mL	   insulin,	   and	   were	   grown	   for	   an	  
additional	  3	  days.	  Images	  were	  taken	  everyday	  to	  observe	  cells	  accumulating	  lipid	  droplets.	  After	  treating	  
the	   cells	  with	   the	   differentiation	  medium	   for	   7	   days,	   accumulation	   of	   lipid	  was	   idenfified	   by	  Oil	   Red	  O	  
staining.	   The	   cells	   were	   then	   observed	   via	   light	   microscope	   with	   100X	   magnification	   and	   then	  
photographed	  using	  Kodak	  DC	  290	  Zoom	  Digital	  camera	  (NY,	  USA).	  (b.)	  Comparison	  of	  integrated	  density	  
values	  between	  PSFCs	  and	  PGI2-­‐PSFCs.	  Intensities	  were	  determined	  using	  AlphaEase	  FC	  software	  from	  Cell	  





Figure.	   16.	   Illumina	   gene	   expression	   assay	   showing	   change	   in	   expression	   of	   mRNAs	   in	   PGI2-­‐PSFCs	  
compared	   to	   PSFCs.	   i)	   Upregulation	   of	   354	   mRNAs,	   ii)	   Downregulation	   of	   471	   mRNAs.	   Total	   RNA	   was	  
amplified	  and	  the	  first	  and	  second	  cDNA	  strands	  were	  synthesized	  with	  the	  help	  of	  T7	  oligo	  (dT)	  primers	  
and	   reverse	   transcriptase	   and	   DNA	   polymerase.	   In	   vitro	   transcription	   was	   performed	   and	   biotinylated	  
cRNA	  was	  	  amplified	  and	  illumina	  hybridization	  array	  was	  run	  and	  scanned	  with	  Bead	  array	  reader.	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4.17.	  Down-­‐regulation	  of	  Akt1	  expression	  in	  PGI2-­‐PSFCs	  using	  Immunoblot	  analysis.	  	  
	  
Using	  a	  monoclonal	  Akt1	  primary	  antibody,	  we	  detected	  the	  down-­‐regulation	  of	  
Akt1	  expression	   in	  PGI2-­‐PSFCs	  (Figure.	  17,	  Lane	  2)	  as	  compared	  to	  PSFCs	  (Fig.	  17,	  Lane	  
1).	   The	   experiment	   was	   normalized	   using	   GAPDH	   primary	   antibody.	   This	   finding	  
suggested	  that	  the	  up-­‐regulated	  microRNAs	  711,	  744,	  148b	  may	  be	  down-­‐regulating	  the	  
Akt1	  gene	  expression.	  	  	  
	  
Figure.	   17.	   Western	   blots	   showing	   the	   expression	   of	   Akt1	   (Lane	   1)	   in	   PSFCs	   and	   PGI2-­‐PSFCs	   (Lane	   2).	  
GAPDH	  was	  used	   to	  normalize	   the	  expression	   level	  of	   the	  Akt1.	  Cells	  were	  harvested	  and	   lysed	   in	   lysis	  
buffer	   [50mM	   Tris-­‐HCl	   (pH	   7.4),	   1%	   Triton	   X-­‐100,	   150mM	   NaCl,	   1mM	   EDTA,	   1mM	  
phenylmethanesulphonylfluoride,	   1%	   aprotinin,	   10mg/mL	   leupeptin,	   1mM	   sodium	   orthovanadate,	   and	  
1mM	  sodium	  fluoride.	  Cell	  lysates	  were	  centrifuged	  at	  12,000	  g	  for	  10	  min	  at	  4ºC.	  Protein	  concentration	  
of	  the	  cell	  lysate	  was	  determined	  by	  performing	  BCA	  protein	  assay.	  SDS-­‐PAGE	  sample	  buffer	  was	  added	  to	  
the	  lysates,	  which	  were	  then	  heated	  to	  100°C	  for	  5	  min.	  25μg	  of	  protein	  was	  loaded	  in	  each	  well	  of	  10%	  
acrylamide	   gel	   and	   separated	   by	   electrophoresis.	   Proteins	   were	   transferred	   onto	   a	   nitrocellulose	  
membrane,	   which	   was	   incubated	   with	   primary	   antibody	   against	   Akt1	   and	   a	   horseradish	   peroxidase	  




4.18.	  Generation	  of	  transgenic	  mice	  (TG)	  over	  expressing	  COX-­‐1-­‐10aa-­‐PGIS	  to	  increase	  
endogenous	  PGI2	  level	  
First,	  the	  cDNA	  fragment	  of	  human	  COX-­‐1-­‐10aa-­‐PGIS	  from	  pcDNA3.1	  vector,	  with	  
a	  general	  expression	  promoter,	  PCMV	  (Figure.	  18),	  was	  successfully	  created	  by	  the	   lab	  
and	   used	   for	   expressing	   the	   active	   COX-­‐1-­‐10aa-­‐PGIS	   in	   mice.	   Using	   pronuclear	  
microinjection	   transgenic	   mice	   technology,	   from	   the	   30	   founders	   generated,	   two	  
transgenic	   founders	   were	   identified	   by	   PCR	   (Figure	   19i	   and	   ii)	   at	   445bp.	   These	   2	  
founders	  were	  bred	  with	  wild-­‐type	  FVB/N	  mice	  and	  were	  found	  to	  pass	  the	  transgene,	  
following	   Mendelian	   rules.	   To	   test	   for	   expression	   of	   the	   transgene,	   tail	   PCR	   was	  
performed	   (Figure	   19iii).	   The	   resulting	   heterozygous	   mice	   were	   bred	   to	   get	   the	  




Figure	  18:	  Construction	  of	  the	  cDNA	  construct	  of	  COX-­‐1-­‐10aa-­‐PGIS.	  The	  sequence	  of	  COX-­‐1	  linked	  to	  PGIS	  
through	   a	   10	   amino	   acid	   linker	   (COX-­‐1-­‐10aa-­‐PGIS)	   was	   generated	   by	   PCR	   approach	   and	   subcloning	  
procedures	  provided	  by	  the	  vector	  company	  (Invitrogen).	  The	  resulting	  cDNA	  was	  successfully	  subcloned	  
into	  the	  pcDNA	  3.1	  vector	  at	  Kpnl	  and	  BamHl	  sites	  containing	  a	  cytomegalovirus	  early	  promoter	  using	  PCR	  
cloning	  approach.	  	  The	  pcDNA3.1	  vector	  containing	  COX-­‐1-­‐10aa-­‐PGIS	  was	  cut	  at	  the	  Nrul	  and	  Sphl	  sites	  to	  




Figure.	  19.	  Genotyping	  of	  the	  transgenic	  mice	  by	  PCR	  analysis.	  The	  expression	  of	  COX-­‐1-­‐10aa-­‐PGIS	  was	  
determined	  by	  performing	  PCR	  showing	  band	  at	  445bp,	  i)	  in	  founder	  transgenic	  mice	  lane	  11	  and	  lane	  26,	  
lane	  3	  is	  the	  COX-­‐1-­‐10aa-­‐PGIS	  cDNA.	  ii)	  F1	  transgenic	  mice	  in	  lanes	  4,	  6,	  8,	  9	  and	  10	  whereas	  lane	  3	  is	  the	  
positive	  standard	  COX-­‐1-­‐10aa-­‐PGIS.	  Briefly,	  tails	  (1.5-­‐2	  mm)	  were	  digested	  in	  100	  μl	  of	  1xPCR	  buffer	  with	  
added	  detergents	  (0.45%	  NP40,	  0.45%	  TWEEN	  20)	  and	  10	  μl	  Proteinase	  K	  (10	  mg/ml)	  @	  60°C	  overnight.	  
The	  sample	  was	  further	  denatured	  for	  the	  Proteinase	  K	  by	  boiling	  for	  15	  min,	  and	  then	  cooled	  on	  ice	  for	  5	  
minutes.	   The	   isolated	   genetic	   DNA	   (2uL	   tail	   DNA	   was	   added	   into	   a	   final	   20uL	   volume	   reaction)	   was	  
subjected	  to	  PCR	  analysis	  using	  PCR	  Reaction	  Buffer	  (1x	  PCR	  buffer,	  2.5	  mM	  MgCl2,	  200	  μM	  dNTPs,	  1	  μM	  
each	  designed	  primer	  and	  1	  unit	  Taq	  Polymerase	  with	  conditions	  (hold	  @	  94°C	  for	  4.5	  min,	  30x	  step	  cycles	  
of	  94°C	  for	  30	  sec,	  72°C	  for	  1	  min	  and	  holding	  @	  4°C	  until	  ready	  to	  analyze.	  The	  primer	  sets	  for	  the	  COX-­‐1-­‐
10aa-­‐PGIS	  gene	  are:	  sense	  5’-­‐CCTCAAGGGTCTCCTAGGGA-­‐3’	  and	  antisense	  5’-­‐GTGCTTCTCCTTCATCCTCGT-­‐






4.19.	  Generation	  and	  Characterization	  of	  homozygous	  transgenic	  mice	  	  
The	  transgenic	  mice	  carrying	  the	  gene	  of	  COX-­‐1-­‐10aa-­‐PGIS	  was	  identified	  by	  PCR	  
approach.	  First,	  two	  males	  (out	  of	  	  30	  new	  birth)	  permenantly	  carrying	  COX-­‐1-­‐10aa-­‐PGIS	  
gene	   (Figure.19.i	   and	   ii)	   were	   identified	   by	   PCR	   using	   a	   set	   of	   designed	   and	   specific	  
primers	  covering	  the	  C-­‐terminal	  COX-­‐1,	  10aa	  linker	  and	  N-­‐terminal	  PGIS	  ,	  and	  named	  as	  
COX-­‐1-­‐10aa-­‐PGIS-­‐transgenic	   mice.	   Homozygous	   mice	   were	   obtained	   by	   breeding	   the	  
heterozygous	   transgenic	   mice	   and	   these	   mice	   did	   not	   show	   any	   physical	   phenotype	  
change	   when	   compared	   with	   the	   wild	   type	  mice	   (Figure	   20).	   	   The	   homozygous	  mice	  
were	   further	   bred	   and	   identified	   by	   qPCR	   approach.	   It	   was	   found	   that	   Ct	   values	   for	  
heterozygous,	   homozygous	   and	   wildtype	   individuals	   were	   24.57,	   23.61	   and	   34.82	  
respectively.	  Thus	  mice	  were	  characterized	  as	  heterozygous,	  homozygous	  and	  wildtype	  
by	  comparison	  of	  the	  Ct	  values	  with	  the	  respective	  standard	  Ct	  values	  (Figure.	  21).	  
	  
4.20.	  	  Endogenous	  production	  of	  PGI2	  is	  increased	  in	  COX-­‐1-­‐10aa-­‐PGIS	  transgenic	  mice	  
The	  catalytic	  activity	  of	  the	  over	  expressed	  COX-­‐1-­‐10aa-­‐PGIS	  in	  the	  TG	  mice	  was	  
investigated	  by	  determination	  of	  the	  PGI2	  metabolite	  in	  the	  urine	  of	  the	  TG	  mice	  using	  
LC/MS	  analysis.	  It	  was	  observed	  that	  the	  ratio	  of	  the	  metabolite	  of	  PGI2,	  6-­‐keto-­‐PGF1α	  to	  
PGE2	  and	  TXB2	  was	  7	   in	  TG	  mice	  and	  1	   in	   the	  wild	   type	  mice	   (Figure	  22A	  and	  B).	  This	  
demonstrates	   more	   than	   5	   fold	   increase	   in	   PGI2	   biosynthesis	   in	   the	   TG	   mice.	   These	  
observations	  have	  clearly	  confirmed	  that	  the	   induced	  COX-­‐1-­‐10aa-­‐PGIS	  gene	   in	  the	  TG	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mice	  had	  been	  successfully	  expressed	  in	  the	  tissues	  and	  	  functionally	  active	  to	  produce	  
PGI2.	  
	  
Figure.	  20.	  Image	  showing	  physical	  comparison	  between	  the	  WT	  and	  the	  TG	  mice.	  	  Images	  were	  taken	  of	  
the	  homozygous	  transgenic	  mice	  and	  wild	  type	  mice	  with	  the	  camera	  to	  see	  if	  there	  was	  any	  phenotype	  




Figure.	  21.	  Characterization	  of	  homozygous	  transgenic	  mice	  by	  qPCR.	  Shown	  here	  is	  the	  amplification	  plot	  
obtained	  after	  running	  the	  qPCR.	  Briefly,	  RNA	  was	  isolated	  from	  the	  tail	  tissue	  (100mg)	  collected	  from	  a	  
set	  of	  heterozygous,	  homozygous	  and	  wild	  type	  mice	  with	  TRIZOL	  reagent.	  The	  concentration	  of	  RNA	  was	  
measured	  using	  Nanodrop	  Bioanalyzer.	  First	  strand	  cDNA	  was	  synthesized	  using	  the	  Superscript	   III	  First-­‐
Strand	  Synthesis	  System.	  The	  first	  strand	  cDNA	  obtained	  in	  the	  synthesis	  reaction	  was	  further	  amplified	  by	  
PCR	   and	   Qiagens	   QuantiTect	   SYBR	   Green	   PCR	   kit	   and	   platinum	   Pfx	   DNA	   polymerase.	   Real	   time	  
quantitative	  PCR	  was	  run	  using	  the	  ABI7500	  Fast	  Real	  Time	  PCR	  system.	  PCR	  amplification	  consisted	  of	  35	  
cycles	  with	   95°C	   for	   15s,	   annealing	   at	   60°C	   for	   30s	   and	   72°C	   for	   30s.	   GAPDH	  was	   used	   as	   the	   internal	  




Figure	  22:	  LC/MS	  analysis	  of	  prostanoid	  	  in	  the	  urine	  	  of	  transgenic	  (TG)	  and	  wild	  type	  (WT)	  mice.	  A)	  Ratio	  
of	  6-­‐keto-­‐PGF1α	  to	  PGE2	  in	  both	  the	  TG	  and	  WT	  mice,	  B)	  Ratio	  of	  6-­‐keto-­‐PGF1α	  to	  TXB2	  in	  the	  both	  the	  TG	  
and	  WT	  mice.	  Each	  of	  the	  WT	  and	  TG	  mice	  were	  placed	  in	  metabolic	  cages	  and	  urine	  was	  collected	  (n=6).	  
Then	   the	  urine	   samples	  were	  passed	   through	  C18	   cartridges	   and	   then	  eluted	  with	   acetone.	   The	  eluent	  
was	  dried	  with	  nitrogen	  gas.	  The	  dried	  substrate	  was	  then	  diluted	  in	  buffer	  A	  and	  injected	  for	  detection	  by	  
LC/MS/MS	  analysis.	  The	  spectrum	  (molecular	  weight)	  and	  chromatogram	  (retention	  time)	  was	  obtained	  
and	   compared	  with	   the	   standards	   for	   6-­‐keto-­‐PGF1α,	   TXB2	   and	   PGE2	   for	   the	   respective	   prostanoids.	   The	  
signal	  values	  obtained	   from	  the	   injected	  urine	  samples	  were	  normalized	  with	   the	  background	  and	   then	  
ratio	  of	  6-­‐keto-­‐PGF1α	  to	  PGE2	  and	  TXB2	  was	  found	  to	  be	  7	  for	  the	  transgenic	  mice	  and	  1	  for	  the	  wild	  type	  
mice.	  The	  above	  graph	  represents	  mean±SD	  (p<0.001).	  
	  
	  
4.21.	  Effect	  of	   increased	  endogenous	  PGI2	  production	  on	  haemodynamic	  parameters	  
in	  COX-­‐1-­‐10aa-­‐PGIs	  transgenic	  mice.	  
Prostacyclin	  is	  a	  potent	  inhibitor	  of	  platelet	  function	  and	  a	  vasodilator.	  Thus	  the	  
bleeding	  time	  of	  the	  transgenic	  mice	  was	  increased	  to	  55	  mins	  (n=6)	  as	  compared	  to	  the	  
wild	  type	  mice	  which	  showed	  a	  mean	  bleeding	  time	  of	  15	  mins	  (Figure	  23i).	  One	  of	  the	  
most	   important	   risk	   factor	   for	   up	   regulated	   prostacyclin	   production	   is	   it	   may	   cause	  
lowering	   of	   blood	   pressure.	   However,	   blood	   pressure,	   both	   systolic	   and	   diastolic	  
 82 
(Figure.23ii)	  along	  with	  heart	   rate	  measurement	   (Figure	  23iii)	  of	  both	   the	  TG(+/+)	  and	  
WT	  mice	  showed	  no	  significant	  difference	  .	  	  
	  
4.22.	  The	  gene	  profile	  of	  the	  COX-­‐1-­‐10aa-­‐PGIS	  expression	  in	  different	  organs	  
Unlike	  COX-­‐1,	  PGIS	  is	  tissue	  specific	  .	  In	  general,	  it	  is	  largely	  localized	  in	  vascular	  
endothelial	  cells	  to	  produce	  PGI2	  for	  vascular	  protection	  through	  the	  biological	  functions	  
of	  vasodilatation	  and	  anti-­‐platelet	  aggregation.	  It	  becomes	  very	  interesting	  in	  finding	  the	  
tissue	  specificity	  of	  the	  gene	  and	  proteins	  in	  different	  tissues	  after	  combining	  the	  COX-­‐1	  
and	  PGIS	   in	  one	  molecule.	  The	  general	   level	  of	  distribution	  of	   the	  COX-­‐1-­‐10aa-­‐PGIS	   in	  
different	  tissues	  of	  the	  transgenic	  mice	  was	  identified	  by	  PCR	  using	  the	  specific	  primers	  
as	  described	  above.	  Figure.	  24i	  shows	  the	  different	  organs	  expressing	  COX-­‐1-­‐10aa-­‐PGIS	  
gene	  permanently.	  It	  is	  particularly	  valuable	  to	  find	  the	  gene	  expressed	  in	  heart,	  kidneys	  
and	  brain	  which	   suggests	   that	   the	  gene	   could	  provide	  protection	   from	   ischemic	  heart	  
disease,	  kidney	  failure	  and	  stroke	  due	  to	  thrombosis	  and	  vasoconstriction.	  The	  protein	  
level	   expression	   of	   the	   COX-­‐1-­‐10aa-­‐PGIS	   enzyme	   in	   the	   major	   organs	   was	   further	  
identified	   by	   Western	   blot	   analysis	   (Figure.	   24	   ii).	   COX-­‐1-­‐10aa-­‐PGIs	   have	   an	   unique	  
molecular	   weight	   at	   130	   kDa,	   which	   could	   be	   easily	   distinguished	   from	   endogenous	  
COX-­‐1	  and	  PGIS	  using	  specific	  anti-­‐COX-­‐1	  and	  PGIS	  antibodies.	  COX-­‐1-­‐10aa-­‐PGIS	  protein	  
was	  overexpressed	  in	  the	  important	  organs,	  heart,	  lungs,	  brain	  and	  kidneys.	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Figure	   23:	   Measurement	   of	   haemodynamic	   parameters	   in	   mice.	   i)	   Bleeding	   time	  
measurement	  in	  TG	  and	  WT	  mice.	  After	  clipping	  the	  tail,	  blood	  was	  blot	  on	  filter	  paper	  
every	  30s	  until	  bleeding	  stopped.	  Bleeding	  time	  was	  55	  mins	   in	  TG	  and	  15	  mins	   in	  WT	  
mice.	   ii)	   Blood	   pressure	  measurement	   by	   tail	   cuff	  method.	   Both	   systolic	   and	   diastolic	  
blood	  pressure	  was	  measured	  in	  both	  TG	  and	  WT	  mice.	  iii)	  Heart	  rate	  measurement	  by	  
tail	  cuff	  method.	  Heart	  rate	  was	  measured	  along	  with	  blood	  pressure	  in	  both	  the	  TG	  and	  






Figure	   24.i.	   PCR	   analysis	   of	   the	   different	   organs	   of	   the	   transgenic	   mice.	   An	   arrow	  
indicates	   445bp	   length	   COX-­‐1-­‐10aa-­‐PGIS.	   Lanes	   1)	   Positive	   control,	   2)	   Negative	  
control,	  3)	  Lung,	  4)	  Adipose	  tissue,	  5)	  Intestine,	  6)	  Brain,	  7)	  Wild	  type	  tail,	  8)	  Heart,	  9)	  
Liver,	  10)	  TG	  tail,	  11)	  pancreas,	  12)	  prostrate	  and	  13)	  uterus.	  ii)	  Western	  blot	  analysis	  
of	   the	  different	  organs	  of	   the	  transgenic	  mice.	  The	  arrow	   indicates	  COX-­‐1-­‐10aa-­‐PGIS	  
protein	   expression	   at	   130kDa.	   Lanes	   1)	   Lung,	   2)	   Heart,	   3)	   Intestine,	   4)	   pancreas,	   5)	  
Adipose	  tissue,	  6)	  Brain,	  7)	  Uterus	  and	  8)	  Liver	  	  	  
	  
4.23.	  	  Effects	  of	  overproduction	  of	  PGI2	  on	  live	  birth	  	  
PGI2	   is	   reported	   to	   help	   in	   embryonic	   development.	   It	   was	   observed	   that	   the	  
reproductive	  activity	  of	  the	  TG	  mice	  were	  significantly	  increased	  which	  was	  indicated	  
by	  higher	  numbers	  of	  live	  birth,	  compared	  to	  that	  of	  the	  bred	  wild	  type	  mice	  (Figure.	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25).	  It	  provided	  direct	  evidence	  to	  settle	  a	  conclusion	  that	  PGI2	  could	  increase	  female	  
reproductive	  activity	  to	  increase	  the	  live	  birth	  in	  mice,	  and	  put	  forward	  the	  idea	  that	  
that	   any	   drugs	   and	   approaches	   reducing	   PGI2-­‐biosynthesis,	   such	   as,	   NSAIDs	   might	  
reduce	   the	   fertility	   in	  women.	  The	  existing	  clinical	  protocol	  using	  aspirin	   to	   improve	  
success	   rate	  of	   fertility	  procedures,	   such	  as	   IVF	  may	  be	  needed	   to	  be	   reevaluated	   if	  
this	  observation	  is	  further	  clarified	  by	  indepth	  studies.	  
	  
4.24.	  Anatomical	  study	  of	  the	  different	  organs	  of	  the	  transgenic	  mice	  
Since	   a	   transgene	   was	   overexpressed	   in	   the	   mice,	   we	   wanted	   to	   study	   if	   its	  	  
overexpression	  in	  the	  different	  organs	  changed	  the	  anatomy	  of	  the	  organs.	  Therefore	  
heart,	  lung,	  kidney,	  brain,	  liver	  were	  isolated	  from	  both	  the	  TG	  and	  WT	  mice	  (n=3)	  and	  	  
pictures	  were	  taken	  with	  camera	  and	  compared	  to	  observe	  any	  difference	  .	  None	  of	  
the	  organs	  showed	  any	  anatomical	  difference	  as	  observed	  from	  the	  Figure	  26.	   	  Thus	  









Figure	  25:	  Determination	  of	  the	  number	  of	  litters	  born	  from	  the	  TG	  and	  wild	  type	  (WT)	  mice.	  Transgenic	  
mice	  when	  bred	  were	  able	  to	  give	  birth	  to	  higher	  number	  of	  pups	  (~12)	  compared	  to	  wild	  type	  mice	  (~7).	  
Observations	  were	  done	  in	  5	  different	  breeding	  pairs	  of	  mice.	  The	  photograph	  here	  shows	  the	  number	  of	  





Figure.	  26.	  Anatomical	  differences	  in	  the	  organs	  of	  the	  TG	  and	  WT	  mice.	  Organs	  like	  heart,	  brain,	  kidney	  
and	   liver	  were	   isolated	   from	  both	   the	   TG	   and	  WT	  mice	   (n=3)	   and	   images	  were	   taken	  with	   the	   help	   of	  
camera.	   The	   organs	   of	   both	  WT	   and	   TG	   as	   shown	   in	   the	   picture	   above	   did	   not	   show	   any	   anatomical	  
difference.	  
	  
4.25.	  Resistance	  to	  thrombosis	  in	  the	  transgenic	  mice	  using	  carotid	  artery	  thrombosis	  
model	  
	   	   The	  effect	  on	  vascular	  protection	  in	  cases	  of	  vascular	  disease	  by	  the	  permanent	  
COX-­‐1-­‐10aa-­‐PGIS	   gene	   expression	   was	   demonstrated	   in	   a	   carotid	   artery	   thrombosis	  
model.	   In	   this	   the	   both	   the	   TG	   and	   WT	   mice	   were	   tested	   for	   their	   resistance	   to	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thrombosis	   which	   is	   one	   of	   the	   major	   causes	   of	   stroke	   and	   heart	   diseases.	   The	  
combination	   of	   laser	   beam	   and	   rose	   bengal	   induced	   thrombosis	   in	   the	   carotid	   artery	  
which	  was	  associated	  with	  a	   reduction	   in	  blood	   flow	  within	  10	  mins	  after	   injection	  of	  
rose	  bengal	   leading	   to	  death	   in	   the	  wild	   type	  mice	  within	  2	  hrs	   (Figure	  27B	  and	  C(red	  
squares),	  n=10).	  Whereas,	  in	  the	  transgenic	  mice	  the	  decreased	  blood	  flow	  was	  reversed	  
after	  rose	  bengal	  injection	  and	  thus	  they	  survived	  from	  the	  thrombosis.	  (Figure	  27A	  and	  
C(black	  squares),	  n=10).	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Figure	   27:	   Study	   of	   resistance	   to	   thrombosis	   in	   TG	   mice	   by	   using	   the	   photochemical	   carotid	   artery	  
thrombosis	   model.	   Representative	   graphs	   recorded	   on	   the	   Laser	   doppler	   perfusion	   imaging	   system,	  
showing	  the	  change	  in	  blood	  perfusion	  in	  response	  to	  photochemical	  vascular	  injury	  in	  A)	  TG	  mice	  and	  B)	  
WT	  mice.	  C)	  Percentage	  change	  in	  perfusion	  was	  calculated	  at	  different	  time	  intervals	  and	  plotted	  against	  
time.	   Red	   squares	   and	   black	   squares	   indicate	   perfusion	   change	   in	  WT	   and	   TG	  mice	   respectively.	   Rose	  
bengal	   (50mg/kg)	  was	   injected	   through	   the	   tail	   vein	   and	   this	   time	   of	   injection	  was	   considered	   as	   zero	  
mins.	  	  The	  blood	  perfusion	  was	  recorded	  for	  a	  period	  of	  120	  mins.	  (n=10,	  p<0.01).	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5.	  DISCUSSION	  
5.1.	  Stable	  expression	  of	  COX-­‐1-­‐10aa-­‐PGIS	  in	  adipose	  tissue	  derived	  primary	  culture	  of	  
mature	  adipocytes	  
PGI2	   is	   a	   potent	   endogenous	   inhibitor	   of	   platelet	   aggregation	   and	   vascular	  
smooth	  muscle	  cell	  proliferation	  and	  a	  vasodilator.	  Therefore,	  since	  decades	  there	  have	  
been	  ongoing	  attempts	  to	  use	  PGI2	  and	   its	  analogues	  to	  treat	  vascular	  diseases.	  Many	  
studies	   have	   been	   reported,	   in	   which	   PGI2	   and	   its	   mimics	   have	   been	   used	   to	   treat	  
pulmonary	  arterial	  hypertension	  (Gomberg	  et	  al.,	  2008),	  atherosclerosis	  (Arehart	  et	  al.,	  
2007),	   peripheral	   vascular	   diseases	   (Berman	   et	   al.,	   2006)	   and	   congestive	   heart	   failure	  
(Kerbaul	  et	  al.,	  2007).	  Inspite	  of	  having	  such	  benefits	  in	  several	  vascular	  disorders,	  use	  of	  
PGI2	  and	  its	  analogues	  is	  challenged	  with	  a	  major	  limitation	  of	  short	  half-­‐life.	  Therefore	  
they	  have	  to	  be	  administered	  as	  continuous	  intravenous	  infusion	  for	  a	  beneficial	  effect,	  
which	   results	   in	   bleeding	   and	   injury	   at	   the	   site	   of	   injection.	   Our	   study	   was	   aimed	   at	  
providing	  new	   insights	   for	  developing	   a	  novel	   approach	   for	  using	  endogenous	  PGI2	   to	  
protect	  the	  vascular	  system.	  	  	  
	   Cell	   therapy	   is	   widely	   used	   to	   promote	   therapeutic	   angiogenesis	   in	   several	  
vascular	  disorders.	  Adipose	  tissue	  serves,	  as	  a	  rich	  source	  of	  wide	  array	  of	  cells	  and	  it’s	  
easy	   to	   obtain	   and	   culture	   them.	   The	   fact	   that	   mature	   adipocytes	   could	   be	  
differentiated	   into	   cells	   that	   had	   the	   capacity	   to	   metabolize	   endogenous	   AA	   to	  
prostanoids	  (Figure	  4a	  and	  5)	  provided	  the	  evidence	  that	  these	  prostanoid	  synthesizing	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fat	  cells	  (PSFCs)	  could	  be	  further	  modified	  to	  therapeutic	  cells.	   Initially,	  adipose	  tissue-­‐
derived	   stem	   cells	  were	   compared	   against	   the	  differentiated	   adipocytes	   to	   determine	  
which	  cell	  type	  produced	  more	  PGI2.	  Although	  many	  similarities	  exist	  between	  the	  two	  
types	   of	   cells,	   it	  was	   determined	   that	   the	  differentiated	   adipocytes	   had	   a	   higher	   PGI2	  
production.	  	  
It	   was	   particularly	   interesting	   to	   see	   that	   the	   PSFCs	   showed	   a	   capacity	   to	  
metabolize	  endogenous	  AA	  predominantly	  into	  PGI2	  and	  PGE2,	  one	  of	  the	  characteristics	  
of	   stem,	   stromal,	   and	   endothelial	   cells	   (Kleiveland	   et	   al.,	   2008,	   Denizot	   et	   al.,	   1998,	  
Taylor	  et	  al.,	  1987).	  Another	  stromal	  cell	  characteristic	  also	  seen	  in	  the	  PSFCs	  was	  their	  
ability	  to	  reproduce	  over	  a	  long	  period	  of	  time.	  This	  implied	  that	  the	  cells	  might	  have	  the	  
capacity	   to	   survive	   in	   vivo	   for	   a	   long	   period	   as	   well,	   and	   further	   differentiate	   into	  
functional	   tissue.	   Recombinant	   protein	   cDNA-­‐based	   gene	   transfer	   for	   primary	   culture	  
cells	   is	   often	   unpredictable	   and	   unstable.	   It	   is	   particularly	   challenging	   when	   using	  
pcDNA3.1.	  vector.	  Our	  current	  study	  has	  shown	  that	  the	  COX-­‐1-­‐10aa-­‐PGIS	  cDNA	  could	  
be	   transferred	   into	   the	   PSFCs	   using	   Lipofectamine	   2000	   (Figure	   6	   and	   7).	   This	   has	  
provided	   a	   general	   approach	   for	   transferring	   other	   enzymes’	   cDNA	   into	   the	   cell	   line	  
derived	  from	  the	  primary	  cultured	  fat	  cells,	  which	  have	  potential	  to	  be	  developed	  into	  
therapeutic	  intervention.	   	  
	   The	   COX-­‐1-­‐10aa-­‐PGIS	   gene	   transfer	   was	   not	   only	   able	   to	   produce	   PGI2	   in	   the	  
PSFCs,	   but	   also	   shifted	   the	   metabolized	   production	   of	   endogenous	   AA	   into	   a	   more	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favorable	   PGI2	   production	   and	   a	   reduced	   PGE2	   production	   in	   the	   cells	   (Figure	   7).	   This	  
demonstrated	   a	   dual	   effect	   on	   potential	   vascular	   protection	   by	   increasing	   PGI2	  
production	   and	   reducing	   PGE2	   production.	   Such	   specific	   vascular	   protection	   is	   not	  
available	  through	  existing	  treatments	  with	  drugs	  like	  Aspirin,	  COX-­‐2	  inhibitors	  and	  PGI2	  
analogs.	  Additionally,	  we	  would	   like	  to	  further	   investigate	  the	  effect	  of	  overexpression	  
on	  VEGF,	  HGF,	  and	   IGF1	  secretion	  by	   the	  PGI2-­‐PSFCs	   to	  confirm	  any	  paracrine	  effects.	  
The	  effect	  of	  PGI2	   indirectly	  and/or	  directly	  enhancing	  VEGF/HGF	  activities	   through	  an	  
autocrine	   action	   of	   adipose	   derived	   cells	   needs	   to	   be	   further	   investigated,	   and	   is	  
currently	  part	  of	  our	  future	  work.	  It	  has	  been	  reported	  that	  the	  overproduction	  of	  PGI2	  
in	  HEK293	  cells	  transiently	  expressing	  PGIS	  promoted	  cell	  apoptosis	  and	  led	  to	  cell	  death	  
(Hatae	  et	   al.,	   2001).	  However,	   our	   established	   stable	   PGI2-­‐PSFC	   line,	  which	   constantly	  
synthesizes	   high	   levels	   of	   PGI2,	   showed	   no	   signs	   of	   apoptosis	   after	   over	   30	   passages.	  
Additionally,	  we	  have	  determined	  that	  intramuscular	  injection	  of	  the	  PGI2-­‐PSFCs	  into	  the	  
mice	   did	   not	   result	   in	   tumor	   formations	   -­‐	   after	   three	   weeks.	   However,	   the	   primary	  
culture	  PSFCs	  may	  adopt	  different	  properties	  in	  comparison	  to	  the	  HEK293	  cells,	  which	  
were	   used	   for	   previous	   studies	   (Hatae	   et	   al.,	   2001).	   Therefore,	   it	   becomes	   very	  
interesting	  to	  differentiate	  between	  primary	  cultured	  cells	  and	  the	  HEK293	  cell	   line	  for	  
PGI2	  signaling.	  For	  example,	  HEK293	  cells	  contain	  a	  very	   low	  level	  of	  PGI2	  receptor	  (IP)	  
protein;	  however,	   a	   significant	  amount	  of	   IP	   is	  present	   in	   the	  PSFCs	   (Figure	  4Bii).	   This	  
raises	  the	  possibility	  that	  PGI2-­‐mediated	  apoptosis	  in	  HEK293	  cells	  could	  be	  through	  its	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binding	   to	   other	   receptors,	   such	   as	   nuclear	   receptor	   PPAR.	   This	   remains	   to	   be	  
investigated.	   This	   study	   will	   provide	   a	   model	   for	   the	   future	   engineering	   of	   PGI2-­‐
producing	  cells	  derived	  from	  other	  cell	  types,	  such	  as	  stem	  cells	  and	  stromal	  cells.	  	  
	  
5.2.	  Effect	  on	  hindlimb	  ischemia	  and	  thrombogenesis	  after	  treatment	  with	  PGI2-­‐PSFCs	  
in	  mice.	  
In	  the	  present	  study,	  the	  efficiency	  of	  a	  new	  strategy	  involving	  treatment	  of	  limb	  
ischemia	  and	  thrombogenesis	  with	  therapeutic	  cells	  producing	  PGI2	  was	  examined.	  The	  
adipose	   tissue	   derived	   cells	   could	   not	   only	   be	   converted	   to	   PGI2	   producing	   cells	   by	  
overexpressing	   COX-­‐1-­‐10aa-­‐PGIS	   but	   these	   cells	   could	   also	   be	   used	   as	   a	   medium	   to	  
transfer	  COX-­‐1-­‐10aa-­‐PGIS	   in	   vivo.	   This	   strategy	  minimizes	   the	  adverse	  effects	  of	  using	  
adenoviral	  vectors,	  which	  pose	   immune	  reactions	  as	  well	  as	   tissue	  toxicity.	  To	  achieve	  
the	   benefits	   of	   cell	   therapy,	   it	   is	   necessary	   for	   the	   cells	   to	   home	   and	   survive	   in	   the	  
tissue.	  But	  majority	  of	   the	   cells	   don’t	   survive	   for	   a	   long	   time.	  Here	  our	   study	   showed	  
that	  the	  PGI2-­‐PSFCs	  could	  survive	  and	  produce	  PGI2	  for	  a	  longer	  time.	  Urine	  prostanoid	  
profile	  analysis	  was	  used	  to	  monitor	  the	  survival	  time	  of	  the	  PGI2-­‐PSFCs	  in	  vivo	  because	  
the	  increased	  6-­‐keto-­‐PGF1α	  level	  in	  the	  urine	  is	  directly	  related	  to	  the	  PGI2	  produced	  by	  
the	  PGI2-­‐cells	  in	  vivo	  (Figure	  11).	  	  From	  a	  therapeutic	  point	  of	  view,	  monitoring	  the	  cell	  
functions	  in	  vivo	  through	  the	  detection	  of	  the	  urine	  6-­‐keto	  PGF1a	  level	  does	  not	  contain	  
the	   risk	   of	   triggering	   immuno-­‐rejection	   and	   damaging	   the	   cells	   like	   GFP,	   a	   foreign	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protein.	   	   Figure	   11A	   showed	   the	   up-­‐regulated	   6-­‐keto-­‐PGF1a	   peak	   in	   urine	   at	   7	   days,	  
which	   then	  decreased	  after	   another	   two	  weeks	   following	   injection	  of	   the	  PGI2-­‐cells	   in	  
mice.	  This	  suggested	  that	   the	  cells	  were	  active	   in	  vivo	   for	  up	  to	  3	  weeks.	   	   In	  addition,	  
using	   a	   PSFC	   line	   could	  minimize	   immune	   rejection	   issues,	   since	   these	   cells	   could	   be	  
generated	   from	   the	   same	   subject.	   Critical	   limb	   ischemia,	   a	   consequence	   of	  
atherosclerosis	  is	  characterized	  by	  vascular	  endothelial	  injury	  and	  therefore	  a	  decrease	  
in	   the	   production	   of	   PGI2.	   We	   tried	   to	   mimic	   this	   vascular	   disorder	   by	   ligating	   the	  
femoral	   artery	   of	  mice	   and	   thus	   the	  mice	   developed	   ischemia	   in	   the	   hindlimb	   of	   the	  
mice.	  It	  was	  observed	  that	  treatment	  of	  these	  mice	  with	  PGI2-­‐PSFCs	  increased	  perfusion	  
and	  decreased	  the	  rate	  of	  amputation	  (Figure	  10).	  PGI2	  acts	  in	  a	  paracrine	  and	  autocrine	  
manner.	  So	  it	  could	  be	  that	  PGI2	  released	  by	  the	  PGI2-­‐PSFCs	  may	  cause	  the	  neighboring	  
endothelial	  cells	  to	  promote	  the	  production	  of	  PGI2	  through	  induced	  expression	  of	  COX-­‐
2	   and	   PGIS.	   This	   needs	   to	   be	   investigated.	   Critical	   limb	   ischemia	   patients	   suffer	   from	  
pain	  at	  rest.	  Thus	  treadmill	  run	  of	  the	  mice	  was	  used	  to	  assess	  the	  functional	  mobility	  of	  
mice	   after	   ischemia	   and	   treatment	   with	   PGI2-­‐PSFCs	   (Figure	   11B).	   Many	   recombinant	  
human	  membrane	  proteins	  mediate	  important	  pathophysiological	  functions	  in	  cells	  and	  
are	  great	  candidates	  for	  correcting	  cell	  disorders	  in	  many	  diseases.	  However,	  membrane	  
proteins	  are	  only	  dissolved	  in	  detergent	  solvents,	  which	  are	  not	  suitable	  for	  general	  use	  
in	   vivo.	   In	   the	   current	   studies	  we	  were	   able	   to	   deliver	   the	  overexpressed	  membrane-­‐
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bound	  COX-­‐1-­‐10aa-­‐PGIS	  into	  mice	  using	  the	  stable	  cell	  line	  strategy,	  and	  have	  provided	  
a	  model	  for	  developing	  membrane	  proteins	  into	  potential	  therapeutic	  reagents.	  	  
	   Anti-­‐platelet	  aggregation	  assays	  provide	  an	  important	  method	  that	  confirms	  the	  
benefits	  of	  the	  newly	  engineered	  Trip-­‐cat	  Enzyme-­‐1	  in	  anti-­‐thrombosis	  function.	  Human	  
platelet	   cells	   are	   rich	   in	   COX-­‐1	   and	   TXAS.	   Following	   the	   AA	   released	   from	   the	   cell	  
membrane	  (via	  stimuli	  on	  the	  platelets),	  the	  majority	  of	  the	  AA	  is	  converted	  to	  TXA2	  by	  
the	  coordinated	  action	  of	  COX-­‐1	  and	  TXAS.	  The	  resultant	  TXA2	  binds	  to	  its	  receptor	  on	  
the	  surface	  of	  the	  platelet	  and	  causes	  platelet	  aggregation.	  The	  inhibition	  of	  the	  platelet	  
aggregation	   by	   the	   PSFC	   cells	   stably	   expressing	   the	   Trip-­‐cat	   Enzyme-­‐1	   (Figure	   8)	   has	  
strongly	   indicated	  that:	  1)	  The	  expressed	  Trip-­‐cat	  Enzyme-­‐1	  was	  able	  to	  compete	  with	  
the	  endogenous	  COX-­‐1	  and	  use	  AA	  as	  a	  substrate;	  2)	  The	  PGH2	  produced	  by	  the	  Trip-­‐cat	  
Enzyme-­‐1	  was	   readily	   available	   to	   the	  PGIS	   active	   site,	   even	   in	   the	  presence	  of	   TXAS,	  
which	   competitively	   binds	   to	   the	   PGH2;	   and	   3)	   The	   immediate	   increase	   in	   PGI2	  
production	  by	  the	  Trip-­‐cat	  Enzyme-­‐1	  reduced	  the	  amount	  of	  PGH2	  available	  for	  TXAS	  to	  
produce	  TXA2	  ,	  which	  further	  prevented	  platelet	  aggregation.	  These	  factors	  have	  led	  the	  
Trip-­‐cat	   Enzyme-­‐1	   to	   possess	   dual	   functions:	   increasing	   PGI2	   and	   reducing	   TXA2	  
biosynthesis,	  which	   is	  a	  unique	  and	  novel	  anti-­‐thrombosis	  and	  anti-­‐ischemic	  approach	  
that	  has	  not	  yet	  been	  available	  thus	  far.	  Thus	  to	  translate	  this	  in	  vitro	  study	  into	  in	  vivo	  
results,	   the	   effect	   of	   PGI2-­‐PSFCs	   on	   thrombogenesis	   in	   carotid	   artery	   induced	   by	  
photochemical	  vascular	  injury	  was	  studied.	  Injury	  to	  the	  endothelium	  causes	  activation	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of	   the	   circulating	   platelets	   in	   the	   blood	   vessel.	   These	   activated	   platelets	   release	   TXA2	  
and	   thus	  are	   responsible	   to	   form	  aggregates	  as	  well	   as	   cause	   vasoconstriction.	   This	   is	  
one	  of	   the	   first	   steps	   in	   atherosclerosis.	   Thus	   treatment	  with	  PGI2-­‐PSFCs	   inhbited	   this	  
platelet	  activity	  of	  thromboxane	  through	  overproduction	  of	  PGI2	  at	  the	  site	  of	  injury	  and	  
therefore	  protected	  from	  thrombogenesis	  (Figure	  9).	  	  
Engineering	   of	   therapeutic	   cells	   producing	   PGI2	   by	   overexpression	   of	   fusion	   enzyme	  
(COX-­‐1-­‐10aa-­‐PGIS)	   is	   a	   novel	   model	   in	   PGI2	   therapy.	   This	   cell	   therapy	   will	   have	  
advantages	  like:	  1)	  The	  enzyme	  will	  be	  expressed	  for	  a	  longer	  time	  thus	  producing	  PGI2	  
continuously;	  2)	  Long	  term	  care	  is	  possible.	  	  	  
	  
5.3.	  Study	  of	  microRNA	  expression	  regulation	  in	  PGI2-­‐PSFCs	  	  
The	  recombinant	  hybrid	  enzyme	  (COX-­‐1-­‐10aa-­‐PGIS)	  overexpressed	   in	  a	  primary	  
culture	   of	  mouse	   adipose	   tissue	  was	   able	   to	   integrate	   its	   triple	   catalytic	   functions	   of	  
COX-­‐1	  and	  PGIS	  to	  effectively	  and	  continuously	  convert	  endogenous	  AA	  into	  PGI2.	   	  We	  
were	  able	  to	  detect	  the	  stable	  production	  of	  PGI2	  through	  the	  presence	  of	  6-­‐keto-­‐PGF1α	  
(the	  stable	  byproduct)	  using	  LC/MS	  (Figure	  7ii)).	  The	  miRNA	  microarray	  analysis	  of	  the	  
PGI2-­‐PSFCs	  (expressing	  COX-­‐1-­‐10aa-­‐PGIS)	  versus	  the	  vector-­‐transfected	  primary	  culture	  
adipocytes	   (PSFCs)	   showed	   that	   overproduction	   of	   PGI2	   causes	   an	   up-­‐regulation	   in	  
miRNAs	  711,	  148b	  and	  744,	  and	  a	  down-­‐regulation	  in	  miRNAs	  466f-­‐3p,	  148a,	  7a	  and	  374	  
etc	   (Figure	   12).	   This	   PGI2-­‐induced	   miRNA	   regulation	   was	   IP-­‐	   and	   PPARγ	   receptor-­‐	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mediated	   because	   the	   effect	   was	   reversed	   by	   using	   CAY10441	   (IP	   antagonist)	   and	  
GW9662	  (PPARγ	  antagonist)	  (Figure.	  13a).	  Our	  experimental	  data	  showing	  the	  analyzed	  
correlation	   between	   the	   miRNA	   expression	   and	   IP/PPARγ	   blockade	   (Figure	   13a)	   has	  
provided	  evidence	  that	  the	  effects	  of	  the	  miRNA	  expression	  were	  possibly	  related	  to	  the	  
PGI2	  receptor	  mediation,	  as	  there	  was	  no	  difference	  between	  the	  IP	  and	  PPAR	  receptors.	  
This	  raises	  the	  possibility	  that	  the	  two	  receptors	  may	  coordinate	  together	  for	  the	  miRNA	  
expression.	  Upregulation	  of	  miRNA-­‐711	  was	   further	   confirmed	  by	  quantification	  using	  
quantitative	  real	  time	  PCR.	  	  
MiRNAs	   regulate	   gene	   expression	   either	   by	   inhibiting	  mRNA	   translation	   or	   by	  
causing	  degradation	  of	  mRNAs	  (Farh	  et	  al.,	  2005,	  Pasquinelli et al., 2005).	  MiRNA	  have	  
been	  reported	  to	  play	  a	  role	  in	  adipogenesis	  of	  preadipocytes	  (Kajimoto et al., 2006).	  By	  
referring	   to	  a	   list	  of	   targets	   (microRNA.sangers.ac.uk)	  we	   identified	   that	  C/EBP	  beta	   is	  
one	   of	   the	   predicted	   gene	   targets	   of	  miRNA	   711	   and	   the	   Akt1	   gene	   is	   the	   predicted	  
target	  of	  miRNA	  711	  (Table	  2),	  148b	  and	  744.	  The	  transcription	  factor	  C/EBP	  beta/delta	  
is	  known	  to	  mediate	  the	  transcriptional	  activation	  of	  PPARγ	  and	  C/EBPα	  which	   in	  turn	  
cause	  differentiation	  of	  adipocytes	  and	   induce	  maturation	  of	  pre-­‐adipocytes	   into	   lipid-­‐
containing	   fat	   cells	   (Tang	   et	   al.,	   2004).	   Similarly,	   the	   phosphatidylinositol-­‐3-­‐kinase	  
(PI3K)/Akt1	   pathway	   regulates	   the	   process	   of	   adipocyte	   differentiation.	   It	   has	   been	  
reported	   that	   absence	   of	   Akt1/PKBα	   in	   primary	   mouse	   fibroblasts	   cells	   does	   not	  
promote	  adipocyte	  differentiation	  (Yun et al., 2008).	  Akt1	   in	  association	  with	  ProF	  has	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been	   suggested	   to	   produce	   phosphorylation	   of	   FoxO1	   and	   thereby	   cause	   its	   nuclear	  
export.	   This,	   in	   turn,	   results	   in	   the	   inactivation	   of	   FoxO1	   which	   is	   a	   repressor	   of	  
adipogenesis	  and	  a	  negative	  regulator	  of	  insulin	  actions	  (Nakae et al., 2003, Fritzius et  
al., 2008).	  It	  is	  also	  reported	  that	  PGI2,	  through	  its	  paracrine	  effect	  of	  inhibiting	  the	  Akt1	  	  
	  
Figure	  28.	  (a.)	  Schematic	  showing	  the	  proposed	  mechanism	  of	  inhibition	  of	  adipogenesis	  
by	  PGI2.	  The	  box	  indicates	  the	  proposed	  pathway.	  PGI2	  by	  signaling	  through	  the	  IP	  and	  
PPARγ	  receptors	  produces	  a	  change	  in	  the	  expression	  level	  of	  miRNA	  711,	  744	  and	  148.	  
These	   three	   miRNAs	   have	   Akt1	   as	   their	   gene	   target.	   Therefore	   an	   increase	   in	   the	  
expression	  of	  miRNAs	  711,	  744	  and	  148	  produces	  a	  decrease	  in	  the	  expression	  of	  Akt1	  
which	   is	   possible	   the	   reason	   behind	   inhibition	   of	   adipogenesis	   (lipid	   accumulation)	   in	  
PGI2-­‐PSFCs.	  Akt1	  is	  a	  target	  of	  insulin	  signaling.	  (b.)	  The	  proposed	  paracrine	  action	  as	  an	  
application	  in	  obesity	  and	  atherosclerosis	  through	  up-­‐regulating	  PGI2	  biosynthesis.	  PGI2	  
released	   from	   the	  endothelial	   cells	   acts	   in	   a	  paracrine	  manner	  on	   the	   smooth	  muscle	  
cells	  to	  inhibit	  lipid	  deposition.	  
 99 
	  
pathway,	   induces	   inhibition	  of	   vascular	   smooth	  muscle	   cell	   proliferation	   and	  prevents	  
de-­‐differentiation	  thus	  indicating	  its	  role	  as	  atheroprotective	  (Kasza	  et	  al.,	  2009).	  This	  is	  
a	   very	   complex	   system	   that	   has	   not	   been	   settled	   yet.	   Thus,	   we	   have	   initiated	   a	   very	  
preliminary	  study	  for	  the	  regulation	  of	  gene	  expression	  through	  miRNA	  and	  performed	  
an	   RNA	   illumina	   assay.	   The	   results	   showed	   many	   of	   the	   mRNA	   were	   up-­‐regulated	  
/down-­‐regulated	   in	   the	   PGI2-­‐PSFCS	   when	   compared	   to	   the	   vector-­‐transfected	   PSFCs	  
(Figure	  16).	  From	  the	  assay	  we	  were	  able	  to	  show	  that	  there	  was	  a	  down-­‐regulation	  of	  
the	  mRNA	  Akt1	   in	  PGI2-­‐PSFCs	   in	  comparison	  to	  the	  control	  PSFCs.	  Therefore	  Akt1	  may	  
be	  a	  gene	  target	  of	  microRNA	  711,	  148b	  and	  744.	  We	  were	  able	  to	  confirm	  the	  observed	  
RNA	   illumina	  assay’s	  down-­‐regulation	  of	  mRNA	  Akt1	  by	  performing	  an	   immunoblot	  of	  
total	   Akt1	   in	   both	   primary	   culture	   cell	   lines	   (Figure	   17).	   However,	   to	   confirm	   the	  
relationship	   between	   Akt1	   and	   PGI2,	   many	   more	   and	   intensive	   studies	   are	   required.	  
Such	   studies	  would	   exceed	   our	   current	   experimental	   designs,	   however	   they	   could	   be	  
included	  in	  our	  future	  work.	  	  
Thus,	  identification	  of	  the	  signaling	  molecule,	  microRNA	  711	  indicated	  that	  PGI2	  
plays	  a	  role	   in	   inhibiting	   lipid	  deposition	  and	  facilitating	  clearance	  (Table	  2	  and	  3).	  We	  
further	   incubated	  our	  PGI2-­‐PSFCs	  and	  PSFCs	   (control)	   cells	   in	  adipogenic	  medium	  with	  
insulin	   and	   found	   that	   there	   was	   decreased	   lipid	   deposition	   in	   PGI2-­‐PSFCs	   when	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compared	   with	   the	   control	   PSFCs	   (Figure	   15).	   This	   shows	   that	   PGI2	   reduced	   the	  
sensitivity	  of	  insulin-­‐mediated	  lipid	  deposition	  in	  cells.	  	  
	  	  	   Our	   findings	   also	   predict	   that	   the	   loss	   of	   paracrine	   and	   autocrine	   effect	   of	  
endothelial	   PGI2	   could	   be	   responsible	   for	   early	   atherosclerosis	   as	   fatty	   streaks.	   These	  
fatty	  streaks	  are	  lipid	  deposits	  in	  the	  smooth	  muscle	  cells	  underlying	  the	  PGI2-­‐producing	  
endothelium.	   Our	   future	   efforts	   will	   be	   directed	   toward	   studying	   lipid	   deposition	   in	  
smooth	  muscle	  cell	  lines	  transfected	  with	  our	  PGI2-­‐producing	  hybrid	  enzyme.	  	  
In	  conclusion,	  our	  array	  data	  suggests	  that	  PGI2	  regulates	  miRNA	  expression	  that	  
inhibits	   insulin-­‐mediated	   lipid	  deposition	   in	   cells	   (Figure	  28a).	   This	   is	   relevant	  because	  
peripheral	   lipid	   deposition	   (obesity)	   and	   atherosclerosis	   which	   is	   uncontrolled	   sub-­‐
endothelial	  lipid	  deposition	  in	  smooth	  muscle	  cells	  could	  be	  directly	  related	  to	  impaired	  
PGI2	  production	  as	  hypothesized	  (Figure	  28b).	  
The	  cell	  based	  method	  that	  was	  used	  to	  study	  the	  autocrine	  and	  paracrine	  effect	  
of	   PGI2	   in	   the	   primary	   culture	   of	   adipocytes	   is	   novel	   in	   that	   it	   allows	   us	   to	   study	  
endogenous	   PGI2,	   which	   has	   a	   very	   short	   half-­‐life.	   This	   method	   allows	   us	   to	   closely	  
mimic	  the	  in	  vivo	  effect	  of	  PGI2	  produced	  by	  endothelial	  cells	  and	  predicts	  the	  pathway	  
involved	   in	   lipid	   deposition.	   The	   findings	   of	   the	   study	   have	   unravelled	   some	   of	   the	  




5.4.	  Generation	  of	  the	  transgenic	  mice	  overexpressing	  COX-­‐1-­‐10aa-­‐PGIS	  
	   Global	   overexpression	   of	   human	   COX-­‐1-­‐10aa-­‐PGIS	   in	   the	   transgenic	   mice	   was	  
accomplished	   by	   pronuclear	   microinjection	   of	   the	   cDNA	   construct	   directed	   by	   pCMV	  
promoter	  in	  FVB/N	  mice.	  The	  vascular	  protective	  effect	  of	  PGI2	  is	  well	  demonstrated	  by	  
studies	  that	  have	  shown	  an	  increase	  in	  the	  risk	  of	  heart	  attack	  associated	  with	  the	  use	  of	  
COX-­‐2	  inhibitors,	  such	  as	  Vioxx.	  For	  decades,	  increasing	  PGI2	  level	  to	  prevent	  and	  treat	  
vascular	  diseases,	  such	  as	  pulmonary	  arterial	  hypertension	  has	  been	  documented.	  Our	  
results	  presented	  here	  are	  based	  on	  the	  hypothesis	  that	  the	  approach	  of	  increasing	  PGI2	  
biosynthesis	  constantly	   in	  vivo	  could	  be	  a	  genetic	  and	  fundamental	  solution	  to	  reduce	  
the	  risk	  for	  vascular	  and	  heart	  diseases.	  Encouraged	  by	  our	  PGI2-­‐PSFC	  study	  results,	  we	  
were	   able	   to	   generate	   transgenic	   mice	   overexpressing	   COX-­‐1-­‐10aa-­‐PGIS	   and	  
overproducing	   PGI2.	   	   Homozygous	   line	   of	   the	   transgenic	   mice	   was	   generated	   by	  
breeding	  and	  all	   the	  animals	  had	  normal	  phenotype	  appearance	  as	  well	  as	  behaviour.	  	  
Also	   LC/MS	   analysis	   of	   urine	   collected	   from	   the	   transgenic	   mice	   showed	   a	   5	   fold	  
increase	   in	   PGI2	   compared	   to	   the	   wild	   type	   mice	   (Figure	   22).	   This	   indicated	   that	  
overexpression	  of	  COX-­‐1-­‐10aa-­‐PGIS	  in	  mice	  had	  the	  functional	  triple	  catalytic	  activity.	  	  
In	  photochemical	  carotid	  artery	   injury	  model,	  both	   laser	  beam	  and	  rose	  bengal	  
induce	   thrombosis	   in	   WT	   mice	   due	   to	   increase	   in	   the	   production	   of	   TXA2.	   Thus	   this	  
model	   was	   a	   very	   good	   way	   to	   study	   the	   functional	   activity	   of	   COX-­‐1-­‐10aa-­‐PGIS	  
overexpression	  in	  transgenic	  mice.	  Transgenic	  mice	  (TG)	  induced	  with	  the	  carotid	  injury	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protected	   themselves	   from	   thrombosis	   compared	   to	   the	   WT	   mice	   which	   showed	   a	  
complete	  block	  in	  blood	  flow	  by	  the	  end	  of	  2	  hrs	  (Figure	  27).	  The	  mechanism	  of	  action	  
wherby	  COX-­‐1-­‐10aa-­‐PGIS	  overexpression	  provides	  protection	  against	   the	  development	  
of	   thrombogenesis	   are	   likely	   to	   be	   multifactorial.	   We	   propose	   here	   that	   the	  
overexpressed	  COX-­‐1-­‐10aa-­‐PGIS	  in	  the	  TG	  	  were	  able	  to	  divert	  and	  metabolize	  most	  of	  
the	   AA	   released	   during	   injury	   	   towards	   production	   of	   PGI2	   .	   This	   in	   turn	  was	   able	   to	  
inhibit	  the	  platelet	  agreegation	  and	  vasoconstriction	  effect	  of	  TXA2	  .	  Not	  only	  the	  actions	  
of	  TXA2	  might	  be	  inhibited	  but	  its	  synthesis	  also	  might	  be	  decreased	  as	  indicated	  by	  an	  
increase	   in	  perfusion.	  After	  studying	  the	  vascular	  protective	  effect	  of	  COX-­‐1-­‐10aa-­‐PGIS	  
overexpression	   in	   TG	  mice,	   it	  was	   also	   necessary	   to	   study	   the	   risks	   of	   the	  permanent	  
upregulation	  of	  PGI2	  biosynthesis	  in	  vivo.	  	  
Bleeding	   time	   measurement	   indicated	   that	   the	   TG	   mice	   had	   an	   increase	   in	  
bleeding	   time	   (Figure	   23i)	   which	   indicated	   PGI2	   inhibitory	   function	   on	   platelets	  
activation	  but	  also	   indicated	  caution	   in	  cases	  of	   surgery	  where	  excessive	  bleeding	  can	  
take	   place	   during	   the	   process.	   Generation	   of	   transgenic	   mice	   are	   several	   times	  
associated	  with	  embryonic	  lethality.	  However	  homozygous	  colony	  of	  TG	  mice	  producing	  
PGI2	   rather	   showed	   an	   increase	   in	   the	   number	   of	   litters	   when	   compared	   to	   the	  wild	  
types	  (Figure	  25).	  This	  also	  further	  confirmed	  the	  reports	  that	  PGI2	  supports	  embryonic	  
development.	   PGI2	   is	   a	   potent	   endogenous	   vasodilator	   and	   therefore	   it	   can	   cause	  
lowering	  of	  blood	  pressure.	  Therefore	  it	  was	  necessay	  to	  measure	  blood	  pressure	  in	  the	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transgenic	   mice.	   It	   was	   observed	   that	   both	   the	   systolic	   and	   diastolic	   blood	   pressure	  
were	   similar	   to	   that	  of	   the	  wild	   type	  mice	  when	  measured	  using	   the	   tail	   cuff	  method	  
(Figure	  23ii).	  The	  reason	  behind	  no	  change	  may	  be	  either	  due	  to	  the	  variation	  involved	  
with	  using	   the	  non	   invasive	   tail	   cuff	  method	  or	   due	   to	   any	   compensatory	  mechanism	  
that	  regulated	  the	  blood	  pressure	  to	  normal	  in	  TG	  mice.	  
It	  was	  interesting	  to	  observe	  that	  PCR	  analysis	  and	  immunoblot	  analysis	  showed	  
a	  wide	  expression	  of	  COX-­‐1-­‐10aa-­‐PGIS	   in	  several	  organs	   like	  heart,	  kidney,	   lung,	  brain,	  
and	  uterus	  (Figure	  24).	  This	  indicated	  that	  the	  triple	  catalytic	  enzyme	  had	  the	  ability	  to	  
express	  in	  several	  organs.	  Also	  the	  expression	  of	  COX-­‐1-­‐10aa-­‐PGIS	  in	  the	  adipose	  tissue	  
further	   confirmed	   our	   previous	   results	   in	   which	  we	   expressed	   this	   enzyme	   in	   the	   fat	  
cells.	  Thus	  we	  propose	  in	  future	  to	  study	  the	  effect	  on	  miRNA	  expression	  regulation	   in	  










6.	  SUMMARY	  AND	  CONCLUSIONS	  
	  
1) The	   adipose	   tissue	   derived	   mature	   adipocytes	   were	   successfully	   cultured	   and	  
differentiated	  into	  cells	  producing	  predominantly	  PGE2	  and	  PGI2	  endogenously	  as	  
analysed	   by	   LC/MS	   analsysis.	   Therefore	   these	   cells	   were	   referred	   to	   as	  
prostanoid	  synthesizing	  fat	  cells	  (PSFC).	  	  
	  
2) PSFCs	   showed	  endogenous	  protein	  expression	  of	  COX-­‐1,	   cPGES	  and	  PGIS.	  Thus	  
enzyme	  activity	  assay	  by	  HPLC	   showed	   that	  exogenous	  AA	  was	  metabolized	   to	  
PGE2	  and	  PGI2.	  	  
	  
3) Stable	  expression	  of	  the	  triple	  catalytic	  enzyme	  (COX-­‐1-­‐10aa-­‐PGIS)	  in	  PSFCs	  was	  
achieved	   and	   these	   cells	   were	   capable	   of	   redirecting	   the	   endogenous	   and	  
exogenous	  AA	  metabolism	   towards	   a	   stable	   and	  dominant	   production	   of	   PGI2.	  
Therefore	  these	  cells	  were	  referred	  to	  as	  PGI2	  producing	  fat	  cells	  (PGI2-­‐PSFCs).	  	  
	  
4) The	  PGI2-­‐PSFCs	  demonstrated	  superior	  anti-­‐platelet	  aggregation	  in	  vitro	  and	  also	  
protected	  the	  mice	  from	  thrombosis	  induced	  by	  photochemical	  vascular	  injury.	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5) Transplantation	   of	   PGI2-­‐PSFCs	   in	   mice	   with	   hindlimb	   ischemia	   increased	  
reperfusion	   in	   the	   ischemic	   limb	   and	   subsequent	   increase	   in	   mobility	   and	  
decrease	  in	  autoamputation	  of	  the	  mice.	  
	  	  
6) MicroRNA	  microarray	  analysis	  revealed	  a	  significant	  upregulation	  (711,	  148b	  and	  
744)	   and	   downregulation	   of	   miRNAs	   in	   PGI2-­‐PSFCs	   as	   compared	   to	   PSFCs.	  
Treating	   the	  PGI2-­‐PSFCs	  with	   IP	   and	  PPARγ	   receptors	   antagonists	   reversed	   this	  
effect.	  	  
	  
7) Quantitative	   RT-­‐PCR	   analysis	   to	   confirm	   the	   upregulation	   of	   miRNA	   711	   was	  
performed	   and	   indicated	   a	   6-­‐fold	   increase	   in	   miRNA-­‐711	   in	   PGI2-­‐PSFCs	   when	  
compared	  with	  the	  PSFCs.	  	  
	  
8) Insulin	  mediated	   lipid	  deposition	  was	   inhibited	   in	  the	  PGI2-­‐PSFCs	  whereas	  PSFC	  
showed	  significant	  lipid	  accumulation	  as	  indicated	  by	  red	  oil	  staining.	  
	  
	  	  
9) RNA	   illumina	   gene	   expression	   assay	   showed	   more	   than	   2	   fold	   increase	   and	  
decrease	   in	   several	  mRNAs	  and	  one	  of	   them	  was	  Akt1,	   the	  predicted	   target	  of	  
miRNA-­‐711	  which	  was	  decreased	  by	  4	  fold	  in	  PGI2-­‐PSFCs.	  	  
 106 
	  
10) Immunoblot	   analysis	   further	   confirmed	   that	   Akt1	   protein	   expression	   is	  
comparatively	  low	  with	  respect	  to	  PSFCs.	  	  
	  
11) Transgenic	  mice	  overexpressing	  COX-­‐10aa-­‐PGIS	  were	   successfully	  generated	  by	  
using	  pronuclear	  microinjection	  and	  were	  genotyped	  by	  tail	  clip	  PCR	  analysis.	  
	  
12) The	   transgenic	  mice	  were	   succefully	  bred	   to	  get	  a	   colony	  of	  homozygous	  mice	  
which	  showed	  no	  phenotypic	  physical	  change	  or	  anatomical	  changes.	  
	  
13) Increase	   in	   the	   biosynthesis	   of	   PGI2	   and	   decrease	   in	   synthesis	   of	   other	  
prostanoids	  was	  confirmed	  by	  performing	  LC/MS	  analysis	  of	  urine	  collected	  from	  
the	  transgenic	  mice.	  
	  
14) The	  transgenic	  mice	  showed	  an	  increase	   in	  bleeding	  time	  as	  well	  as	   increase	   in	  
the	  number	  of	  litters	  produced	  after	  breeding	  the	  transgenic	  mice.	  
	  
15) PCR	  analysis	  and	  immunoblot	  analysis	  of	  the	  different	  organs	  showed	  expression	  




16) Transgenic	   mice	   significantly	   reversed	   the	   decrease	   in	   blood	   flow	   induced	   by	  
photochemical	  carotid	  artery	  injury	  to	  normal	  wheras	  the	  wild	  type	  mice	  showed	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